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SUMMARY 
A review of the biological properties and the synthesis of 
IX-methylene- 0' - and S-lactones is presented. 
Cholesterol (201) was converted into 4-oxa-3-oxo-5 0< -cholestane (203) 
and the ~-methylene moiety was introduced by ~-hydroxymethylenation. 
diethylamination and elimination of diethylamine after hydrogenation 
to give 2-methylene-4-oxa-3-oxo-50<-cholestane (225). The same sequence 
of reactions was employed to prepare 17~-hydroxy-2-methylene-4-oxa-3-oxo-
5O<-androstane (238) and its 17-yl acetate (239) from androst-5-en-3!3-ol-
17-one (228). Reactions of the above o<-methylenelactones with L-cysteine 
gave the cysteine-lactone adducts in a Michael-type addition. Reaction of 
the lactone (203) with phenylmagnesium bromide gave 4-oxa-3-phenyl-5~­
cholest-2-ene (278]. On epoxidation this oompound gave an unusual 
rearranged product. 3-hydroxy-4-oxa-3-phenyl-5 ~-cholestan-2-one (281) 
which on treatment with ethanol/hydrochloric acid formed 3-ethoxY-4-oxa-3-
phenyl-50(-cholestan-2-one (282). Oxidation of the rearranged product 
(281) with,lead tetra acetate gave 5-benzoyloxy-2.3-seco-5 ~-cholestan-2-
oic aoid (299) which on esterification gave the methyl ester (300). 
The oxidised product (299). after hydrolysis. was cyclised to give A-nor-
3-oxa-50(-cholestan-2-one (274). 
Reaction of the lactone (203) with 4-methoxy phenyl magnesium bromide 
gave three major products,3{4-methoxyphenyll-4-oxa-5", -cholest-2-ene (304). 
3.3-di ( 4-methoxyphenyl)-4-oxa-5 ~-cholestane (305) and 3.3-di ( 4-methoxy 
phenyl)-5,fl-hydroxy-3.4-seco-5 ex-cholest-2-ene (306). 
Hydrogenolysis of (305) gave a saturated alcohol. 3.3-di ( 4-methoxy phenyl) 
-5)3-hydroxy-3. 4-seco-5 0( -cholestane (314) and a ketone. 3.3-di ( 4-methoxy 
phenyl)-3.4-seco-cholestan-5-one (315). The structure of the saturated 
alcohol (314) was confirmed by hydrogenation of the unsaturated alcohol (306). 
i11 
Oxidation of the saturated alcohol (314) with Jones' reagent gave 
a ketone identical with the ketone (315) obtained during hydrogenolysis. 
Treatment of the unsaturated alcohol (306) with a catalytic amount of 
toluene-E-sulphonic acid in benzene afforded a ketone, by a 1,5--
hydride shift, identical to the ketone (315) obtained by successive 
hydrogenolysis and Jones' oxidation. 
Manganic acetate-catalysed addition of acetic acid to 50(-
cholest-2-ene (328) gave the 'I-lactone (329). 
Androst-5-en-3~-ol-17-one (241) was converted to 3p-hYdroxy-17 0<-
oxa-17-oxo-D-homo-5 ()( -androstane (251). The D-ring lactone (251) on 
hydroxymethylation, gave 3fl-hydroxy-16-hydroxymethyl-17 ()( -oxa-17-oxo 
-D-homo-S (){ -androstane (256) and on mesylation resulted in a dimesylate (258) 
which, on base-catalysed elimination, gave an (){-methylene-lactone. (259) 
An ~methylene-D-ring lactone (255) was obtained from the D-ring lactone 
(251) directly by the Mannich reaction with paraformaldehyde/diethylamine/ 
diethylamine hydrochloride in dioxane and an aldol-type condensation with 
paraformaldehyde/potassium hydroxide in ethanol. 
The cytotoxic activity, (L050), determined by a tissue culture technique 
on KB cells was as follows; 2-methylene-4-oxa-3-oxo-5 ~-cholestane 
( o. 80~g/ml), 17ft-acetoxy-2-methylene-4-oxa-3-oxo-5 ~-androstane 
(0.72 )Jg/ml), 17fi-hydroxy-2-methylene-4-oxa-3-oxo-5 (){-androstane ( 0.80 yg/ml), 
16-methylene-170( -oxa-1i1-oxo-D-homo-5 lX-androst-2-ene ( 0.92 }lg/ml) and 3p-
hydroxy-16-methylene-17 0( -oxa-17-o)4o-D-homo-5 o(-androstane ( 1.0 tg/ml) • 
, 
INTRODUCTION 
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INTRODUCTION 
BIOLOGICAL PROPERTIES OF SESQUITERPENE LACToNES. 
(i) CANCER CHEMOTHERAPY. 
There has been a great deal of confusion in the medical 
literature about the growth of cancer. Cancer is widely regarded 
as a condition in which cells multiply without restraint and at a 
very rapid rate. It will be useful to scrutinize the concept that 
the cancer cells multiply rapidly. However, it is easy to show that 
several kinds of normal cells, essential to life. multiply far more 
rapidly than cancer cells. In the normal human being. cells of the 
6 ' bone marrow multiply rapidly enough to produce 2.5 x 10 red blood cells 
each second for a life-time. After haemorrhage this rate can go up 
seven-fold. The cells lining the intestine multiply at least as 
rapidly and there is some evidence to suggest that they may multiply 
even more,rapidly than the bone marrow cells. Even the cells lining 
the mouth. which are not as important to life. multiply at a faster 
rate than cancer cells. Since normal cells. essential to life. 
multiply more rapidly than most cancer cells. it follows that a 
broad-spectrum inhibitor. whether synthetic or naturally occurring, 
which effects all rapidly multiplying cells will affect the bone-
marrow and intestinal lining at least as much as the cancer cells. 
The likelihood is that such a material might temporarily slow tumour 
growth. but before stopping'it completely. would kill the patient. 
On the other hand. a narrow-spectrum inhibitor. which affects one 
kind of cell 'much more than others. offers considerable promise. 
Theoretically • it is possible to find among such inhibitors one 
which will affect a particular cancer more than normal cells. 
-2-
Cancer chemotherapy is a comparatively young science, and 
clinically useful agents have evolved only during the past thirty years. 
During this period, many hundreds of variants of known classes of 
chemotherapeutic agents have been synthesised and there is a goad reason 
to expect that modification of known drugs will continue. However, some 
pessimism is apparent among workers, because of the selectively small 
improvements over the prototype drugs which have resulted from the 
extensive synthetic efforts to date. There is a need for new prototypes 
or templates for the synthetic organic chemist to use in the design of 
potentially superior chemotherapeutic agents. As a corollary statement, 
there is a need for elucidation of new biochemical mechanisms of growth 
regulation which may be more amenable to selective regulation. Recent 
studies in the isolation and structural elucidation of tumour inhibitors 
are yielding a fascinating arr.ay of novel! types of growth-inhibitory 
compounds. There appears to be a reason for confidence that this approach 
may point the way to useful templates for new synthetic approaches to 
cancer chemotherapy. 
The discovery of the anti leukaemic activity of nitrogen mustard 
in the 1940's 1is considered by many to have been the start of modern cancer 
chemotherapy. An enormous amount of work has followsdon the synthesis and 
evaluation of biological alkylating agents. 2 ,3 Although the modification of 
presently known alkylating agents continues, some pessimism is evident due 
to the high degree of reactivity of simple alkylating agents leading to 
indiscriminate reaction with many cell constituents and consequently 
narrow therapeutic indices. 
The recent discovery and structure elucidation of approximately 500 
new sesquiterpene lactones, during a systematic study of Artemisia and 
other genera of the family of Compositae, provided the opportunity for 
further investigations on the potential of these sesqUiterpene lactones 
4 5 
as new therapeutic agents.' Although lactones (eudesmanolides) have been 
-3-
reported from the roots of Liriodendron tuHpifera(Magnoliaceae)6 
~ 7 
and from the bark of Braz~an species of EremanthuaCompositae) , 
they are rarely found in stem and roots and are mostly concentrated 
in the leaves and flowering heads ( Phyllaries)S. 
(ii) ANTI-TUMOUR AND CYTOTOXIC ACTIVITY 
Much of the earlier study on sesquiterpene lactones for the 
medicinal purposes has concentrated mainly on santonin (1), a santonolide, 
and its derivatives, which were known as important anthelmintic and 
ascaricidal agents9• The o(-methylene-l-butyrolactone moiety fused 
on various skeletons characterises a rapidly expanding group of 
10 
sesquiterpene lactones, comprising to date more than 400 members • 
Many sesquiterpene lactones bearing ano(-methylene-t- butyrolactone 
grouping exhibit significant growth-inhibitory activity in vivo against 
animal tumour systems and in vitro against cells derived from 
human carcinoma of the nasopharynx (KB)11. This activity appears to 
be associated with their ability to act as alkylating agents by 
virtue of conjugate addition of biological nucleophiles to tha 
o(-methyleAe lactone moiety. These include costunolide [2)12 and 
6 12 tulipinolide (3). the guanolides. gaillardin (4) J elemanolides, 
13 13 ve~iolepin (5) and vernomenin (6) I the germacranolides, 
elephantopin (7A)14, elephantin (7B)14, helenalin (S)15, euparotin 
acetete(9) and its companions 16 and the pseudoguaianolide, damsin (1oF. 
13 Unfortunately, active sesquiterpene lactones such as vernolepin (5) , 
elephantopin (7A)14 and euparotin acetate (9)16 have therapeutic 
indices which preclude theJr clinical use. 
-4-
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(10) 
In an effort to obtain antineoplastic agents, over 500 
18 
sesquiterpenes from plants were evaluated against numerous 
tumour models and it was found that all the known cytotoxic 
sesquiterpenes contained a lactone function, all but one of these 
was o(JI-unsaturated and the ~-ethylenic linkage was exocyclic 
in each case. 
The most immediate and direct factor responsible for 
cytotoxicity of the compounds was the introduction of the 
O=C-CH= CH2 
19 
system • Compounds having endocycli~ double 
20 bonds gave unstable cysteine adducts and thus were inactive • 
However, sesquiterpene lac tones which incorporated a cyclopentenone or 
0( ,p-unsaturated ketone ( 
appeared to have enhanced 
in addition' to the ()( -methylene-lS -butyrolactone) I 
cytotoxicity whereas monofunctional 
sesquiterpenes containing only an OS ft-unsaturated estsl' or 
cyclopentenone displayed non-significant activity.11A, 21, 22. Most 
bifunctional alkylating agents show a relationship between activity 
and distance between the alkylating sites 23,24. In the series of 
open-chain 0< -methylene- 't - lactones, the distance between the two 
groups is critical and the activity increases as the distance betwen 
25 the groups decreases. No enhancement of the cytotoxicity was observed 
in the bifunctional derivatives with a conjugated ester moiety. 
-6-
Recently the O\.-methylene-'6 -lactone moiety was reported to 
be highly toxic to normal human lymphoid cells as well as to 
CCRF-CEM, human lymphoblastic leukaemia cells in cUlture. 26 These 
cells have been characterised27 as having an absolute nutritional 
requirement for exogenous L-cysteine. The use of CCRF-CEM cells 
to assay the cytotoxic properties was based on the expectation 
20,28 that o(-methylene lactone systems would function as Michael acceptors, 
- 29 
and thus scavenge L-cysteine • The cytotoxicity associated may 
arise from the pronounced ( and indiscrimate) chemical reactivity of 
the ~-methylene lactone moiety, whereas the anti tumour activity 
may arise from concurrent reactions of this moiety with biological 
. nucleophiles of significance to tumour growth. These views are in 
accordance with the theory of tumour inhibition by selective 
alkylation of biological macromolecules. 11A, C, F, 28,30 
Modification of the chemical reactivity of the 0<. -methylene 
lactone moiety, to the extent that anti tumour activity is maintained 
and toxicity is minimised, has not yet been established. In the 
natural compounds the p-carbon ( alkylating site) of the o(-methylene 
lactone is unsubstituted, thus substituent at this pcsition should 
produce changes in physical properties and in chemical reactivity 
which could alter biological activity and therefore have important 
biological implications. Variation of substituents at the 0(-, 
and ~-carbons of ~-crotonolactones has resulted in significant effects 
31 
on anti tumour activity Attempts to modify the activity in simple 
synthetic ~methylene lactones by substitution of an alkyl and/or 
alkoxy group at the alkylation site resulted in compounds Which were 
25,32 
significantly toxic, however-, other factors such as changes in 
solubility, transport ~r metabolism may be involved. 
The antitumour activity of cucurbitacins, datiscoside (11)33, 
34 35 fabacein (12) and cucurbitacin B (13) , a group of highly oxygenated 
36 37 triterpenes, has been demonstrated ' • 
-7 
~ 
H 
1-10 
( 11) 
~ 
H H 
(12) 
(13) 
o 
11 
I 2 3 R=H j R = R =Ac . 
I 2 3 R=R=H. R=Ac ) 
The action of cucurbitacins is more sensitive to the oxygen uptake 
36 than an.aerol1c glycolysis as most cancer chemotherapeutic agents 
have immediate effects on one of the two primary energy-providing 
processes of cancer cell metabolism, namely glycolysis and resPiration. 38 
The isolation and structural elucidation of Withaferin A (14) from 
Withania somninfera L., a prototype of a novel class of polyfunctional 
steroid lactones, the withanolides was reported, at the same time 
but independently, by two groups.39-42 
(14) 
-8-
Lee ~ a143 reported the anti tumour activity of o(-methy1ene 
- ~ - 1actones of the nucleic acid bases, uracil, tpymine and derivatives. 
They found that the introduction of the conjugated ester side chain 
enhanced this activity. The introduction of a carrier moiety into an 
a1ky1ating centre has led to compounds, such as uracil mustard(15) 
of clinical interest, as anti cancer agents44 
(15) 
The work on the synthesis of compounds derived from the combination 
of an active a1ky1ating agent and a carrier moiety, such as a steroida1 
hormone, has led to novel steroidal o(-methylene- ~ -lactone alkylating agents 
• 
which are active against Walker 256 carcinosarcoma in rats45 • These agents 
might be tumour specific ( e.g. for breast or prostatic cancer) and thus 
clinically useful. Steroidal alkylating agents such as phenesterin (16);6,47 
oestradiol mustards (17)48-50 and some homoaza steroid mustards (18)51 of 
52 
significant inhibit-ory activity on growth of various experimental tumours , 
are currently undergoing clinical trials. 
-9-
(17) 
./I'(J, 
H2 C CH2 I I 
H 2C CI-i2 I J 
Cl Cl 
(18) 
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53 C' Grieco !!!:. ~ reported that six-membered o(-methylene- \)-
valerolactone moiety is not necessarily less active than the five 
membered o(-methylene- ~- butyrolactone moiety. despite its larger 
ring size. Also. vernolepin (5) derivatives. which lacked the hydroxy 
groups. were slightly more active than vernolepin. The enhanced activity 
of the deoxyvelnolepins (19) and (20) may be due to improved transport across 
the cell membrane because of increased lipophilicity or to sterically 
more favourable conditions for Michael addition of L-cysteine or other 
biological nucleophiles to the oI../3-unsaturated lactone system. 
(19) (20) 
54 It is well known that certain classes of synthetic compounds • 
as well as naturally occuring substances. owe their antitumour or cytotoxic 
activity to the introduction of the diepoxide or triepoxide functionality. 
e.g. the cyclohexane diepoxide. crotoepoxide (21)55. the sesquiterpene 
18 56 dilactone diepoxide. mikanolide (22) • and the diterpene triepoxides. 
57 18 triptolide (23) and tripdiolide (24) • However. it was suggested • that 
cytotoxicity appears to be independent of the presence or absence of any 
58 
epoxy group. Lee indicated that the o(-epoxy-ketonic moiety played a more 
important role than the o(-epoxy-l( -lactonic moiety in the contribution and 
maintenance of the high level of cytotoxicity. 
?t 
o:-:FH2 0C Ph 
'-___ Ac 
(21 ) 
-11-
OH 
(22) 
(23) R = H 
(24) R =-OH 
59 ZiegleF ~~ concluded that the presence of a lipophilic, 
conjugated ester or haloester situated homoallyl1cally to the double bond 
of many naturally occuring c(-methylene-~ - butyrolactones, enhances the 
11'0. 15 t: cytotoxic actiYity. ' 
ALLERGIC CONTACT DERMATITIS 
A major class of allergens causing allergic eczematous contact dermatitis 
in humans has been shown to be sesquiterpene lactones derived from species 
of the Compositae, Lauraceae, Magnoliaceae and from a liverwo'!t Frullania 
60-69 (JubulaceaeJ. The principle immunochemical requisite for the production 
of dermatitis was shown to be an ~~methylene lactone moiety62,70-72 
A "crude allergen", a glycoside causing an occupational disorder, "tulip 
" 73 fingers", was shown to consist of glucose and o(-methylene- 0 - butyrolactone • 
62 73 
which on hydrogenation lacked allergenicity , • All the known allergenic 
lactones contain the o(-methylene moiety which may conjugate with sulphydryl 
groups of proteins in cells by a Michael-type addition to form complete 
71 
antigens capable of producing cell-mediated contact allergic reactions • 
-12-
PLANT GROWTH ACTIVITY 
Sesquiterpene lactones of different skeletal types have been 
reported to show the plant growth and antimitotic regulatory activity74-81 
Yamaki !:! !!!82 reported that the ()(-methylene-~ -lactone moiety was necessary 
(25) for the suppressive activity of hel1angine in the Avena straight growth 
(25) 
test. Also. heliangine • the major germacranolide of Helianthus 
tuberosus. inhibits elongation of Avena coleoptile sections but promotes 
the adventitious root formation of Phaseolus cuttings83 • The effects of 
(25) heliangine were shown to be countered by thiols. the inhibition of 
83A 
elongation of root formation was reduced by L-cysteine and BAL 
83B (2. 3-dimercapto-propan -1-oll • 
H 
(25) 
Several of the sesquiterpene dilactones ( specifically. vernolepin (5). 
elephantopin (7A) and elephantin (7B) were found to be strong inhibitors 
of"growth of wheat coleoptile 84 If the inhibited sections are washed and 
subsequently treated with indole-3-acetic acid. the tissues responded to 
the auxin but the degree of elongation was determined by prior treatment 
with vernolepin(5). The inhibitory effect of vernolepin was reduced when. 
administering simultaneously. the amount of auxin was increased. The fact 
that vernolepin's plant-growth inhibitory activity is reversible suggests 
that the compound may have a natural function in the regulation of plant 
growth. Similar results were observed for parthenin (26) on Phaseolus 
85 
vulgaris 86 and the crop plant. Eleusine caracana • 
~ 
-13-
(26) 
The sesquiterpene lactones were shown to inhibit lateral root growth 
but to stimulate respiration in Cucumis sativum87 • Alantolactone (27) 
was reported to be a potent inhibitor of seed germination and of seedling 
growth. It was postulated that the lactone inhibits the enzymes associated 
with the degradation of starch ( amylases) and of proteins (proteases), 
but there is no evidence to support this. It was further suggested that 
the presence of Inula and other sesquiterpene lactone-containing plants· 
88 in the agricultural plots might reduce the percentage of crop seeds. 
(27) 
MICROBIAL GROWTH-INHIBITORS 
Some sesquiterpene lactones have been shown to possess anti-bacterial, 
89 
anti-fungal or helminthic properties • The germacranolides, mikanolide (22) 
and dihydromikanolide from Mikania monagasensis inhibit the growth in 
culture of a bacteria Staphylococcus sureus and also of a yeast Candida 
albicans90 • Helenalin (8) exhibited activity against the human pathogenic 
fungi Trichophyton mentagrophytes, 2:: acriminatun 91 and Epidermophyton ~. 
Parthenin (26) was reported·to inhibit sporangial germination and 
zoospore mobility in Sclerospora graminicola but such activity against the 
conidial development of Aspergillus flavus 92 was lacking. Recently 
Vichkanova et a1 93 studied 105 natural lactones for their anti-bacterial 
-14-
and antifungal properties and reported that alantolactone (27) is active, 
particularly against Mycobacterium tuberculosis. 
CHEMOPROPHYLAXIS BY LACTONES IN SCHISTOSOMIASES 
Baker et a1 7 have recently shown that some c:(-methylene- '1-lactones 
have antischistosomal activity. The sesquiterpene o(-methylene- «- lactones, 
obtained from wood-oils of some trees, inhibit the skin penetration by 
cercariae of the trematode Schistosoma mansoni. Recently, a noval 
germacranolide,goyazensolide (28), isolated from Eremanthus goyazensis, 
was shown to have schistosomicidal properties94 • It was suggested that 
the activity of the schistosomicidal lactones me;, be related to inhibition 
of sulphydryl groups in cercarial enzymes. 
o 
11 
(28) 
VERTEERATE POISONING 
The poisoning of the live stock foraging on the bitter tasting 
95-9B plants of the Compositae has been reported • Hymenoxin (29);. the 
major sesquiterpene lactone of Hymenoxys odorata from Texas, was recently 
shown to be the toxin involved in the death of sheep97 Similar poisoning 
( vomitting disease in sheep) has been noted among sheep grazing on South 
African species of Geigeria which contain vermeerin (30)99. It was 
suggested that the sesquiterpene lactone toxicant may alter the microbial 
97 
composition of the rumen and thus affect vital metabolic functions. 
The lactone tenulin (31), a constituent of Helenium amarum, imparted a 
-15- ~ 
98 bitter taste to milk afte'r oral administration to a lactating cow 
H 
-
(29) (30) 
H 
(31) 
CARDIOTONIC ACTIVITY 
Cardiotonic steroids have been shown to possess strong cytotoxic. 
activity against human carcinoma of the nasopharnyx carried in cell culture 
(K.B.)100-103 It has been reported that the active transport of many amino 
acids is inhibited by cardenolides. possibly. because of an inter relationship 
104 between amino acid and sodium transport In as much as tumour cells are 
105 
very active in accumulating amino acids • presumably due to their high 
amino acid requirement for growth, l't is possible that the inhibit ion in 
growth of KB cells in culture by cardenolides is due to inhibition of 
amino acid accumUlation. The fact that similar structural features are 
important for inhibition of transport of sodium-potassium adenosine 
+ + triphosphatase ( Na -K ATPase), KB cytotoxicity and arterial muscle inotropic 
activity refers to the view that the receptors for the cardenolides in the 
-16-
above systems may be structurally very similar. 
In vivo tne activity of cardiotonic steroids have been correlated 
to the ability of the drug to be specific and reversible inhibitor of membrane-
bound Na+-K+ ATPase, involved in the active transport of Na+ and Kt across 
the cell membrane against. the electro chemical gradient106-119 and thus 
the inhibition of transport of many essential 
studies120-126 indicated that the~~saturated 
104 
amino acids. Extensive 
carbonyl of the lactone side 
chain is the active functional group which presumably binds to the 
hydroxyl group of phosphoric acid .residue in the phospho"ylated enzyme, 
resulting in an overall inhibition of the ATPase system 109, 125 - 127. 
128 Recently, Fullerton et ~ synthesised two cardenol1des, with the 
ct.-methylene- ~ - lactone group, from digitoxin and found that the 20 (R) 
isomer (32) in the Na+ - K+ ATPase inhibition studies, was twice as active 
as 14-dehydro-digitoxigenin, whereas the 20 (S) isomer (33) was significantly 
less active. This suggested that the cardenolide receptors are very sensitive 
to changes in geometry in the C17 side group and that the geometry may be 
i rt t th I et i f t 122,129-132 more even more mpo an an e e ron c ac ors. 
R (32) R= 
H 
(33) R= 
MODE OF ACTION OF SESQUITERPENE LACTONES. 
Although the structural requirements for the antitumour or cytotoxic 
133 
activity of some of the sesquiterpene lactones has been postulated and 
11 133 
attempts have been made to explain their mechanism of action, ' ,there 
is still a need for further studies of other structural types of sesquiterpene 
lactones. Some recent observations have focussed attention on the importance 
of the conjugated 0( -methylene lactone function for the biological activity 
of the sesquiterpene lactones. 
-17-
The reaction of ~,4-unsaturated lactones with thiols has been 
suggested to play a key role in several biological growth regulatory 
phenomena. The ability of many ()(7~-unsaturated ketones to react with 
134 
thiols and that a compound capable of reacting with thiol groups should 
produce antibacterial effects is not surprising because of the ample 
135 evidence of the widespread significance of thiol groups in living systems 
The selective growth inhibitory action of S-hexenolactone(34) on certain 
136 animal tissues was shown to be antagonised by L-cysteine, 
Spectrophotometrrc and colorimetric studies showed a direct and reversible 
reaction took place between the lactone and the thiol grouping, and it was 
proposed that S-hexenolactone exerts its effect on cellular proliferation 
mainly through its reactivity with sulphydryl groups essential to enzyme 
function. Further stUdies led to similar proposals concerning their mode 
f ti 11,137,139 o eo on. . 
(34) (35) 
The inhibition of plant growth by protoanemonin (35)~O heliangine (25),83 
and vemolepin (5) 84 is prevented by 6AL and other sulphydryl compounds and 
has been attributed to the reaction of the inhibitors with sulphydryl enzymes. 
A study of the reactions of tumour-inhibitory ()(..methylene lactones with 
model biological nucleophiles revealed that thiols were the most reactive 
of the nucleophiles investigated and the successive thiol addition to 
bis-unsaturated lactones resulted in a marked diminution in the biological 
28A properties of the adducts. The inhibition of sulphydryl· enzymes, 
286 141 phosphofunctokinase and glycogen synthetase indicated that the 
inhibition resulted from the reaction with the sulphydryl groups of the enzyme. 
-1B-
The electrophilicity of the tumour inhibitory quinone methides 
taxodone (36J and taxodione (37J 142, 143 and their inhibition of 
phosphofructokinase upon reaction with selected sulphydryl groups 
suggested that these compounds may also act by alkylation of biologically 
2B important macromolecular thiols. As the active lactones are all 
alkylating agents, their biological effect is probably due to an in vivo 
modification of nucleophilic groups either of proteins ( including enzymesJ 
or of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)145. 
(36) 
Hall ~~, 146 in an attempt to propose a mechanism of inhibition 
of cancer growth, demonstrated that helenalin (B) and tecrulin (31)do not 
alkyl ate nucleophiles of purine bases but rather appear to be reactive with 
thiols of enzymes necessary for DNA replication, whereas the accepted 
mechanism of action of anti tumour agents, e.g., nitrogen mustards, is the 
alkylation at the N7 nucleophile of gUanosine and, to a lesser extent, the 
N1 and N3 position of adenosine44 • Furthermore, they cause an increase in 
cyclic adenosine monophosphate r~AMP) levels of tumour cells which may be 
correlated with the suppression of chromatin protein phospho.rylation 
necessary for cell replication and differentiation. 
-19-
Jatrophone (38)147, a novel macrocyclic tumour inbibitox 
reacts rapidly with simple thiols and with the macromolecular thiol, 
bovine serum albumin, and inhibits DNA-dependent-RNA plymerase from Escherichia 
148 coli with concurrent partial loss of enzyme sulphydryl groups. 
Triptolide (23) and tripdiolide (24)57 may mimic the inhibition of 
tumour growth via selective alkylation of thiols of key enzymes concerned 
with growth regulation. 149 
The presence of a free conjugated ~-methylene lactone systems 
appears to be directly related to the cytotoxicity of sesquiterpene 
lactones. Modification of the unsaturated system results in diminution 
in cytotoxicity. The reaction of the o(-methylene lactone system occurs 
by "Michael-type addition" with nucleophilic reagents such as the 
sulphydryl groups of cysteine. 28 ,72 (SCHEME 1) 
"''', 
(38) 
xr ~ ; 
S 
H3~~ + H3N 
00 00 
SCHEME I 
-20-
SYNTHESIS OF «-METHYLENE-LACTONES. 
150 Since the early work of Jones. considerable efforts to develop 
efficient and versatile synthesis of ()(-methylene- ~ - and S-lactones 
have been in progress due in large part to the intense interest in 
i 1 t 11.16.19.73.83.151.152 naturally occuring cytotoxic sesqu terpene ac ones. 
The general methods for the preparation of el-methylene lactones. up to 
153 154 1975. have been extensively reviewed by Grieco and GammiU • 
150 155' In a further extension of Jones reaction. Norton !l"and 
co-workers have achieved a high yield conversion of trans-2-ethynyl-
cyclohexanol (39) to trans butyrolactone (40). 
H 
Cbll", S 11 H o 
93. 
(39) 
Due to the importance of ~-fused o(-methylene 
97 99 
• the trans-2-ethynyl cyclohexanol (39) was 
and (42) to give the cis-fused O(-methylene lactone. 
o:o~ 156 Ether/Na2Cr207 
H2O/H2S04 
) 
C=CH 
(3cj 
CO J PdCI2 
~o) 
1 t 15.17.82.83. ac ones. 
converted via (41) 
(43) 155§ 
ex C=:CH 
(41) 
L- Selectrlde 1 157 
O:0H 
( 
H H2NCSNHiAcetone C=CH 
~3) ~2) 
-21-
A new facile procedure for the efficient preparation of a number 
of o/.-alkylidene- ~- butyro.lactones (48J and If; p. -butenol1des (49) 
from the readily available ~-lactone (44) was reported158 which is 
comparable ( intermediates (45) and (46J to the procedure of reductive-
159 160 
amination • of oI.-fClI'myl lactones. Application of the reductive-
amination procedure to the S-lactone (SO) resulted in a 42% yield of 
the o/.-methylene-S-lactone (51). 
) H 0':0 
(51) 
-22-
Silver perchlorate-catalysed rearrangement of the methyl ether or 
bromide (52) afforded the o(-methylene-lactone (43). The method is 
analogous to the novel acid and metal ion promoted rearrangements 
of functionally substituted cyclopropanes (53) in the synthesis of 
o(-methylene- ~- butyrolactone (55)161. 
AgCl4J C6 H6 • 40° I 
Ihr 
(52) (R=CH20CH3 orCH2 Br) ~3) 
ZnBri4B%HBr 
1000 ) 
OH C):OOR 
/I 
(53) (54) 
0=0 
11 
(55) 
162 Danishefsky has reported a method ( Scheme 2) whereby suitably 
ti 1 (56) 163-165 can b· t t" 1 t (59) ac vated cyc Opl"opanes e convel" ed in 0 0- ac ones 
with base. 
~ Pi I~L. X !-!p-AClztone(I:2) I~~}~ 
V lr° ) Ho:9-l~ 
(57) 
(56) COOH 
(58) IXCOOH 
+ 
-23-
(57) 
SCHEME 2 
2ieglet 66 has recently reported a site-selective sol volysis of 
a cyclopropylcarbinyl methane sulphonate(61)resulting in the 
o!-methylene lactones (62 and 63). Apparently, cleavage of bond a 
is favoured over bond b due to better overlap with the lactone 
carbonyl during solvolysis. 
H 
MsCI/Et3N 
CH2CI2 
(60) 
(62) 
) 
HOACI! 
Na.QA.c 
(61) 
(63) 
Ms 
-24-
A direct and extremely efficient application of the Wittig 
32 167 
reaction' between formaldehyde and the ylidJ-butyrolactonylidene-
triphenylphosphorane (64), afforded o(-methylene- '! - butyrolactone (55). 
. 168 The Wittig reaction between the ylid and aldehydes to obtainQ{-benzyl~dene-
and o(..-(2-furfurylidene) - ~ - lactone169 derivatives has been reported. 
Minami~~ 170 reported that, in the reaction between o(-phosphono-)(-
butyrolactone carbanion and various carbonyls, the use of aldehydes with 
bulky groups gave only trans C'(-ylididene- 1- butyrolactone whereas a 
mixture of cis -and trans-o(- ylididenes were obtained when aldehydes had 
rather small groups. 
(HCHOh /THF 
N 100% 
(55) 
171 Dehydration over ~lumina of oI.-hydroxymethyl-S-valerolactone (67). 
obtained from S-valerolactcne (65) ~ c(-hydroxymethylene-S-valerolactone 
(66), gave the oL-methylene-S- valerolactone (68). The use of isocyanates 
and carbodimides as in ~ dehydrating agents 172-174 was reported to 
be an improved mild procedure. The insolubility of dicyclohexylurea 
assures that the reaction is driven to completion. 
~) NaHI HCOOEt/Ether V 2)H3 0 + > 
(65) 
0-::::-0 ~ 
(68) 
• 
-25-
A similar dehydration of (69) with triphenylphosphite methiodide (70) 
has been effected in a quantitative yield175 It is presumed that this 
reagent forms the P-iodolactone (71) which undergoes elimination to 
afford the o(.-methylene-l- lactone(72l. 
Ph~ 
o 
\72) 
+ -(Ph'O)3 P Me I (70) 
) 
DMF/ r,t./20hrs 
r -, 
~~ 
o 
171 . 176 In a modification of McGraw's method, Minato and HOr1be 
converted a trans-fused lactone (73) into a trans-fused IX-methylene -'( -
butyrolactone (40, 45-50%). 
H 
~ltll~ 
~==o 
H 
(73) 
1-1 
-26-
NaH/HCOOEt ) 
Ether 
Gi'" I) TsCI/ Pyndlne _ =0 2) Pyrldlne A I 
(40) 
1-1 
(74) H ~HOI-l 
j NaB'"\,! M,OH 
H 
(75) 
The above reduction-elimination procedure has been applied to the total 
171 177 
synthesis of sesquiterpene lactones, iso alantolactone (76) , , 
178 179 180 
carabrone (77) ,(+) damsin (10) and ( + ) -4-deoxydamsin (78) • 
1-1 
(10) (78) 
-27-
A potentially general and useful route for ~-methylene lactone 
181 v 
construction was demonstrated .when o(-carboxy-p-phenyl- 0- butyrolactone 
(79), derived from diethylmalonate and styreneoxide, reacted with form-
aldehyde and diethylamine affording the Mannich product (80) which was 
converted into the o(-methylene lactone (81) ~ base-catalysed elimination 
of tertiary amine from quarternary ammonium salt. Recently. isotelekin (8~~2 
a sesquiterpene lactone, has been prepared employing a complementary 
183 184 
synthetic route from the methoxy-carbonylated lactone (83) • 
HO'''' 
(82) (83) 
An alternative set of conditions and reagents have been offered to 
185 186 
effect the same decarboxylative-elimination ' where methylmethoxy-
187 
magnesium carbonate (MMC) ,as a carboxylating agent, is employed, 
Extension of the above work provided total synthesis of ( dl) -
avenaciolide (85)188 • ( dl)- protolichesterinic acid (86)189 and 
[ + ) -4-isoavenaciolide [87)190, Unfortunately. the use of Stiles 
-28-
reagent (MMC) is limited, as compounds (88) and (89) either failed 
to carboxylate or provided limited amounts of unstable carboxylic acids 
which could not be converted to unsaturated lactonic material. 
HO 
(84) 85) 
~13H27 Htr 
HOOC . 
191 192a Diethyl- and dimethyl-carbonate have been employed for 
carboethoxylation and carbomethoxylation of lactones respectively. 
The resultant products, o(-carboxyesters, can be converted into o(-methylene-
lactones employing the above procedure. Synthesis of ~fo_butenolides 192b 
employing diethylcarbonate and the total synthesis of {+) isotelekin (82) 
182 and Confertin (90)192 utilising dimethyl carbonate have been reported. 
-29-
An efficient <X-carboxylation of lactones (91) permitting a direct 
194 synthesis of an o(-methylene lactone (93) has been reported. 
(92) (93) 
The use of Meldrum's acid, ( cyc~ic isopropylidene ester of 
195 
malonic acid) (95) has been reported, to give the c(-carboxy-t -
lactone (97) via an intermediate (96) and hence led to the ~-methylene-t -
lactone (98). 
0 
+{:< TiCI4/THF PyrldlOIZ ) 
0 
(94) (95) (96) 
IH2S04 COOl-I 
I) HCHO/HNEt2 
( 
2) NaOAc /HOAc 
(98) 
-30-
o(-Carboxy-~-lactones. obtained via the opening of epoxides with 
v 196 
sodium diethylmalonate. have been converted into Ol-methylene - 0- lactones • 
197 Recently. the use of Eschenmoser's salt ( dimethyl (methylene) 
ammonium iodide) (100)198 proved to be an excellent method for introducing 
199 the dimethylaminomethylene group which can be converted into an 
o(-methylene moiety ( Scheme 3). 
Y = AlKYl ,AII<OXY 
(99) 
o 
11 
R-C-C-Y 
11 
CH2 
U03) 
I) LDA Or KH 
+ 
2) CH2=.NMe2 I 
(lOO) 
e 
?i 
R-CH-C-Y 
1 
CH2-NMe2 
000 
1 Me! 
~ 
R-CH-C-Y 
I + 
CH2-NMe31 
~02) 
The introduction of the o(-methylene lactone moiety in vemolepin (5) 
200 
and vernomenin (6) employing the Eschenmoser salt (100) has been reported 
The reaction of Eschenmoser's salt (100) directly with silyl enol 200 et hers 
201 202 
and enol borinates contributes to the synthetic utility of the reaction 
where the regiospecific generation of ester enolates is not possible. 
203 This approach is analogous to carbanion trapping with formaldehyde 
204 
which has been recently applied to regiospecifically generated anions • 
205 A synthetic sequence has been reported that permits construction 
of the cis-fused o(-methylene lactones from the corresponding ((-methyl lactones. 
available either 
10 
from natural or 
206-9 
via direct methylation of lactone enolates derived 
210 
synthetic lactones. Thus the O{-methyl lactone (104) 
is converted via (105) into (43). 
-31-
) 
H 
qj: 
(105) 
(j 
1 DBN/TO/tjlZne Rczfi \J x 
qr 
(43) 
The product of ~-elimination, the endocycl1c olefin, (108) was 
detected in small quantity, whereas the ~bromo-trans-Iactone (107) gave 
exclusively, the endocyclic lactone (108), under a variety of elimination 
conditions. 211 
H 
~ __ =""""II~,:<,=O I) Ph3CliiDME 
H 1-1 2) BrCH2CH2.13r 
H 
:. 1"( 
- • '1(1 
H Br 
(106) (/07) 1 D8N/ Toluene Reflux 
H 
di~ 
(lOB) 
-32-
The utility of this general procedure was demonstrated in the 
synthesis of (+) - frullanolide (110), an allergenically active 
212 
sesquiterpene lactone, from 1,2-dihydro-6-ep1santon1n (109) • 
) 
(109) (110) 
In a recently reported method213 the required functionality is 
introduced at an early stage by the addition of an ap~ropriately sub-
stitufed" ketone and olefin to give the exohalogeno cyclobutanene (111), 
," " 
214 preferentially ,which on Baeyer-Villiger oxidation gave the ~-lactone 
(112)215. 
) 
-----"7' t( 
(I r r ) (112) (55) 
A complementary procedure for the construction of trans-fused 
o(i:methylene-"l! - butyiolactones, based on a pYro1ytic (c1s) elimination, 
has been demonstrated 211,216 in the synthesis of t~) arbusculin B (115) but 
a mixture of endo-and exocyclic lactones was obtained. 
-------- ----
-33-
• 
-l 2) (PhCOO)2/DME 
(113) 
(115) 
Direct OC-hydroxymethylation of lactone enolates followed by 
successive mesylation and heating in pyridine under reflux gave the 
203a 
o(-methylene lactone in high yield and is exemplified by the 
conversion of the lactone (73) through the mesylate (116) to the 
o{-methylenelactone (40), 
H H 
LDA/(CH20h d~ THF, -780 
= .!7z, H HH CH20H 
(3) (75) 
~ 
C Ph 
1 MsCI/ Pyr,dlne 
H H 
cb= 11 H H f\ -
(4q) 
H CH20Ms 
0 016) li 
Ms= CH3~S~' 
~ 
--- ----- ----,-------------------------------------------------
-34-
The utility of the above sequence has been demonstrated in the 
studies directed towards the synthesis of vernolepin (5) 13,217. 
Since the isolation and structural elucidation of vernolepin (5) 
and vernomenin (6), a substantial amount of research 200,203, 217-221 
has been performed aimed at the synthesis of these novel elemanolide 
200 218 D,E dilactones. This has recently resulted in their total synthesis' , 
218 F 222 in the synthesis of deoxyvernolepin (20) and £!.-yomogin (117) 
A sulphur analogue (121) of tU_Iipalin A (55) was recently 
223 
reported ,employing the above sequence. 
6 
(118) 
~ 
(121) 
o 
11 
Ms-=. CH3-S-
11 
o 
(120) 
Recently a synthetic scheme224 was reported in which the crucial step 
225 is a base-catalysed intra-molecular Michael-type cyclisation of the 
enone-malonate (122) to produce a cis- fused A-ring in vernolepin (5) and 
vernomenin (6). 
-35-
o-l-() ~./'...~ '-
. bOOEt 
.VernOlepln (5) 
~~ 
Vernomentn(6 ) 
022) Q23) 
. 
The fact that alkylation of a thioether, formed via a Michael-
type addition, gives a sulphonium salt which on mild base treatment, 
generates the ~methylene group, suggests a nJvel route to ~methylene 
181A. 226 227 J lactones . • This sequence is illustrated . on the <A:"carboxylactone 
(124) giving rise to the ~methylene-~;" lactone (40) through the thioether 
(126) and the sulphonium salt (127) intermediates. 
H 
(124) 
H 
1-1 
(127) 
1 
H 
H 
(40) 
eo OH 
( 
lXylene, Reflux 
H 
-- ------------------------------------------------------------------------
-36-
228 A similar method involving alkylation of ketone and carboxylate 
enolates (128) with bromomethyl sulphide. followed by sulphoxide 
elimination. gives \X-methylene ketone and acid (130.) However. ester 
and lactone enolates are not alkylated in useful yields. 
(128) 
o LDA (2 Equlv.) 
) 
(129) 
(130) 
11) Nal04 2) Heat 1200 
o 
/I 
Bis (phenylthio) methyl lithium ( ( PhS)2 CH Li) and methoxy-
. phenylthiomethyll1thium ( PhS .... ~~e Li) may be used to provide a 
convenient method for conversion of the readily available ~ -butyrolactones 
into ()( -alkoxy-or i;>(-methylene-. t - lactones229 • A nitrogen species 
l e.g. piperidino) may be used instead of sulphur. as p-aminolactones 
undergo facile elimination with generation ofO(-methylene unit. 227 
A similar. high Yield" o(-methylenation sequence" employing 
206 
"alkylphenylselenoxides" has been developed in which selenoxides 
undergo facile elimination at low temperature with exclusive formation of 
exocyclic olefin. 
-37-
H H 
ct:r , ctJ= :: ,$''''' H HH 
(73) (06) J 
H H 
<: d:r S'll/ 1/ :: 1111/1 
H Se=O H Se 
.- ..-
Ph (131) Ph 132) J H 
The formation of (40), with the oomplete exolusion of the endocyolio 
isomer (108) comes about as a result of stereospeoific alkylation of 
the enolate of the lactone (106) with diphenyl-diselenide, whioh 
establishes the required ~- relationship between the o(-phenyl seleno-
substituent and the adjacent methine proton. 
230 The usefulness of the above seQuenoe was demonstrated for 
the transformation of ~-santonin (1) into tuberiferene (133Af 31 
arteoalin (1333PO, anglanine C1341\f32 and santamsx>ine (134B) 232 
Y" 
~ ~ 
1111, H 
-
(I) U33A) 
H 
(1338) 
-38-
OH 
(1348) 
Recently a similar" o(-phenylselenation sequence" has been 
233 
reported in which an epoxide is opened with 2-phenylseleno-propanoic 
acid (135), giving rise to the Q(-methylene- 't-lactone (43) via the 
elimination of phenylselenoxide(138). 
2LDA > 
Q35) 
~38) 
1 
err H 
(43) 
234 A complementary "c(-methylenation sequence" utilises (43) the 
ability of oc-phenylsulphinyl ketones to undergo facile thermal ~-
elimination where the ~-phenylsulphinyl substituent and the adjacent 
methine proton possesses an anti-relationship ( 139- 140), as is 
235 illustrated by the conversion of ( 141) into (40) • 
-39-
t! 
:: 0 ~ H;r--v"=o ~III 
. H SPh 
~39) 
H 
H 
.4 
(40) 
H 
) 
SPh 
(141) 
1 
H 
(42) 
The successful application of the above method to the cis-fused 
lactone (143) was dependent upon the proper stereochemical relationship 
between the~-phenylsulphinyl substituent and the adjacent methine 
proton. 
(143) 
H H 
< 
(43) 
H 
~Q44) 
H ;:"'SPh f---
H 
tl 
.W"SPh 
H H 045) 
H 
PI1-S 
(146) 
- -- - ----- - -------------------------
-40-
In an elegant synthesis of [ dl ) - avenaciolide (85), 
236 Schlessinger has employed a "sulphoxide" sequence to obtain 
an ~methylene function. The stsreoelectronic factors governing 
the cl-sulphoxide elimination are analogous to those in the selenoxide 
206,234 
cases. 
I) mCPBA 
( 
2) SuccInIc 
anhydrIde 1400 
R 3) HCI 
(85) 
(149) 
I) P Toluene 
sulphonIc acrd/C6H6 
2) NaHC0:3 
H3C 
H 
R 
(150) 
237 Trost and·Leung has reported a procedure in which opening of 
an epoxide with 2- (thiophenyl)-propionic acid} (151) leads to 
cX-methylene- '6 - lactone (40) via intermediates ( 152 - 154). 
--------------------------- - - - - - -
-41-
PhS-C-COO 
I 
CH3 
(151) 
) 
OOMe 
(MeobP/THF 
( 
COOH 
SPh 
SPh 
+ 
o Q54) 
C6H6 j P_ Toluene 
sulphoOlc aCId 
(153) 
H 
(40) 
Recently. a total synthesis of 4-isoavenaciolide (87) in high 
yield. has been reported. in which the key step is the conjugate 
addition of t.he latent carbonyl anion (155) to the butenolide (14B). 
> 
R 0 0 
ij 5 8) 
EtOxCOOEt 
EtO \ 
R-Q~ 
(156) 1 Perc~lorlc aCId) 
lOO} 48 hrs 
~OOHH R~~ 
Q57) 
- -------
-42-
) 
Q59) 
An efficient route 186. 238. 239 has 
treatment of the o(-(bromomethyl) acrylic 
) 
been reported involving 
240 
ester (160) with zinc 
(Reformatsky Reaction) to form organozinc intermediates that react 
with a variety of aldehydes and ketones to provide cl. -methylene-~ -
lactones (162). 
• RI 
Br~CH2-C-COOR "'- ZnLTHE~ R'1J= + C=O . 11 RII/' RIi CH2 
Q6Q) (161 ) (162) 
The observation that P -ketoesters. ~ -ketoaldehydes and 
f; -diketones are reduced. ~ their enolates. to allyl1c alcohols by 
lithium aluminium hydride ( LiAl.H4) led to the use of the malonic 
ester derivatives (163) in the synthesis of the C>(-methylenelactone (40t41 
H 
COOEt 
(163) 
H 
(40) 
-43-
\) NaH/THF/Ether 
2) LIAIH4 
, 
DCC I Pyrlcilne 
( 
H 
co OH 
1-1 
Similar treatment of the eis-methylene diol (166) with activated 
manganese dioxide afforded the cis-lactone (43) presumably via 
oxidation of the intermediate lactol (167). 
(166) 
H 
167) 
1 
H 
-44-
The above described reductive-elimination method 242,243 was applied 
to the synthesis of ~-alantolactone (27) and a trans~used o(-methylene-
244 lactone (168) • Analogous to the above described procedure is the 
preferential oxidation of allylic alcohol of diol (169), by silver 
carbonate, to the carboxylic acid, with subsequent formation of 
the lactone (55) 245 • 
~H VH 
(169) 
) 
(55) 
246 The observation, that primary acids when treated with lead (IV) 
acetate in the presence of copper (II) acetate, undergo oxidative 
247A 2476 decarboxylation, resulted in Rao and Ho independently developing 
a route to the O<:-methylene lactones (171) from the lactonic acid (170). 
COOH Cu 2+ 
(170) 
Interest in the o(-methylene-S-lactones has resulted in a new 
248 facile synthesis involving alkylation of enamines (1Z2) with 
methylo(-bromomethyl acrylate (173)249 to form unsaturated keto esters (174) 
that can easily be converted into o(-methylene-S-lactones (175) via 
saponification, reduction and lactonisation. 
- - --- ._-----------------------
(172) 
·-45-
H C 0 2!1 11 
BrCI-2- C-C- oMei'173) 
> 
2 
/(74) 
250 In an elegant use of a cycloaddition reaction, Eschenmoser 
developed an excellent rElute to ~- o(-methylene- ¥ - butyrolactones 
starting with simple olefins. Treatment of an 0( -chloronitrone (176) 
with silver tetrafluoroborate ( Ag BF4) yields an extremely powerful 
enophile (177) which undergoes a smooth 1,4-cycloaddition with 
unactivated olefin (178) and the resulting species has been subjected 
to a variety of transformations including conversion to ~-lactones and 
to ()(-methylene- t - lactones (scheme 4' ). 
R 
Cl 
R 
(176) ~77) 
-
BF4 
KCN dJD 
R f 
CH2-X 
(179) 
---------------------------------------------------~--------- -- - -
X=CI 
R=H 
(43) 
-46-
X=H 
R=H 
SCHEME 4 
A further efficient method for ()(-methylene lactones, 
involving formation of an ethoxyoxalyl derivative (183) and reaction 
with an aldehyde to give a diketolactone (184) followed by base 
251 
cleavage to yield the unsaturated product (55) has been reported ~ 
---~) ~COOEt 
11 
HCHO 1 0 (183) U82) 
er ( 
(55) 
252 Recently, a method has been introduced in which methallyl 
alcohol dianion (186) addition to aldehydes and ketones yields allylic 
diols (187) that can subsequently be oxidised by activated manganese 
dioxide 2~3 to t:<-methylene- t - lactone (162) via the presumed hemiacetal 
intermediate ( 188 - 189), 
(185) 
R~ ~HO R~H\C 
Q88) 
r 
R~ It 
I?Y--O)-oH 
(189) 
-47-
Mn O 2 
Eo 
) 
fiH2 
CH2-C-CH;p 
(186) RI, 
. j I Fil/C=O 
2 H;P 
R' ~ 
",/\CH 20H R~H' 
(187) 
253 254 Analogous to the above scheme, Carlson ' introduced 
a direct method which employs itaconic acid anion (194) instead of 
meth9llyl alcohol dianion (186) to obtain o(-methylene lactones. 
Itaconic acid anion (194), a derivative of methylacrylic acid dianion 
(1921, is a structural equivalent of methallyl alcohol dianion (186) 
(Scheme 5) 
CH2 11 
CI-:,-C- COOH 
(100) 
CH2 
11 
CH 2-C- CH20 
(186) 
o CH2 
I \1 - il 2 
R OC- CH- C-COOR 
) 
~(4) 
SCHEME 5 
CH2 
11 -
CH3-C-COO 
(191) 
CH2 
I I -
CH2-C-COO 
([92) 
-48-
Since the presence of a lipophilic, conjugated ester side-chain 
located homoallyl1cally to CX'-methylene-if - butyrolactone contributes to 
t i ti it 110,15C, 59 oxygenated the enhancement of, the cyto ox c ac v y, 
o(-methylene-~-lactones have been synthesised21~ 
rI H 
W ) 
H HO 
(195) (191) / 
H H 
( \15= 
H 
HO RO 
U98) (197) 
The need to effect protection of an OC-methylene' function involving 
the synthesis of complex molecules possessing o(-methylene moiety has 
led to a search for mild and potentially useful new blocking sequence, 
Kupchan 20 , 228 required a method for protecting o(-methylene unit conjugated 
with both ¥- and -S-lactones in order to determine the reqUirements for 
biological activity among derivatives of vernolepin (5), The protecting 
reagents employed included diethylamine 255, thiols 136,142 propan-1-
252 28A thiol ,cysteine ' 
257 thiophenoxide anion , 
142, 181) h I I i 256 
, P eny se enium an on and 
The regeneration of the ~-methylene function involves the conversion 
of the diethylamino adduct and thio-ether into their methiodides and 
subsequent treatment with either saturated sodium hydrogen carbonate 2550 
142 255B 256 
or pyrolysis ' ,Grieco's approach employs a Michael-type 
addition of phenylselenium anion to the ~-methylenelactone (40),and a 
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"retro-Michael" reaction ~ the corresponding selenoxide (200) 
which re-established the oLmethylene function. 
H 
(40) 
H 
d''''''= ti 
(40) 
H 
) 
~H ~CH2SePh 
1 
( 
258 259 The above method is based on the observation • that alkyl-
phenylselenoxides readily undergo elimination to give olefins. 
Th hi i 257,258 i 1 t e t ophenoxide an on is s mi arly elimina ed. 
Since the observation that the anti tumour activity of sesquiterpene 
Cl{ -methylenelactones is due to the ()(, P -unsaturated lactone system with 
an exocyclic methylene unit S,11,18,19,133, it was decided to synthesise 
steroidal c{-methylene lactones and evaluate their anti tumour activity. 
Lipophilicity appeared to enhance the cytotoxic activity of sesquiterpene 
w 11D, 15C,59 V'-methylenelactonss and as steroids are more lipophilic than 
sesquiterpenes, it was thought that this, in conjunction with ~methylene-
lactones moiety, would lead to important cytotoxic compounds. The 
distribution of these compounds should present very little difficult 
since steroids are present in the body as steroidal hormones. 
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The fact that steroid hormones function through the recognisation 
of the receptor, at the active site, in the target tissue, this would 
appear to suggest that the synthetic steroidal ~methylenelactones 
may function in an analogous manner. 
When the project was undertaken, there was no evidence of 
steroidal D<-methylenelactones in the literature, but in the 
duration of the project, there appeared a pubUcation describing 
45 the synthesis of steroidal C<-methylenelactones with anti tumour 
activity. The main aim of the project undertaken was to synthesise 
steroids containing an ~-methylenelactone system as a part of the 
normal ring system of the steroid. 
DISCUSSION 
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Peracid oxidation of ~,~-unsaturated ketones, may, lead to enol 
260 
esters, epoxy esters and epoxy ketones. However, peracid oxidation 
of tJ. 4-3-ketostero'ids may result in an even larger variety of products, 
depending on the peracid being used. Thus, potassium persulphate 
. 261-264 
and sulphuric ac~d furnished 3-keto-4-oxa-9x-steroids , 
whereas, perbenzoic acid containing perchloric acid in chloroform 
was reported to yield a mixture of enol-lactones and epoxylactones265 
Recently, rearranged products, the ~-aldehydo-3-keto-4-oxa-derivatives, 
were obtained when ~4-3-keto-steroids were treated with trifluoroperacetic 
id266 ac • 
267-282 Although there are many methods for the preparation of lactones, 
the literature methods were employed in the synthesis of the steroidal 
lactones. Oppenauer oxidation 283 of cholesterol (201) gave 
cholest-4-en-3-one (202, 70%) which under the conditions of 
264 Baryer-Villiger oxidation produced 3-oxo-4-oxa-5~-cholestane (203) 
in 40% yield. 
) 
H 
(200 (202) 
(203) 
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Once the formation of the lactone was successfully carried 
out, then the procedures for the synthesis of "t:(-methylene" structural 
unit on the preformed lactone were sought. 195 The "o<-carboxylation" 
sequence was optimised with ~-methyl- t- butrolactone [204) and the 
presence of an <X-carboxylic acid lactone (205) was indicated by the 
presence of a polar spot on T.L.C. and by the infra-red spectrum 
v max, 3600-3200 cm-1 [-OH), 1780 cm-1 [¥-lactone C=O) and 1740 cm- 1 
[Co'O) ). The appearance of a 020-exchangeable peak at 1.77 [ S, IH) 
in the 1H n.m.r. spectrum was also indicative of the acidic proton. 
LDA/THF ) ;:;):v0H 
(204) (205) 
Application of this "o<-carboxylation" procedure to 3-oxo-4-oxa-
5~-cholestane [203) was unsuccessful, despite several attempts. It was 
thought that the ~carboxylated lactone formed was so unstable that it 
reverted to the starting lactone [203) during the workup, even though 
the reaction mixture was acidified with cold dilute hydrochloric acid 
and extracted with cold ether. 
Many carboxylic acids can be successfully decarboxylated, either, as the 
284 free acid or in the salt form, but not simple fatty acids The 
decarboxylation of ~-keto acids is well known 285 and is known to proceed 
286 by a cyclic, six-centre transition state [207) leading to the enol 
form [208) which undergoes ta~tomerism to the stable keto-product [209). 
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R-C-CH2-COOH g > 
(206) 
R-C-CH-
11 .j 
( + 
o 
(209) 
Assuming the reaction with lactone (203) proceeded as expected, then 
it must be concluded that the carboxylic acid lactone (210) is particularly 
unstable. However, it is possible that the carboxylation step did not 
take place. Although there was no direct evidence, the instability of 
the 2-formyl derivative (222) supports the former possibility. 
HOOC 
) 
(203) (210) 
The rate of carbo~ylation is dependent upon the rate of formation 
of the enolate anion (211). The "stereoelectronic effect" results in 
th f ti 1 10 f th axial proton 287,288 e pre eren a ss 0 e This may be 
envisaged as arising from the possibility of overlap of the carbonyl 
'iI -orbital with the axial <r-bonding orbital (212), while no such 
overlap is possible with the equatorial ,,--bonding orbital, which lies 
near the nodal plane of the carbonyl it -orbital (213). 
----~-----------------------------------------
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(203) (21 I) I 
o 
1-1 
(212) (213) 
Orbital overlap in the transition state permits maximum electron 
delocalisation and a smooth transition from carbonyl "-bonding to the 
enolic structure with C=C lI-bonding or in the base of the enolate 
anion. three centre ,,-bonding embracing the IC == C ~~ system. 
Ringold289 confirmed the operation of stereoelectronic control by 
revealing strong preferences for the loss of the 2p and Sp-protons during 
enolisation of 3-keto- and 7-keto-steroids respectively. 
The electrophilic species. carbon dioxide. must approach in the plane 
of the TI -obrital in order to secure maximum bonding in the reacting complex. 
probably resulting in the formation of 2 ~-carboxylic acid lactone (214) 
by analogy with 2 ~-bromination of 3-oxo-steroids. 
-------------------------------------------------------------_. " 
--------------------------------------------------------------------.----
H 
HOOC,,", 
:: 
H 
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H 
(214) 
Similar kinetically controlled bromination of the enol-acetate (215) 
290 
was found to give the 2~-bromo-3-keto-product (216) • 
H 
Br ",1/11 
8r2 (Bu ft er) 
·AeO ) 
j:j 
(215) (216) 
Also thsse results appear to contravene the principle that 
-H 
stereoelectronic control leads to the 2p-axial product, it was established 
that the stereoelectronic preference for axial attack is fulfilled by 
the molecular adopting a ring A boat or flexible conformation (218) 
during attack by bromine. Reversion of the chair conformation (219) 
leads to the bromine becoming equatorial. 
H ---- -- ---
-- --
Br-c.Br (217) 
(219) 
) 
H 
/ 
Br (218) 
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Initial ~-bromination is a consequence of steric hinderance to 
~-face attack up the enol due to the shielding effect of the C19-
methyl group, thus preventing perpendicular approach of bromine to the 
p-face of the double bond as required for maximum bonding. The ~-face, 
however, is unhindered and permits approach of bromine to the ~-lobe 
of the "-orbital of the double bond, although, as indicated, this 
requires ring A to adopt a boat-like conformation. 
Carbon dioxide, being a larger reacting species, SUffers 
considerably more 1,3-diaxial hinderance than bromine in the axial 
position. The above stated steric and conformational factors, operating 
in bromination of 3-keto-steroids, may also be oparating in the 
carboxylation step and thus contribute towards this instability of 
the carboxy-lactone (210) or the difficulty in preparing this compound. 
291 . The"OI'-hydroxymethylenation" of ~-cholestan-3-one (220)with 
ethyl formate and sodium ethoxide gave 2-hydroxy methylene-5~-cholestan-3-
one ( 221, 67%) as was indicated by a polar spot on TLC by the infra-
red spectrum ("i) max, 3600 - 3100 cm-1 (OH), 1562 cm- j iJx,p-unsaturated 
p-flydroxy ketone) and the U.V spectrum ((I max 283 nm (E 16,837) J. 
H 
(220) 
NaOEt 
) 
HCOOEt 
H 
(221) 
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The above O(-formylation reaction, was attempted with 3-oxo-4-oxa-
5~-cholestane (203) under the same conditions but was unsuccessful. 
160 The modification of the procedure of Yamada et al was 
performed on 3-oxo-4-oxa-~-cholestane (203), employing sodium 
I 
hydride, a stronger base, instead of sodium ethoxide. The reaction 
160 
was not terminated after twelve hours, as stated, but continued 
until there was no starting lactone(203) observed on T.L.C., requiring 
approximately 90 hours for completion. The formation of 2-hydroxy methylene 
-3-oxo-4-oxa-5~-cholestane [222, 84%) was indicated by a polar spot on 
T.L.C, by the infra-red spectrum ('V max, 3600-2400 cm-1 (OH), 1715 cm- 1 
-1 [C=O) and 1620 cm ' (C=C) and the, UV spectrum (t. max 251nm (10 6.95 x 10 3)). 
The 'H n.m.r. spectrum displayed signals at 'C2.82,'and "C 2.2(bs, 1H, l - and 
s - HO-Ct!. = C - ). [See Experimental P 130 and 131). 
(203) 
NaH/Ether 
HCOOEt 
• 
(222) 
The 2-hydroxymethylene lactone (222) was not very stable as it 
reverte'CI to the starting lactone (203) even on standing at -20oC. In 
the subsequent reactions, the 2-hydroxymethylene-lactone [222) was 
used directly with purification. 
The 2-hydroxy methylene-3-oxo-4-oxa-5~-chQlestane (222) was heated 
under reflex for 80 hours ( the dispppearance of the starting material [222) 
was followed by T.L.C) with diethylamine in benzene to obtain 2-(N,N-
diethyl amino)-methylene-3-oxo-4-oxa-~-cholestane (223, 90%). 
The formation of the diethylamino adduct [223) was indicated by the infra-
red spectrum (,) max. 1675 cm-1 [CcO] and 1560 cm-1 [C=C)) and 
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the U.V. spectrum (i\max 301nm (E 2.84 x 104 ) ). The 'H n.m.r. displayed 
signals at L 2.82 and ~ 2.30 (bs. 1H. Z - and ~-Et-N C~ = C -)(See P 131'and 13~ 
The diethylamino adduct (223) was hydrogenated in glacial 
acetic acid using platinum oxide catalyst to give the saturated 
product. 2-(N.N-diethylamino) methyl-3-oxo-4-oxa-5x-cholestane (224) 
which. without purification. was treated with sodium acetate in glacial 
acetic acid to yield the ~-methylene-lactone. 2-methylene-3-oxo-4-oxa-~-
cholestane ( 225. 58% overall). It was shown by T.L.C. that during 
the hydrogenation step some of the saturated amino product (224) 
undergoes elimination to form the ~-methylene lactone (225). However. 
it was necessary to heat. under reflux. the diethylamino adduct (224) 
with sodium acetate in glacial acetic acid for four hours to complete 
the elimination (Scheme 5). 
OH 
I 
H '-..:::::-,/ 
H 
(222) 
(225) 
, 
(223) 
j 
H 
(224) 
SCHEME 5 
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The formation of 2-methylene-3-oxo-4-oxa-5x-cholestane (225) 
was indicated by the infra-red spectrum (v max. 1725 cm-1 [CoO), 
and 1620 cm- 1 (C=C) and the U.V. spectrum (i\max 213nm (."-7190) ). 
The 1H n.m.r. spectrum displayed signals at ~ 4.43 and t 3.50 Un,2 H, 
o 
o -t'-C=C~ ) corresponding to the C2-methyJ.ene olefinic protons. 
The 2-methylene-3-oxo-4-oxa-5x-cholestane (225), on reacting 
with L-cysteine (226) gave the cysteine-lactone adduct (227, 79%) 
under the conditions of Dalton and Elmes' procedure 186 
+ 
(225) 
(226) 
o 
(227) 
H 
The formation of the cysteine-lactone adduct (227) was indicated 
by the absence of C2-methylena olefinic prOtons in the ' H' n.m.r. 
spectrum and the presence of ( V max 3700-2300 cm-1 ( COOH and NH2 ) 
1725cm-1 ( CoO of COoH and lactone) and 1630 cm-1 (COO), in the infra-
red spectrum. 
To observe if the side chain on C17 of the steroid nucleus has 
any effect on the cytotoxicity, it was deaided to synthesise the ~-methylene 
moiety in the A-ring of the androstane nucleus (Scheme 6). 
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· H 
(228) (229) 
1 
OAc 
< 
(23~ (230) 
1 
OAc OH 
) 
H 
o ;: 
H 
(232) (233) 
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Oppernauer oxidation 283 of androst-5-en-3p-bl-17-one (228) gave 
androst-4-en-3.17-dione(229) in 85% yield. A partial reduction of 
androst-4-en-3.17-dione (229) was attempted to obtain androst-4-
en-17~01-3-one (230). Sodium borohydride (1.5M equivalent)292 in 
methanol at OOC was employed and the crude product contained not only 
the expected product. androst-4-en-17p-ol-3-one (230). but a more 
polar product. androst-4-en-3~. 17~-diOl (234) was also present. 
Ho/~ 
H (234) 
The disappearance of v max 1735cm-1 and 1660cm-1 in the infra-red 
spectrum indicated the reduction at both the C"3 and C-17 carbonyl groups. 
A multiplet in the 1H n.m.r. spectrum at 5.38 was also indicative of the 
3 D( -methine of the diol (234 J. The ratio of androst-4-en-17~-01-3-one (230) 
to androst-4-en-3~.17~-diol (234) was approximately 2:1. as observed 
from the 1H n.m.r. spectrum of the reduction product. It was then 
decided to reduce the concentration of sodium borohydride ( 1.0M equivalent). 
In this case. there was a small amount of androst-4-en-3~. 17P-diol 
(234. ~ 10%). However. the starting material. androst-4-en-3.17-dione 
(229, ~ 10%) was also present. as well as the required product (230). 
To circumvent this problem. the concentration of sodium borohydride was 
increased ( 1.2 M equivalent) and the reduction mixture consisted of 
androst-4-en-17~-ol-3-one (230) and androst-4-en-3~.17~-diol (234). 
The separation of the crude reduction products on alumina (activity Ill) 
column chromatography gave androst-4-en-17~-ol-3-one (230. 81%) and 
androst-4-en-3~, 17~-diol (234. 12%). 
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293 Androst-4-en-3~, 17~-diol (234) was oxidised with activated 
manganese dioxide294 to obtain androst-4-en-17~-ol-3-one (230, 87%). 
OH 
H 
(234) (230) 
Androst-4-en-17~-ol-3-one (230), after acetylation, gave 
testosterone acetate, 17p-acetoxy-androst-4-en-3-one (231, 88%) 
which under the conditions of Baeyer-Villiger oxidation~64 . yielded 
the lactone, 17fi-acetoxy-3-oxo-4oxa-5~-androstane (232'~4%). The 
formation of the lactone (232) was indicated by the infra-red spectrum 
[ '~max. 1720 cm-1 [CoO) and disappearance of 1660 cm-1 [CoO) and 
1615 cm- 1 [ C=C) due to the conjugated ~J~-unsaturated system of 
testosterone acetate (231). 
295 
17p-Acetoxy-3-oxo-4-oxa-5 ~-androstane [232) was hydrolysed 
to obtain 17 ~-hydroxy-3-oxo-4-oxa-5 ~-androstane (233, 77%). The 
formation of lactone (233) was shown by a polar spot on T.L.C., the 
infra-red spectrum ( V max. 3500 '- 3200 cm -1 (OH) ) and the disappearance 
of the C1r.6-methyl resonance at ",(2.01 and a shift of C17 -«- methine 
chemical shift from L 5.40 to 1:6.34 in the 1H n.m.r. spectrum. 
The ~-hydroxymethylenation procedure of Yamada et al 160 was 
employed to obtain 17 ~-hydroxy-2-methylene-3-oxo-4-oxa-5~ -androstane 
(238) [ Scheme 71. 
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) 
(233) 
(237) 
H 
(238) 
OH 
I 
HC 
o 
(235) 
(236) 
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Reaction of ethyl formate and sodium hydride in ether with 
17 jI-hydroxy-3-oxo-4-oxa-50( -androstane (233) gave 17f!-hydroxy-2-
hydroxymethylene-3-oxo-4-oxa-5<>: -androstane (235, 86%). The reaction 
required approximately 90 hours for completion. The presence of 
2-hydroxymethylene lactone (235) was indicated by a polar spot on 
T.L.C., the infra-red spectrum ( ~ max, 1706 cm-1 ( C=O) and 1612 cm- 1 
, 
( C=C) and the U.V. spectrum (r-max 252 nm (~ 7863) ). The H n .m. r. spectrum 
displayed signals at t 2;78 and '(2.16 (bs, 1H, Z- and E -HO-CH = CH). (see P131 
- - and 144) 
17~-Hydroxy-2-hydroxymethylene-3-oxo-4-oxa-5 ~-androstane (235) 
was heated under reflux for 80 hours ( the disappearance of the starting 
lactone (235) was followed by T.L.C) with diethylamine in benzene to 
obtain the d~thYlaminO adduct, 17~-hydroxy-2- ( N,N-diethylamino) 
msthylene-3-oxo-4-oxa-5 ~-androstane ( 236, 93%). The infra-red 
1 -1 . -1 
spectrum (V max. 3440 cm- (OHl 1670 cm (C=O), and 1570 cm (C=C), 
the U.V spectrum (1) max 300-1nm (E: 1.3171 x 104 ) ), the 1H n.m.r ....... 
spectrum (L 6.64 ( q, 4H, N-CH2 -CH3 ) , 1: 8.78 (t, 6H, - N - CH 2-CH 3) 
1 2.83 and "(2.30 (bs, 1H, Z - and f - Etz N-C.!::!. = C ) ), and a polar spot 
on T.L.C. indicated the formation of the diethylamino-adduct (236). (See P 131 
and 145) 
17~-Hydroxy-2-! N,N-diethylamino)-methylene-3-oxo-4-oxa-5-~-
androstane (236) was hydrogenated with platinum oxide in glacial acetic 
acid to obtain the saturated amino-adduct, 17~-hydroxy-2-(N,N-diethylamino) 
methyl-3-oxo-4-oxa-5 ~-androstane (237) which, without isolation, was 
heated under reflux with sodium acetate in glacial acetic acid to 
eliminate diethylamine. The crude product appeared to be a mixture of 
two compounds on T.L.C. The compound corresponding to the lower spot had 
the same RF value as the original lactone, 17~-hydroxy-3-oxo-4-oxa-5 ~­
androstane (233). However, on closer inspection, this compound appeared 
to be the ex-methylene lactone, 17P-hydroxy-2-methylene-3-oxo-4-oxa-5 0(-
androstane (238, 28%). The presence of 
was confirmed by the infra-red spectrum 
the ~-methylene lactone (238) 
-1 ( Y max. 3440 cm (OH), 1712 -1 cm 
( _ ) -1 
C - 0 and 1623 cm (C=C), the U.V. spectrum ( I\. max 215 nm (10, 6680) 
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and the 1H n.m.r. spectrum cr 6.35 (t. 1H. C17D(-H. J = 8.0 H2 ) ) 
and't 4.42 { m. 1H. o-g-c=eti..H) and 'T 3.51 (m. 1H. o-g-y=C~Hl 'corresponding 
to the C2-methylene olefinic protons. 
The product with a higher RF value was shown to be the acetylated 
~-methylene lactone. 17~-acetoxy-2-methylene-3-oxo-4-oxa-5 ~-androstane 
(239. 30%) by the infra-red spectrum. (v max. 1735 cm- 1 ( C=O.ester). 
-1 ' -1 1723 cm (C=O. lactone). 1625 cm (C=C] and the disappearance of 
the hydroxyl absorption). the U.V. spectrum (" max 214-5 nm (~: 7936) 
and the 1 H n. m. r. spectrum (L" 7.96. 
t 5.40 ( t. 1H. C17 O<-H. J = 8.0H2 ) fl H 
andL3.48 (m. 1H. O-vC =C--H). 
I 
OAc 
H 
(S. 3H. C17~-acetate methyl). 
and "(4.39 (m, 1H. o-g-C=CH-H) 
(239) 
It appears that the acetylation of 17~-hydroxy-2-methylene-3-oxo-
4~oxa-5 ~-androstane (238) occurs during the elimination of diethylamine 
with sodium acetate in glacial acetic aCid. as there is no evidence of this 
happening any earlier. The existence of 17~hydroxy-2-methylene-3-oxo-4-oxa-
5 ~-androstane (238) was corroborated by conversion to 17~-acetoxy-2-
methylene-3-oxo-4-oxa-5 ~-androstane (239) with acetic anhydride in 
pyridine. 
185 The reaction of L-cysteine (226) with 17p-acetoxy-2-methylene-
3-oxo-4-oxa-5 ~-androstane (239) gave a cysteine-lactone adduct (240. 
69%). The formation of the cysteine-lactone adduct (240) was indicated by 
the infra-red spectrum Cv max. 3700-2300 cm-\ COOH and NH21. 1735 cm-1 CC=O 
of-carboxylic acid and lactone) and 1621 cm- 1 ( COO-) and the absence of 
C2-methylene definic protons in the 1 H n.m.r. spectrum. 
- -----------------------------------------------------------
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-H + 
(239) 
H 
(240) 
It was decided to synthesise ~-methylene lactones in the D-ring 
of the steroid nucleus to compare the cytotoxic activity with the 
A-ring ~-methylene lactones. Androst-5-en-3p-ol-17-one (241) was 
utilised for the formation of the D-ring lactone, 3!>-acetoxy-17-oxo-
17a-oxa-D-homo-S ~androstane (244) (Scheme 8), 
) 
H AeO 
(240 (242) 
1 
~ 
, 
Ac 
-
Ac 
-H H 
(244) 
SCHEME 8 
(243) 
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Acetylation of androst-S-en-3~-ol-17-one (241) with acetic 
anhydride in pyridine gave 3~-acetoxy-androst-S-en-17-one (242, 85) 
which was hydrogenated with palladium-charcoal (10%) catalyst in glacial 
acetic acid to obtain 3~-acetoxy-5 ~-androstan-17-one (243, 88%). 
295 Baeyer-Villiger oxidation of 3p-acetoxy-5 ~-androstan-17-one (243) gave 
~-acetoxy-17-oxo-17a-oxa-D-homo-5 ~-androstane (244), isoandrololactone 
acetate, in 65% yield. Recently an alternative, high yield conversion 
of cyclic ketones to a lactones employing hydrogen peroxide in glacial 
acetic acid was reported 29&1, Band also an application of selenylation 
and dehydroselenylation was utilised in the conversion of 17-oxo-
steroids into D-homolactones296 ~ 
0< -Carboxylation of 3!3-acetoxy-17-oxo-17a-oxa-D-homo-S o(-androstane 
(244), according to the procedure of Grieco and Hiroi19~ ~ave a mixture 
of the starting lactone and carboxylactones ( 245 and 246). 
Ac ) A co/' 
H H 
(244) (245) 
H 
(246) 
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The presence of the carboxylactone (245) in the crude Feaction 
product was indicated by 1H n.m.r. spectrum (t 7.9 ( S, 3H, 3~-acetate 
CH3), t5.2 ( m, IH, C3 IX -H) and (0.23 ( bs, 1H, C16 - COO ~ ). The 
presence of the carboxylactone (246), also in the crude product, was 
indicated by the 1H n.m.r. spectrum (t 7.38 ( m, 2H, C16-2H),t6.58 (S, 2H, 
f1 
. C3 - 0 - C - ~ - CDOH) , T5.2 ( m, IH, C3 O(-H) and to.23 ( bs, 1H, -
CDOH) ). The crude product was taken up in ether and washed with 
saturated sodium hydrogen carbonate solution followed by water. 
The neutral fraction obtained was the starting lactone (244) as indicated 
by the spectral data and T.L.C. The combined aqueous washing was 
acidified ( pH ~ 3-4) and extracted with ether. The acidic fraction, 
consisting of carboxylactones ( 245 + 246), was unstable as the acidic 
proton signal in the 1H n.m.r. spectrum at 0.23 had disappeared 
and the appearance of a multiplet at t 7.36 ( 2H, C16-H2),which is 
characteristic of the startin~ material, indicated that the carboxylactone 
(245) had reverted to (Z44). The acidic fractions 1H n.m.r. spectrum 
still exhibited the acidic proton at t' 1. 05 which indicated that compound 
(246) is relatively stable. Further treatment of compounds (245+246) 
with saturated sodium hydrogen carbonate solution gave the neutral fraction, 
the starting lactone (244) ( T.L.C. identification) and the acidic fraction, 
the carboxylactone (246), which was esterified with diazomethane to 
obtain the methylester (247). Although this was not fully characterised, 
its presence was indicated by the 1H n.m.r. spectrum (t 7.36 ( m, 2H, 
C16-HZ),1.6.25 ( S,. 3H, Ester-CH3 ) and 15.25 ( m, IH, C3 o(-H) , ), the 
infra-red spectrum ( no hydroxyl group absorption), a non-polar spat 
c 0 
(' 11 + 
on T.L.C. and the mass spectrum ( M-CH3 0 - C - CH2 - C - OH) = 288). 
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o 0 
11 11 
C H3-0-C-H2C-C-O-
-
H 
(247) 
291 An " O(-hydroxymethylel)ation" procedure of Volovelskii was 
performed with 3~-acetoxy lactone (244) under ths same conditions as 
for 5o(-cholestan-3-one (220). The crude product, a mixture of the 
starting lactone (244] and ths O(-hydroxymethylens lactone (248) was 
taken up in ether and triturated with acetone. The precip~tate 
appeared to be the ~-hydroxy-methylene lactone (248) as indicated 
by a polar-spot on T.L.C. and the infra-red spectrum (v max. 3600-3300 cm- 1 
(OH). 1695 cm-1 (C=O) and 1610 cm-1 c.C=C) ). 
(248) R=H 
Ac 
(249) R=Ac 
The acetone insoluble product was acetylated and, after chromatographic 
purification, the fraction that was thought to be the o(-hydroxy~methylene 
lactone (249) showed no characteristic absorption, in the infra-red 
spectrum due to the C>\,p-ursaturated system of the lactone [249). It 
appeared that the product was either unstable on silica gel or it decomposes 
on standing for a time or both. The" 0( -hydroxymethyltnation" procedure 
of Knox et al 297 was also unsuccessful on 3~-acetoxylactone (244). 
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The method of Yamada et al 160 was applied to 3~-acetoxy lactone 
[244) and the reaction was continued until there was no starting lactone 
[244) present, as observed on T.L.C. [ 90 hours). The crude product was 
crystallised from ethyl acetate/pet ether [ 40-60 0 ) to give the 
~-bydroxymethylene lactone, 3~-hydroxy-16-hydroxy methylene-17-oxo-
17a-oxa-D-homb-S 0( - androstane (250) as indicated by the infra-red 
spectrum [ V max. 3700-3100 cm- 1 [OH), 1695 cm- 1 [ C=O) and ~610 cm- 1 
[C=C)). 7he mother liquors contained 3~-hydroxy-17-oxo-17a-oxa-D-homo-5~­
androstane (251) which presumably arises by hydrolysis during the 
reaction owing to traces of water and/or during workup. 
1-1 1-1 
H 
(250) (251) 
160 To avoid this complication, the " O<-formylation" procedure was 
applied to isoandrolo.lactone (251) which was obtained from the hydrolysis 
of 3p-acetoxylactone (244), The crude product was shown to be a mixture 
of three compounds as indicated by T.L.C. and 1H n.m.r. spectrum. 
--------------------------------------------------------------------------- ---. 
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o 
1\ _/ He-v 
H (252) 
HOH 
H 
H 
(253 A) (2538) 
The presence of the starting lactone (251) was indicated by T.L.C. 
and the jH n.m.r. spectrum (~7.39 (m,.2H, C1S-2H)). 3~-Hydroxy-17-
oxo-17a-oxa-D-homo-5 o(-androstant-formate (252) was shown to be present 
by a non-polar spot on T.L.C. and 1H n.m.r. spectrum (t2.0 ( S, 1H, 
c 
C3 - 0 - C - H)). The presence of (253) was indicated by a polar spot 
on T.L.C. and 1H n.m.r. spectrum (t 1.94 1 S, 1H, C16 - ct! =0). The 
product ( 253) may be in equilibrium with its hydroxymethylene isomer ( 253A-
2536), but there was no evidence to support this. 
The above reaction was repeated using sodium ethoxide, instead of 
sodium hydride, as a base. Although the reaction was complete on T.L.C. 
the product, «-hydroxymethylene lactone (2S~) appeared to revert to the 
starting lactone (251) during workup. It was thought that the use of 
dilute hydrochloric acid for acidification of the aqueous fraction may 
cause decomposition of the ~-hydroxymethylene lactone which may be unstable 
at pH 3-4 . 
... _------------------------------ - - -
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When 5% aqueous acetic acid was employed to acidify the aqueous 
fraction ( pH 6-7), the crude product was shown to be a mixture of 
the starting lactone (251) and the ~-hydroxymethylene-lactone (250). 
The above crude product was heated under reflux with diethylamine in 
benzene, in an attempt to obtain the diethylamino adduct, 3p-hydroxy-16 
( N, N-diethylamino) -methylene-17-oxo-17a-oxa-D-homo-5 oi-androstane (254) 
but only 3p-hydroxylactone (251) was recovered. 
HO 
H 
(254) 
It appears that the diethylamino adduct (254) is even more unstable 
than the ~-hydroxymethylene lactone (250). When the diethylamino adduct 
(254) was formed in the reaction, as indicated by T.L.C., the infra-red 
spectrum and the U.V. spectrum (r-max 298-300 nm), attempts to carry 
out hydrogenation and subsequent elimination of diethylamine gave only 
3p-hydroxylactone (251) but not the expected ~-methylene lactone, 3p-
hydroxy-16-methylene-17-oxo-17a-oxa-D-homo-5 ~-androstane (255). 
(255) 
HO = H 
To obtain the D~ring ct-methylene lactone (255), the ~-hydroxy­
methylation" procedure of Grieco and HiI'Qi. 203A was applied to isoandro-
lolactone (251) (Scheme 9J. 
• 
-73-
LDA/THF 
> 
HCHO 
H HO 
H 
(256) 
1 
H HO R 
(255) (257) 
H 
(258) (259) 
(Scheme 9) 
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The yield of 3~-hydroxy-16-hydroxymethyl-17-oxo-17a-oxa-O­
homo-5 ~-androstane (256) was 18% with isoandrololactone (251) being 
(256 ) 
recovered in a yield of 78%. The low yield of 16-hydroxymethyl lactone 
was attributed to difficulties associated with the introduction of 
formaldehyde vapour into the reaction mixture. When the inlet carrying 
a nitrogenous stream of formaldehyde vapour, generated by heating 
paraformaldehyde to 180oC, was underneath the surface of the reaction 
mixture, the tip of the inlet became blocked owing to the polymerisation 
of the formaldehyde. When the tip of the inlet tube was placed just 
above the surface of the reaction mixture, after a few seconds, 
there appeared a film of polymerised formaldehyde at the surfaoe, 
even though the rate of flow and stirring was quite fast. 
The procedure of Lucast and Wemple223, in which the reaction. 
mixture was kept at - 780 C [ acetone/dry C02) instead of raising 
o the temperature to - 20 C [ carbon tetrachloride/dry CO2),before 
introducing the formaldehyde vapour, did not improve the yield of 
the ~-hydroxymethyl lactone (256). 223 This procedure was applied 
so as to reduce the time between the generation of the anion and the 
flow of formaldehyde vapour. 
The formation of 3P-hydroXy-16-hydroxy methyl-17-oxo-17a-oxa-
O-homo-5 ~-androstanB [256) was indicated by a polar spot on T.L.C. 
(solvent system, chloroform/methanol: 95/5) and the 1H n.m.r. spectrum 
displayed a signal at t 6. 36 ( d, 2H, J = 8.0HZ) corresponding to 
the methylene protons of the C16 - hydroxymethyl substituent. 
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298 An attempt to obtain the mono-mesylate (257) was unsuccessful 
and the dimesylate (258, 82%) was obtained as indicated by a non-polar 
spot on T.L.C. ( chloroform/methanol; 95/5), the infra-red spectrum 
( the absence of hydroxyl absorption, ~ max 1724 cm-1 ( CoO) and 1355 cm-1 
and 1176 cm-1 
-S02-0-) and the 1H n.m.r. spectrum, 't 6.97 and 
'C 7.02 ( S. 6H. 2x - 0 - S02-E!:!.:3 ). It was expected that selective 
mesylation would have been possible owing to the fact that primary 
alcohols react faster than secondary alcohols and that the reaction 
was performed at a low temperature ( -20oC) and further that selective 
sulphonation has previously been reported 298.299 
The di-methylsulphonate lactone (258). on heating under reflux 
with pyridine. resulted in the eliminated product. 16-methylene-17-oxo-
17a-oxa-D-homo-5 ~-androst-2-ene (259) in a low yield (28%). This 
has been confirmed by the infra-red spectrum (V max. 3030 cm -1 (c=cl. 
1709'cm-1 (C=O) and 1620 cm-1 (C = C) ). the U.V. spectrum (t- max 213-4nm, 
« 59(9) 1 and the 1H n.m.r. spectrum. 14.51 (m'. 3H.c 2.3 Hand -
o H 0 H 
O-e-C=C-H; T3.60 ( m. 1H, O-e- C=t-H]. 
I -, I 
As the ~-hydroxymethylene O-ring lactone (250) could be obtained. 
even though unstable and impure, it was decided to synthesise the 
~-hydroxymethyl-D-ring lactone (256) by the reduct1ve procedure of 
Minato and Horibe176 • 
HOH 
H H 
H 
(250) (256) 
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The above reductive method was unsuccessful even though sodium 
borohydride has been employed for reduction of eX ,~-unsaturated 
systems ( 250~256) in the synthesis of various natural cytotoxic 
171 177-1BO 
sesquiterpene lactones' • The use of palladium-charcoal 
(10%) in ethanol, ethylacetate and acetic acid and platinum oxide in 
ethyl acetate 'and acetic acid was also unsuccessful. The low reactivity 
of the olefinic bond towards reduction may be due tosteric and 
conformational factors. 
In studying the microbiological hydroxylation of steroids, 
300 Bridgemann ~~ required oxygenated steroids of the less common 
type ( e.g. 260 -262) prepared by the removal of 17-oxo-groups from 
the benzylidene ketones (263) by lithium aluminium hydride-aluminium 
chloride. The preparation of benzylidene-ketones(263) by a type of base 
301 
catalysed aldol condensation has been reported. 
R 
H H 
(260) (261) 
HPh 
RO J, H 
(262) (263) 
... _----------------------------_. -
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The ketone (264) on condensation with formaldehyde results in an 
~,~-unsaturated compound (266) after iodine-catalysed dehydration 
of the initially formed ketal (265). 
(264) 
HCl-iO ) 
(265) 
(266) 
Bearing this in mind, the aldol condensation was attempted on 
the D-ring lactone (251) to obtain an ~-methylene-D-ring lactone (255), 
al though an aldol condensation with ester seems unfavourable owing to a 
lack of acidity of the ~-methylene protons. 
H 
H 
(251) 
HCl-iO/EtOH 
KOHj H20 > HO = H 
(255) 
The yield of ~-methylene lactone (255) was 27% with the starting 
lactone [ 251) being recovered in 34% yield. The formation of 3p-hydroxy-
- ------
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16-methylene-17-oxo-17a-oxa-D-homo-5 ~-androstane (254) was indicated by 
the infra-red spectrum (~max. 3420 cm-1 (OH), 1715 cm-1 ( CoO) and 1613 
-1 
cm (C=C)), the U. V. spectrum [(.. max. 214-5 nm, (E. 3760) ) and the 
o H 
1 " L - . H n.m.r. spectrum, T4.30 Lm,.:1H, O-C-C=C·-!! ) 
o H 
andt3.52 l m, o:-C'-C;;l:-H) 
The low yield of the ~-methylene lactone (255) could be explained 
by the fact that the base, potassium hydroxide, does not only abstract 
a proton to form the lactone enolate but also causes the hydrolysis 
to the hydroxy acid (267) which on acidification relactonises to 
the starting lactone. Also, the equilibrium between the formation of 
the lactone enolate anion and hydrolysis may be in favour of hydrolysed 
product(Z67l. 
H 
OOH 
H 
H 
(251) 
Condensation at the methylene group of acyclic ketones often fails 
because of the intermediate aldol prod uct undergoes a retrograde aldol 
302 
reaction more rapidly than it dehydrates • Apparently, there was no 
indicaticn far the formation of the ~-hydroxymethyl-lactone in the crude 
product. 
To overcame the problem of hydrolysis, sodium ethoxide, instead of 
potassium hydroxide, was employed as a base but theCB was no evidence of 
the «-methylene lactone (255) in the reaction mixture. There was some 
evidence for the formation of the C<-hydroxymethyl lactone (256) but 
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repetition of the reaction was unsuccessful. The utilisation of 
dimethylsulphoxide (OMSO) and benzene as solvents and piperidine as 
a base also appeared to be unsuccessful. 
A more satisfactory method for the introduction of a single carbon 
atom is the reaction of an active methylene compound with formaldehyde 
303 
and an .amine to form a p-amino-carbonyl compound - the Mannich reaction • 
A literature survey revealed that although the Mannich reaction has been 
303 304 
applied to carbonyl compounds ' and activated lactones, i.e. 
181 182-192 ~-carboxy- and ~-carboxyester-lactones , this has never 
been applied to lactones in the 
An application of the procedure 
synthesis of ~-methylenelactones. 
305 
of Miller and Smith ( 37% aqueous 
formaldehyde, diethylamine and diethylamine hydrochloride in dioxan heated 
at 800e for 80 hours under nitrogen) to the O-ring lactone, isoandrololactone 
(251) gave the ~-methylene lactone, 3~-hydroxy-16-methylene-17-oxo-17a-oxa 
-O-homo-5 ~-androstane ( 255,27%) but there was no evidence of the 
diethylamino adduct, 3~-hYdroxY-16-(N,N-diethylamino) methyl-17-oxo-
17a-oxa-O-homo-5 ~-androstane (268). 
--;> 
H 
H 
(2S[) (268) I 
HO 
H 
(255) 
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The formation of the ~-methyI8nelactone (2551 was confirmed by 
the spectral data which were identical to that of ~-methylene-
lactone (254) obtained with the base-catalysed aldol condensation 
with formaldehyde. The ~-aminolactone (268) undergoes elimination 
of diethylamine. under the reaction condition. to form the ~-methylene 
lactone (255). 
(268) (269) 
1 
HO --
= H 
(255) 
As there was a lot of starting lactone (251) recovered. it was 
decided to add more of the reagents after eight hours and keep the 
reaction mixture under reflux for further twelve hours. However. there 
was no improvement in the yield of the ~-methylenelactone (255). 
Even keeping the reaction mixture under reflux for 72 hours showed no 
improvement. 
---------------------------------_ .. _- - -
-81-
The most widely used solvents in the Mannich reaction are ethanol, 
other alcohols such as methanol and isopropanol, water and acetic acid306 • 
In some reactions involving wsakly reactive substrates, 1-2,dimethoxy-
307,308 
ethane ( glyme) has been used as a solvent. The employment of glyro~ .. as 
308 
a solvent instead of dioxan did result in an ~-methylene lactone (255) 
but in a very low yield whereas the use of glyme with pyrrolidine 
as a base instead of diethylamine was unsuccessful. Recently ketones 
198A, 308, 309 have been allowed to react with preformed im~nium ions 
to obtain ~-amino adducts which, under the elimination conditions, 
could be converted to -methylene compounds. 
Preliminary attempts using S-trioxan and N-methylanilinium 
310 trifluoroacetate (TAMA) in dioxan were however unsuccessful but 
further work in this area including the use of Eschenimoser's salts, 
dimethyl (methylene) ammonium iodide 197,199 and dimethyl (methylene) 
1986 
ammonium chloride may be useful. 
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As an o(-methylene- 0 - lactone structural unit is present in 
most natural cytotoxic sequiterpene lact'ones, it was decided to 
synthesise 0- lactones. The application of the Barbier-Weland 
degradation 311 with the S-lactone (203) was expected to lead to 
the a-lactone (274) (Scheme 10). 
if./ 0 =: 
H 
(203) 
HOO 
(272) 
HOOC 
HO -
H 
j 
(273) 
PhMg Br ) 
) 
Ph 
Ph 
o 
(270) j 
H H 
(271) 
H 
(274) 
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(271) OH 
HO 
-H iT (275) 
I~ 
H 
H 
(274) SCHEME 10 (276) 
The reactions of Grignard reagents with lactones were first 
investigated by Hauben 312 and in view of their relationship to the 
esters, the relatively simple a-lactones gave tertiary alcohols. 
The reaction of as-lactone, 4-oxa-5 (X-cholestan-3-one (203) with 
Grignard reagent, Phenylmagnesiumbromide,313 was performed to obtain 
a tertiary alcohol (270). Unfortunately, the product obtained was 
not the expected product (270) but a dihydropyran, 4-oxa-3-phenyl-5~-
cholest-2-ene (278), although the reaction of Grignard reagents 
314 
with lactones forming tertiary alcohol products have been reported 
Ph 
er 
MgGr 
(203) (277) 
Ph 
(Scheme 11) (278) 
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At first glance it might appear that the reaction involves 
a rather unusual type of rearrangement. However, if it is assumed 
that the Grignard reaction terminates at the first stage with the 
formation of an intermediate (277), then the final product (278) is 
readily explicable as a result of dehydration of the resultant alcohol 
. from (277) during work-up (Scheme 11). Similar dehydrated products, 
dihydropyran, have been obtained with androstane derivatives when 
treated with Grignard reagents315 • The stability of the product, 
dihydropyran (278), may have been enhanced due to the conjugation 
of the olefinic bond with the aromatic ring. 
The dihydropyran (278, SO%) obtained was less polar than the 
starting lactone (203). The formation of dihydropyran (278) was 
I indicated by the H n.m.r. spectrum which showed a triplet at 
t 4.72 ( C2-H, olefinic proton), a quartet centred at tS.42 
( CS-c< H) and a multiplet centred at '(2.58, the aromatio protons. 
The U.V. spectrum ( A max 264 nm, ( E 9250) ) also supported this 
structure. There was no evidence of the formation of the tertiary 
alcohol, the expected product ( 270),in the crude reaction mixture. 
Attempted ozonolysis of the dihydropyran (278), to cleave the 
C2-C3 bond, gave an aldehyde (279Jalthough an oxidative work-up 
was followed. The presence of an aldehyde (279) was indicated by the 
I H n.m.r. spectrum ('( 4.91 ( q, 1H, Cs ()(-H),"C1.9 - 2.73 ( m, 5H, 
Aromatic protons) and t 0.21 ( 1H, - CH) 
l~t 
) . 
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03 OH 
) 
Phii Ph -H 0 H 
(279 ) 
(278) 1 KOH/MeOH 
HO-- ( ) 
OH 
H H 
(275) 
Hydrolysis of (279) was performed in an attempt to obtain the 
hydroxy-aldehyde (275). But, a number of products were obtained 
which were not characterised due to low yield. However. the hydroxy-
aldehyde (275) may be in equilibrium with the lactol (276), 
although there was no evidence to support it. 
The dihydropyran (278) was allowed to react with excess 
316 
monoperphthalic acid • It was envisaged that this would lead to 
the 0( -epoxide (Z80) or other products which could be utilised to 
cleave the CZ-C3 bond. 
H 
(278) ~280) 
-86-
The product obtained was not the expected ~-epoxide, 
4-oxa-20( ,3 cl -oxido-3-phenyl-5 QC -cholestane (280) as indicated by 
r 
the absence of the C2-H signal in the H n.m.r. spectrum. The infra-
red spectrum of the product showed the presence of the carbonyl 
(1730 cm-1) and the hydroxyl (3300 cm- 1) groups. The presence of 
C1-methylene protons as AB quartet ( thus C1-methylene protons adjacent 
to ,13 carbonyl group) and the hydroxyl proton broad multiplet, 
exchangeable with deuterium oxide, in the 'H n.m.r. spectrum 
indicated the structure of an hemiacetal ketone (281). 
(281) 
Although the composition of the epimeric mixture of he:miacetal 
2,"""e 
ketones, 3-hydroxy-4-oxa-3-phenyl-5~-cholestan1,(281) was variable, 
its presence was confirmed by the presence of the carbonyl (1730 cm- 1) 
-1 
and the hydroxyl (3300 cm ) groups in the infra-red spectrum. 
, 
The H n. m. r. spectrum showed quartets at "[ 5.7 and t 6 .45 which were 
assigned to the Cs -0( - methione in the 3 !X-hydroxy - and 3p-hydroxy-
hemiacetal Ketones (281) respectively. The methylene protons at C1 
displayed two overlapping AB quartets centred at t' 7.43 and 7.53, and the 
lower-field quartet was assigned to the 3~-hydroxy-hemiacetal Ketone. 
The hydroxyl proton appeared as a broad mul tiplet at '[ 6.8 which was 
exchangeable with deuterium oxide. The mixture of epimere could not be 
separated by crystallisation. The reaction of the h'emiacetal-Ketone (281) 
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with acetyl chloride in ethanol resulted in an acetal-ketone, 3-ethox'y-4-oxa-
3-phenyl-501-cholestan-2-one (282, 65%), thus giving support to the 
hemiacetal -ketone structure (281). 
CH3COCI/C2HSOH 
\281) 
> Ph 
(282) 
Crystallisation of the acetal-ketone (282) from ethanol resulted 
in a single epimer and was assigned the 3 ~-etho&y configuration due to 
I 
a single N3 quarter of C1-methylene protons centred at T 7 .43 in the H 
n.m.r. spectrum. The absence of absorption at 3300 cm-1 in the infra-
red spectrum indicated the absence of the hydroxyl group. The 
methylene protons of the ethoxy substituent gave two overlapping 
quartets owing to their diastereospecificity. It appears that the 
3 oc-ethoxy-epimer is the thermodynamically stable epimer and hence 
isolable on crystallisation. It was thought that this reaction was 
air oxidised to produce the 3-ethoxy compound, however, the same product 
was obtained when the reaction was performed in a nitrogen atmosphere. 
It appears that the 0( -epoxide (280), which may have been formed 
in the reaction, undergoes rearrangement to give rise to the compound (281). 
The formation of the compound (281) can be formulated in a number of 
ways (Scheme 12)317. 
-88-
lA) _~, HO_~ Ph/eo~ 
+ H 
(280) (283) 
1 
Ph 
(285) (284) 
1 
pO:: 
OH H 
(8 ) 
(281) 
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rc) 
) 
H H 
(280) 
H-O 
\281) Ph 
H 
SCHEMEI2 (284) 
There have been essentially two processes reported for the 
318-321 
reaction of enol-ethers with peracids • The initially 
formed epoxides are attacked by the carboxylate or peroxycarboxylate 
anion to give the intermediates (287) or (288), respectively, which 
could sither rearrange or fragment as shown (Scheme 13). 
~ .. RI R4 ,ArCOOH ) H-~ 
R3 R2 
1 
(287) 
ArC0 3H t RI OR4 ~Ot ArC02 ) ( O-H D 11 H-O -&C-Ar 
R R3 R2 R3 . 
(288) 1 
1 RI OR4 0 RI 
<0 O~ ~ Ar-g-o) + ~ R2 R3 
SCHE.ME 13 
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The product obtained from the _epoxidation procedure with 
dihydropyran (278) was not the expected ~-epoxide and also it did 
not appear to be the products corresponding to those in Scheme 13. 
In order to obtain compounds which possess ambergris-type odours, 
Cambie et a1320 required the epoxide (290) whose formation was 
attempted by epoxidation of the enol-ether (289)322 with 
monoperphthalic acid. However, although the successful isolation 
318 of the epoxides of some enol-ethers has been reported, the only 
322 323 products isolated were the known acetoxy-acid (291)' and 
one which was identified as the dimer keto ether (292). 
(289) (290) 
OOH 
(291) 
(292) 
The acetoxy-acid (291) probably arises by a fragmentation 
2 
reaction (Scheme 14) similar to that observed during the epoxidation 
324 319 
of tetrahydrochromans and certain steroidal enol-ethers • 
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o 
- 11 ° ,,5 K..../O-O-C-Ar 
II 
/l/fO$"C-Af' 
,,0 
(290) 
( 
(290 SCHE.ME.14 
(293) 
J ?i-H 
" ',o~=o \\ 
The stabilisation of the intermediate (283) by the 3-phenyl 
group may be of importance particularly since nucleophilic attack at c3 
in (280) by phthalate or perphthalate anion (Scheme 13) would not be 
(stereoelectronically) . 
favouredAassuming that C>(-epoxidation would mainly occur. The opening 
of epoxide ring to give "1,2-disubstituted" compounds occurs very readily 
under acidic catalysis, for protonation of the epoxide oxygen atom 
greatly enhances the normal polarisation of the C-O bond, permitting 
nucleophilic attack by an anion or solvent molecule in concert with 
breaking of a C-O bond. Epoxide-opening reactions have the stereoelectronic 
feature that the attacking nucleophile approaches the epoxide ring 
to give a trans diaxially substituted product.' 
H~~~( _ PI~O ~ 
- H Nu 
) 
H~(~ Ph~~ 
Nu H 
(280) (295) 
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Accordingly, the formation of (295) would be unfavourable 
and the opening to r296) would be stereoelectronically favoured • 
NLl 
} 
o :: 
H 
(280) 
• L· ... _: 
> 
Nu 
Ph ~ 0 ~ 
OH H 
(296) 
However, the epoxide ring of epoxyethers (297) has been opened 
with acid at the C1 atom holding two oxygen functions to give the ester 
of a hemiketal (298). 319B It is of ~nterest to note that 
contains a stabilising aryl group similar to (280) 
follows the normal reaction pathway (Scheme 13). 
Ar-cA-2 M€ 
. I I 
M€O Me 
(297) (298) 
The low solubility of phthalic acid in ether may also be of some 
importance in inhibiting the efficiency of the epoxide opening reactions. 
The structure of the hemiacetal-ketone (281) was further 
supported by the evidence that the treatment of the hem1acetal-ketone 
with lead tetra-acetate in benzene gave 2, 3-seco-S~-benzoate-S 0< -
cholestan-2-carboxylic acid (299). The presence of the carboxylic 
acid (299) was indicated by the T.L.C., the infra-red spectrum 
(v max 3600-2800 cm- 1 (OH), 1720 cm-1 (C~O) ) and a downfield shift 
r 
of Cs IX -methine proton toL4.91 in the H n.m.r. spectrum. 
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Further confirmation of the structure of the carboxylic acid (299) 
was afforded by its reaction with diazomethane to obtain the methyl 
ester (300). I The prese~ce of a singlet at t 6.43 in the H n.m.r. 
spectrum and an absence of the hydroxyl absorption in the infra-red 
spectrum indicated the formation of the methyl ester (Scheme 15). 
HOO 
H 
o -
OH H 
(281) 
H 
(301) 1 pTSA 
/""-,.1/ ~ 
o 
(274) 
HOO 
Ph/fJ'O o H 
MeOO 
Ph~O I~ 
(300) 
SCHEME [5 
The carboxylic acid (299) was hydrolysed with potassium hydroxide/ 
methanol to obtain the hydroxy-acid (301). The absence of aromatic 
I 
protons in the H n.m.r. spectrum and the presence of a polar compound 
on T.L.C. was indicative of the formation of the hydroxy-acid (301). 
Treatment of the hydroxy-acid with toluene-p-sulphonic acid in benzene 
afforded a if-lactone, 3-nor-4-oxa-5 cX-cholestan-2-one (274) indicated 
by the infra-red spectrum (v max -1 1785 cm (C=O)) (Scheme 15). 
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In their studies on the effect, on physiological properties, 
of modification of the size of the A-ring in various steroids Jacobs 
and Takahashi32S obtained at-lactone, 3-nor-4-oxa-cholestan-2-one (303) 
from the hydrogenation of the enol-lactone, 3-nor-4-oxa-cholest-5-en-
2-one (302). 
Adorns 
) 
Cataly st 
(302) 
This l-lactone (303) [M.P. 12S-127oC 
from the r-lactone (274) 
H 
(303) 
25 (methanol), (00 El 
M.P. 10S-10SoC 
+ 8.8 
(CHC1 3) ) differed 
(methanol), (0() 2S 
o + 2S.07 ( CHC1 3) ). The stereochemistry of l-lactone 
(303) at Cs has not been specified whereasrlactone (274) has its 
. . 203 
determined ( Sex) by its starting $-lactone . stereochemist ry 
and it is presumed that the earlier prepared lactone (303) in the sp-
epimer. 
The overall yield of the ¥-lactone (274) is very low and thus 
()(-methylenation procedure. was not performed. 
To determine the importance of electronic effects in the 
Grignard reaction with S-lactone (203) and subsequent epoxidation step, 
the reaction of 4-methoxy-phenyl bromide with S-lactone was performed. 
. . v 
The crude product, on separation by preparative T.L.C., gave the 
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dihydropyran, 3- [4-methoxy phenyl) -4-oxa-5 eX -cholest-2-ene (304), 
the tetrahydropyran, 3,3-di [ 4-methoxyphenyl) -4-oxa-5 0< -cholestane 
(305) and the hydroxyolefin, 3,4-seco-5p-hydroxy-3,3-di (4-methoxyphenyl) 
- 5C(-cholest-2-ene (306). There were also three other minor products 
which were not identified. 
!-I 
(203) (304) 
MilD- DJ--.... 0 
A 
+ 
o 
(305) (306) 
< The spectro~opicdata of the dihydropyran [304) were similar 
f to those for the dthydropyran (278). The H n.m.r. spectrum of the 
dihydropyran (304) displayed a singlet at'[ 6.2 ( 3H, -0 - CH3 ) and a 
triplet at T 4.92 ( 1H, C2-H). The occurence, in the 
f H n.m.r. spectrum 
of the major product ( 37%), of two singlets at '[6.17 and t'6.25 
( 2x -0 - CH3), a multiplet at r 2.5 - 3.4 ( 8H), confirming the presence 
of two phenyl groups and a multiplet at t6.96 assigned to the C5 IX-
.- -- -- ----------------------
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326 methine, conTirmed the tetrahydropyran structure (305). Kuhn 
reported that when an ether solution oT a ¥-lactone is permitted 
to react vigorously with 3 equivalents OT phenyl-magnesium bromide, 
the product is a tetrahydropyran derivative. 
The identity OT the hydroxyoleTin, 3,4-seco-5p-hydroxy-3,3-di-
(4-methoxyphenyl)-5C(-cholest-2-ene ( 306, 17%) was conTirmed by 
r 
the H n.m.r. spectrum which displayed two singlets at '"(6.2 and T6.;?7 
( 6H, C3 - MeD-Aromatics), a multiplet at r 2;8 - 3.4 ( 8H, Aromatic H 
and a triplet at L 4.1 ( 1H, C2-H) and by the infra-red spectrum 
(v max. 3640 ~ 3200 cm-1 (OH) ). The formation of the tetrahydropyran 
(305) and the hydroxyolefin (306) could be postulated as shown (Scheme 16). 
(203) 
(309)1 
I H 
MgBr 
ArMgBr 
~ ;>r:a 
---1 ?/~ 
J MgBr 
dr9 (3(0) 
) 
H 
OMgBr 
(3071 
rJ 
~ - R "~gBr 
(308) 
Ar-...........I 
t~ 
Ar~ ~~ 
H 
(311 ) 
Ar ~f), = 
Ar lo H H 
H H 
(311 ) 
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Ar ) 
Ar 
(305) 
(306) 
Ar::: Me 0-(0)-
SCHEME 16 
The compound (310), on workup, would give rise to compound (311) 
which would be an intermediate forming the tetrahydropyran (305) and the 
hydroxyolefin (306) by cyclisation and dehydration, respectively. 
It could be stated that the removal of the hydroxyl group from C3, 
as a water molecule, would form a benzylic carbo cationic intermediate 
(312) which could cyclise to form the tetrahydropyran (305) and abstract 
a proton from C2-methylene to form the hydroxyolefin (306), The benzylic 
cationic intermediate (312) would be favoured by the strong electron 
donating properties of the 4-methoxyphenyl substituent as indicated in 
(313). 
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(312) 
(313) 
The structure of the tetrahydrapyran (305) was further supported 
by its palladium/charcoal acid catalysed hydrogenolysis to the 
saturated alcohol, 3, 4-seco-3, 3-di- (4-methoxy-phenyl) -5« -cholestan-
5~-01 (314,) which was accompanied by the ketone, 3,4-seco-3,3-di-
(4-methoxYPhen~1)-cholestan-5-one (315). 
Ar Ar 
Ar 1-1 
(305) (3/4) 
Ar=MCZo-Q- Ar 
Ar 
(315) 
+ 
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The formation of the saturated alcohol (314) was indicated by 
-1 , 
the infra-red spectrum (v max 3300 cm (OH)) and the H n .m. r. 
spectrum in which a downfield shift of Cs 0( -msthine from't 6.96 to r 
6.S1 occurred. The ketone (31S) was indicated by a non-polar spat an 
T.L.C., the infra-red spectrum (v max 170S cm-1 (C=O) ) and the 
absence of the Cs 0( -methine in the 'H n.m.r. spectrum. The formation 
of the saturated alcohol (314) and the carbonyl compound (31S) has 
been postulated as shown (Scheme 17). 
H 
H~ 
Ar 
Ar 
Ar H I~ 
(314) 
Ar 
Ar= Meo-<O) 
SCHEME 17 
(306) 
1 
a Ar 
(315) 
The structure of the saturated alcohol (314) was further 
supported by its formation from the hydroxyolefin (306) by 
hydrogenation. 
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Ar Ar 
Ar H H ArH H 
(306) 
Ar=MeO (0) (314) 
Confirmation of the transformation of (306) to the carbonyl 
compound (315) was obtained when it was treated with toluene-p-
sulphonic acid in benzene. 
Ar 
Ar 
(306) 
Ar = MrzO-Q 
(315) 
This rearranegement. which involves a hydride shift from 
Cs to C3 • appears to be novel in the steroid field. although a 
327 
similar rearrangl,iTent of (316) to (317) has been reported • 
H 
(316) (17) 
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Thus, 1,5' hydride transfer, rearran,' gement was supported 
with deuterium labelling experiment, as shown below. 
*-H H+ ~H ) 
(318) / (319) 
~= 
(320) 
The saturated alcohol (314), on oxidation with Jone~ reagent, 
resulted in a carbonyl product which was identical to the carbonyl 
compound (315) obtained from the aCid-catalysed hydrogenolysis and from 
the hydroxyolefin (306) on treatment with toluene-p-sulphonic acid in 
benzene. 
Mrz 
(314) 
Cr0:3 Mrz ) 
(315) 
This also corroborated the structure of the saturated alcohol (314) 
as well as that of the ketone (315).Crystallisat1on of the carbonyl 
product (315) was not successful and thus it was converted to the 
oxime (321). 
---------------------------------- - - - - --
I 
I 
I 
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(315) 
o 
Me 
(321) 
The structure of the hydroxyolefin (306) and the saturated 
alcohol (314) was further supported by the formation of 3,5-dinitro-
benzoate esters ( 322 and 323) respectively. 
=0 
(322) 
N02 
(323) 
There is a need for further work to be carried out on the 
dihydropyran (305) to ascertain whether an epoxidation would result in 
a normal epoxide or some rearranged product(s). The low yield of this 
product thus far has prevented this investigation. 
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As o(-methylene- ¥ -lactones display various biological properties, 
it was decided to synthesise a r-lactone onto rather than in the 
steroid nucleus. In their studies on the oxidation mechanism of 
269Ai 269Bii, 328 
metal carboxylates, Heiba ~ ~' observed a 
novel reaction of manganic and ceric carboxylates with olefins 
leading to r-butyrolactones in excellent yields. 
269F The procedure of Heiba ~~ employing manganic 
acetate was applied with cholest-4-en-3-one and there was no 
reaction. The lack of reactivity of cholest-4en-3-one may be 
due in part to the electron deficiency in the conjugated double 
bond. Reaction with cholest-S-en-3p-acetate was also unsuccessful 
and suggest steric hinderance may also be important269F • 
Reaction with 5 ~-cholest-2-ene, which was synthesised from 
cholesterol ( Scheme 18) was, more successful. 
Pyrldlne Ae 
AeO H~ H 
(326) H (325) 
L hell Py rid, ne 
-- - - -- ----------------------
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DMSO, 1000 
> 
no 3hrs 
H H 
327 328 
Ts = CH3-<O)-~-
o H 
329 
SCHEME 18 
• The formation of a ~-butyrolactone, 3-(2 -acetic acid)-
2-hydroxy-5 0< -cholestan-¥- lactone [330) [See later) was indicated 
by the infra-red spectrum (v max. 1768 cm-1 [ C: 0) l. The 
1 f · 2S9Ai, 2698 i:l, 328, therma decomposition 0 manganlc and ceric acetate 
329, 330 has demonstrated the intermediacy of the free-carboxy-methyl 
radical. The first step in the lactone synthesis (Scheme 19) is the 
addition of this radical to the olefin. 
·CH2COOH + >=<~ 
R2 R3 
1 
R2 R3 
R' R4 R' R4 ;- M 3+ • 
H ~ n H 
--- ------------------------------------------------------------------
-105-t- H+ 
3 
(Scheme 19) 
The direct formation of carboxyalkyl radicals from carboxylic acids 
by manganese (Ill) most probably involves initial enolisation of 
the carboxylic acid followed by electron transfer from either the 
enol or the enolate anion (Scheme 20). 
OAc 
» 
OR 
OH 
• +/ 
CH2-C 
"'OH 
(Scheme 20) 
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This has been indicated by the fact that highly enolisable 
carboxylic acids such as cyanoacetic acid react much more rapidly 
with manganese (Ill) than do simple alkyl carboxylic acids. 
The importance of base-catalysed enolisation in these reactions 
was demonstrated by the relative rates of disappearance of P-
substituted benzyl phenyl ketones, where electron-withdrawing groups 
. 269B1 increased the reaction rate with manganlc acetate • The 
preference for formation of the least substituted ~-keto radical 
269Bi from unsymmetrical ketones is further support for the 
intermediacy of the enolate anion. 
The lactone synthesis depends upon five basic mechanistic 
requirements: 
(1) the selective direct generation of carboxyalkyl radicalsl 
(2) the difficult oxidation of the initially formed carboxyl radical: 
(3) the rapid and selective addition of this radical to the olefin: 
(4) the fast oxidation of the resulting adduct radical to the 
carbonium ion, and 
(5) the rapid cyclisation of the carbonium ion to the lactone. 
The low yield of the ~-butYiolactone(329)obtained may be directly 
attributed to problems related to one or more of the mechanistic 
requirements. 
The reaction of the carboxymethyl radical,·CH2 COOH, with 
5 ~-cholest-2-ene (328) may result in eight regio-and stereo-isomeric 
o-butyrolactones. The structure of the major product isolated (329) 
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I 
was assigned from the H n.m.r. spectrum in which the signal ( 5 
linesl for the low field methine at C-2 was an overlapping doublet 
( J = 12.0 Hzl of triplets ( J = 6.0 Hzl ( Fig 1Al. 
0-
H 
H H 
G' 
b 
I 
N 
I 
H~ 
(329) 
I 
8--
The smaller spin-spin coupling is to the equatQ~ial protons 
at C1 and C3 and the larger spin-spin coupling is to the axial proton 
at C1 ( Fig 1 B). 
The carboxyalkyl radical would be expected to attack preferentially 
at the C-3-position. from the unhindered ~-face. giving rise to a 
radical at C-2. which on oxidation \~ould form a carbonium ion which in turn 
---------------------------------- .- - -_._--
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would give the thermodynamically stable cis - r -lactone (33$). 
The hydrolysis of the lactone resulting in a 2-hydroxy-3-
(2-acetic acidl-501. -cholestane and the oxidation of the hydroxy-
acid to 2-oxo-acid may give further support for'the structure of the 
t-lactone. However, the low yield of the o-lactone prevented 
further investigation, of the structural assignment. This low 
yield also prevented the investigation of reactions leading to 
the preparation of an o(-methylene ., 't - lactone. 
- -----------~------------------------
-109-
MATERIALS: 
Human carcinoma of the nasopharynx (KB) cells were obtained 
from Flow Laboratories Limited, Irvine, Scotland. 
Minimal Essential Medium (MEM) containing Earle's salts, 
L-Glutamine [ 200 mMJ 1%) and Non-Essential Amino Acids [1%). 
Foetal Bovine Serum (10%), Phosphate Buffered Saline [PBS). 
Oulbecco's formula ( modified) without calcium and magnesium. 
Trypsin [2.5%) in PBS were obtained from Gibco Bio-Cult Limited, 
Scotland. Sodium hydrogen carbonate was of analytical grade. 
Penicillin G [ Potassium benzylpenicillin) and Streptomycin Sulphate 
were obtained from Sigma Chemical Company Limited, Poole, Dorset. 
Dimethylsulphoxide (DMSO) was distilled from Calcium hydride under 
vacuum and stored over molecular sieve. 
PROCEDURE: 
Minimum Essential Medium [MEM) pre-mixed powder was dissolved 
in sterilised distilled water ( approximately 500 ml) with stirring. 
Sodium hydrogen carbonate ( 2.0 g/l) was dissolved in sterilised water 
[ 100 ml) and added to the MEM solution, with the flask being well 
rinsed with water. The pH of the medium was adjusted with IN hydrochloric 
acid. The medium was stirred slowly all the time during the addition 
of the acid. As the pH of the medium rises during filtration, the pH 
of the medium was adj usted such tbat the pH was 0.2 - 0,'3 units lower 
than the final desired pH value [7.4). The medium was made up to 
a final volume of one litre with sterilised water. Penicillin G : 
[potassium benzyl-penicillin) 40.0 mg/l) and streptomycin sulphate 
[50.0 mg/l) were added to the medium under sterile conditions. 
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The medium was filtered. under a positive pressure to prevent 
the loss of carbon dioxide. through a sterile membrane filter. 
Foetal Bovine Serum was added to the medium to give a final 
concentration of 10%. The medium was aseptically dispensed into 
sterile 500 ml containers and stored at 40 C. Trypsin ( 0.25%) 
was prepared by the addition of trypsin solution ( 2.5 % W/Vl 10 ml) 
to Oulbecco's PBS solution without calcium and magnesium and 
stored at -200 C. 
The (KB) cells were incubated at 370 C for 24 hours. upon receipt. 
in an atmosphere of 5% CO2 - 95% air. The medium was removed. from 
the culture vessel. by suction. and sUfficient trypsin solution 
( 0.25%. 1.0 ml) was added so that the monolayer of cells was 
adequately covered. The culture vessel was then incubated at 370 C 
for about 5-10 minutes. The resultant cell suspension was centrifuged 
for 5 minutes at a speed of 250g/minute. The medium was removed 
and the pellet of cells was resuspended in MEM solution. The 
suspension was aspirated thoroughly and the above sequence was repeated 
to obtain trypsin free cells. The cells were suspended in fresh 
MEM solution and incubated at 370 C for 4-6 days to obtain a monolayer 
of cells. 
By employing the above procedure actively dividing cells. ready 
for assay, were obtained. The drugs were assayed following a rapid 
331 
visual assay method and the active drugs were assayed following 
the Cancer Chemotherapy National Service Centre (CCNSC) procedure 332 
The resuspended cells. obtained after the trypsination sequence. were 
counted using a haemocytometer. The cells were dispersed in MEM 
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solution to ensure even distribution for the cytotoxic assay and 
approximately 5 x 105 cells were transfered to Gibco's Screw-cap 
tissue culture tubes containing 4.0 ml of the medium. Cells were 
incubated for 24 hours. Two tubes were used to obtain base-line 
cell number. 
Dimethylsulphoxide ( DMSDl 10 fl1 was added to two further 
tissue culture tubes and incubated to act as a control, and to the 
rest of the tubes, ~-methylene-S-lactones ( 0.1 - S.OjUg/mll in 
DMSO (1~lJ were added and incubated for 72 hours. All the assays 
were run in duplicate. After incubation, the cells were isolated 
employing the above trypsinisation sequence. The pellet of cells 
was taken up in 0.5 ml of the medium and cells were counted using 
a Coulter Counter ( Model Z, Coulter Electronics Limited, Herts, 
England). Dilution of samples was necessary to enable realistic 
number of cells to be counted. After conversion of Coulter Counter 
readings to total cell number, a graph of percentage death against 
concentration was plotted and an LD50 value, the concentration at 
which 50% of the total cells were added, was determined. ( See Appendix). 
• 
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RESULTS AND DISCUSSION 
The potent cytotoxic action of many sesquiterpene plant 
products and their ability to inactivate selected enzymes in vitro 
have been attributed to the presence of an ~-methylene butyrolactone 
mOiety4A,11C. These compounds can be viewed as a special class of 
naturally occurring alkylating agents, though the exact biological 
role these agents might have in plants remains undefined. Interest 
in OI-methylene butyrolactone derivatives as medicinal agents has 
been stimulated by the possibility that some of them might show 
enough selective cytotoxicity against neoplastic cells to be of 
therapeutic value as anti cancer agents. A number of sesquiterpenes 
containing the ~-methylene butyrolactone function have shown high 
t 11 i it .110,19,25,29,32,333 levels of cytotoxici y against tumour ce s n v ro 
Preliminary cytotoxic testing, employing a Rapid-Microtitre method, 
indicated that all the synthetic steroidal ~-methylenelactones were 
active at a concentration under 10 ~g/ml. The procedure of the Cancer 
332 Chermotherapy National Service Centre was employed to obtain an 
accurate LOSO value and all the steroidal ~methylene-S-lactones 
exhibited approximately equal significant cytotoxic activity at a level 
of 1.0 yg/ml or less against KB cells. (Table 11. 
R fi H2 
1t11lIO-C-C-CH3 
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TABLE 1 
".> ' 
LD 0 ug,ml 5 I 
COMPOUND MICRO TITRE METHoD331 CCNSC METHOD 332 
7A < 10 0.31 (0.32) 331 
225 < 10 0 •. 80 
.. -
230 < 10 1.271(0.58.0.44) 331 
233 NO ACTIVITY -
238 < 10 0.80 
239 <. 10 0.72 
255 < 10 1.0 
259 <. 10 0.92 
329 NO ACTIVITY -
Elephantopin. vernolepin, eriolangin and erioflorin were used as standards 
in the microtitre procedure. Elephantopin, the most active of the natural 
compounds and the one of comparable cytotoxic activity to the synthetic 
«- methylene lactones, was employed solely in the CCNSC procedure. 
------------------------------------------------------------------------_. 
-- - -- --------------
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(225) (230) 
OR 
(233) (238) R = H 
(239) R=OAc 
H 
(255) (259) 
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C8HI7 
H 
(329) 
Although only a few steroidal ~-methylenelactones 
structures were evaluated, the degree of activity appears 
to be independent, irrespective of whether the ~-m9thylene lactone 
moiety was in the A or 0 ring of the steroid nucleus. However, the 
A-ring ~-methylene lactones are relatively more active than the D-ring 
counterparts which could be due to a change in the configuration of 
ths D-ring in the steroid nucleus. 
The simple synthetic ~-methylene lactones are approximately 
29 as cytotoxic as more complex natural products This supports 
the tentative conclusion that in cell cultures, as opposed to the 
whole animal assays, the ~-methylene lactone, the alkylating function, 
is sufficient to confer cytotoxic properties upon the molecule, even 
in the absence of other reactive functionalities. Selective modification 
110 of the ~-methylene lactones moiety by hydrogenation or alkyl 
SUbstitution 32 always resulted in complete loss of cytotoxicity, 
thus identifying the activity conferring functionality. 
L _____________________________________ ____ ----" 
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The cytotoxic activity of testosterone (230). confirms previous 
finding on HEp-2-cell line331 • and of 5 ~-pregnan-3.20-dione (331)45 
suggests that cytotoxicity may be associated with steroid nucleus. 
In addition. it has been learned in clinical practice334.335 that 
testosterone can cause regression of neoplasm in certain women with 
advanced mammary cancer and several related steroids. such as 
(332) 17 0<: -methyltestosterone • and 5o<-dihydrotestosterone (333) 
have been found to have similar beneficial activity. The ~echanisms 
involved in the restraint of human mammary cancer by androstane 
I 
compounds are unclear. ~-Testololactone (334). which lacks hormone 
336 properties in man and animals was studied for" the effectiveness in 
337 patients with advanced breast cancer and 30% remission was observed • 
H 
(333) 
cY~ 
(229) 
(332) 
(334) 
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In certain androgen-sensitive tissues. 5 ~-dihydrogen-testosterone 
(333) is believed to be an actiue form of androgen338.339 and the 
presence of 5 ~-reductase. membrane bound. in mammalian tissues340-3S5 
. 356 357 
and in bacter~a • may help to explain the activity of testosterone. 
However. all attempts to reverse the reaction utilising mammalian 
enzymes have been unsuccessful. because although the first step in 
reversal ( enolisation) occurs the energy barrier for hydride 
abstraction is extremely high35B.359 Recently. the findings that 
human breast cancer can metabolise testosterone in vitro to 
androstendione (229) and the potent androgen 5 ~-dihydrotestosterone (333160 
. 361 has been confirmed • but contradict that 5~-reductase activity is 
absent in normal breast361 • 
The androgen-dependent Shionogi 115(S 115) and the androgen-
independent Shionogi 42 ( S 42) tumours 362 contain the NADPH-dependent . 
5 c< :'reductase enzyme necessary for forming 5 OI.-dihydrotestosterone (333) 
363 364 364 
• • although the activity is somewhat higher in S115 cells • 
It was also indicated that numerous active metabolites are necessary 
for the full expression of the androgenic response as this cannot be 
365 
elicited by 5 ~-dihydrotestosterone (333) alone • 
Since the early observations of Beatson.366.367 hormonal 
manipulations have become accepted modalities of therapy in leukaemia 
388 369 370 
and lymphomatous disease • breast cancer. endometrial and 
371 prostatic cancer A principle deterrent to wider use of these 
compounds has been the inherent hormonal side-effects. From the 
knowledge that most. if not all classes of steroid hormones result 
372 from relatively similar interactions of hormone with target tissue. 
it seems reasonable to assume that steroid receptor is at least a 
necessary. if not sufficient. condition for steroid hormone 
responsiveness in a target tissue. 
--~ 
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The responsiveness of some human leukaemias to glucocorticoids is 
demonstrated in previously untreated childhood acute lymohoblastic 
373,374 leukaemia (ALL) though many patients fail to respond. 
Unfortunately, glucocorticoid administration is associated with 
numerous serious and potentially life threatening complications. 
375 The failure of glucocorticoids to respond to ALL has been demonstrated 
"to be due to lack of steroid receptors in cancer cells. Corticoids 
cause lysis of several cultured cell lines, one of the fast effects 
being the inhibition of precursor uptake of nucleic aCids 376 and 
testosterone has been shown to be active in such systems. 
Glucocorticoids, such as cortisol (335) are employed in the 
treatment of ALL, if the tumour cells have steroid receptors and 
only if the glucocorticoids are active hormones as the receptors shown 
critical specificity in differentiating biologically active steroids 
from their inactive congenus. The 11p-hydroxyl configuration strongly 
favours binding to the receptor and the more potency of the glucocorticoid 
374 the greater the activity against ALL • 
(335) 
Experiments with rat 
380 data in human patients 
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377-379 
mammary tumours and preliminary 
indicate that tumours which contain 
appreciable cytoplasmic oestrogen receptor regress after endocrine 
ablation therapy whereas tumours without receptors,fBil to respond •. 
The cytoplasmic oestrogen receptor in human mammary tumours has 
properties similar to that from rat tumours381,383. Lack of oestrogen 
receptors satisfactorily predicts a lack of hormone responsiveness in 
human breast cancer although the presence of a receptor is clearly 
no guarantee that a tumour is responsive to the hormone. It has 
been shown that a breast tumour cell line ( MCF 7) which does contain 
receptors is stimulated by low doses of oestrogens but inhibited by 
384 high doses • In addition, these cells are killed by the anti-oestrogen 
Tamoxifen (336), used in the treatment of breast cancer. Tamoxifen has 
no action on cell lines that do not respond to oestrogen e.g. Hela and 
other breast cell lines and it binds to the oestrogen with 1000 x less 
the affinity of oestrogen; its action is reversible by oestrogens. 
The suppression of growth of population of leukaemia L5178Y cells 
in vivo and in vitro 385 by glucocorticoids was not surprising since 
the growth inhibitory activity of this class of steroids against other 
386-393 
cellular populations of mesenchymal origin is well established. 
(336) 
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It has been proposed28,141 that ~-methylenelactones can act 
as the alkylating centre for cytotoxic anti tumour lactone via 
Michael-type addition between biological nucleophiles. However, 
the target of attack for oc-methylenelactone is unlikely to be 
cysteine-scavenger, since KB cells have no absolute requirement 
for cysteine, as has been demonstrated from the studies on CCRF-CEM 
29 human lymphoblastic leukaemia cells in culture. In addition, 
the concentration of L-cysteine in medium is far greater than the 
concentration of the o<-methylenelactone. Thus, the cytotoxicity 
of these compounds cannot be due only to cysteine scavenging. 
Several studies have indicated that cancer cells are dependent 
394-398 
on the glycolytic and aerobic pathway for energy which is 
critical for the cells survival in view of the energy required for 
rapid nucleic acid and protein synthesis in proliferating cells. 
399 Recently, helenalin has been demonstrated to inhibit both 
aerobic and anaerobic energy process of tumour cells. 
The mechanism of growth inhibition ( i.e. cytotoxic activity) 
involves a mechanism other than ( or in addition to ) scavenging of 
free cysteine. One possibility is rapid, irreversible S-alkylation 
of various metabolically essential intracellular proteins ( e.g. 
288 
respiratory and other enzymes) • Whereas the inhibition of 
glycolytic metabolism is probably not the major mechanism of action of 
helenalin146, as an anti tumour ( ie the mebhanism most likely is 
inhibition of nucleic acid and protein synthesis although it had little 
effect on ribonucleic acid synthesis of Ehrlich tumour cells400 ) 
the fact that the energy available to cells for synthetic purposes 
is seriously hampered and rate limiting in the presence of helena11n 
~as an additive effect on the drug's action cellular metabolism and 
, 
tumour inhibition. The inhibition of the respiratory enzymes is 
-~ 
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probably of secondary importancel the important mechanism is of 
inhibition of DNA synthesising enzymes. It has been shown far 
sesquiterpene lactones, helenalin and tenulin that they do not 
alkylate nucleophiles of purine bases and this would agree with 
negative finding for steroid ~-methylene lactones in an Ames 
test,401 rather appear to be reactive with thiol groups of enzymes 
necessary for DNA replication. Furthermore, these agents can 
. cause an increase in cAMP levels of tumour cells which may be 
correlated with the suppression of chromatin protein phosphorylation 
necessary for cell replication and differentiation 146 • 
A second passibility is S-alkylation of sulphydryl groups in 
• 
cell surface proteins, as has been suggested for the action of 6,6 -
402 dithionicotinic acid and related cytotoxic pyridine disulphides 
The cytotoxic activity of the synthesised steroidal ~-m9thylene-
lactones is approximately in the same range as the plant sesquiterpene 
lactone, elephantopin. This higher cytotoxic value of elephantopin is 
contributed by two active alkylating sites, whereas the epoxide and 
the endocyclic ~,p-unsaturated lactone moieties do not contribute 
to the cytotoxicity. The cytotoxic activity was absent far lactones 
lacking the ~-methylene function, thus indicating the requirement of the 
~-methylene lactone structure for cytotixicity in this system. 
The presence of an 17p-acetate, conferring increased lipopMilicity, 
appears to increase the activity slightly which may suggest the increase 
in transport of the ~-methylene lactone structure. 
-122-
Preliminary work shows the steroidal ~-methylene-lactones 
to be inactive against Gram positive and Gram negative organisms 
403 
at a concentration of up to 100 fg/m1 • Testosterone and its 
metabolites, however, show antibacterial activity against both G +ve and 
404 G-ve organisms at a concentration of 20 jJg/ml • The ~,p-unsaturated 
lactones (337-339) were shown to be inactive against various G +ve 
405 
and G-ve micro-organisms at concentrations of 100 ~g/ml • 
H 
H 
(338) 
\339) 
---------------------------- - - - _.- _.-~ 
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Although the preliminary results are encouraging, 
the compounds must be tested for activity in vivo, since varied 
success has been achieved previously with steroid derivatives 
substituted with alkylating functions. The steroid receptor is 
406 
a protein which contains an essential -SH function and synthesis 
of hormonally active steroids containing ~-methylene-lactone 
functions could thus provide steroids which irreversibly bind to 
hormone receptors in tumour cells. 
EXPERIMENTAL 
L_ _____________________________________________ ____ __ 
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EXPERIMENTAL 
All solvents were distilled and dried, as appropriate, by the 
conventional methods before use. Solvents were removed in vacuo on a 
rotary evaporator. 
Analytical T.L.C. was performed using 0.75 mm thick layers of 
silica-gel ( P F254 according to Stahl) and preparative T.L.C. 
was performed using 1 metre plates of 0.75 mm thickness. Column 
chromatography was carried out using 'CAMAG'alumina (Brockmann activity 1). 
Infra-red spectra were determined for K Br discs, thin films or 
solutions in chloroform. on a Perkin-Elmer 177 and 257 spectrophotometer. 
Ultra-violet spectra was determined in ethanol, unless stated otherwise, 
on a Pye-Unicam SP 800e spectrophotometer. IH.N.M.R. spectra were 
determined for solutions in deutero-chloroform with tetrarnethylsilane as 
as internal standard, at 60 M Hz on Varian EM 360A or 90 M Hz on 
Perkin-Elmer R32 spectrophotometer, respectively. 
Mass spectra were recorded on an A.E.I. M.S.12 mass spectrophotometer. 
High resolution mass spectrometry was carried out on an A.E.I. M.S. 9 at 
P.C. M.U by courtesy of the S.R.C. 
Melting points were determined on a Koffler block and are uncorrected. 
Optical rotations were measured for solutions in chloroform at 250 C with 
a Bendix polarimeter 143C. 
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1. PREPARATION OF 2-HYoRoXYMETHYLENE-5 IX - CHoLESTAN-3-oNE 
Sodium metal ( 1.3ag; 60.0 mM) was added to dry ethanol [ 200 ml) 
with stirring. After all the sodium had dissolved. it was refluxed for 
45 minutes and then excess ethanol was evaporated to dryness. 
Benzene (150 ml) was added to sodium ethoxide [ formed as above) 
and nitrogen was passed through the solution. After fifteen minutes. 
5IX-cholestan-3-one ( 772.0 mg; 2mM) was added. After ten minutes of 
stirring. ethyl formate ( 4.44gl 60.0 mM) was added and the solution 
was stirred at room temperature for fi vs hours. Water [ 60 ml) was 
added and the stirring was continued for another fifteen minutes. 
The contents were transferred into a separating funnel and the 
aqueous layer was separated. The benzene layer was washed with water 
2 x 50 mll. The combined aqueous extract was washed with benzene 
( 3 x 100 ml) and the combined benzene extract was washed with water 
3 x 50 mll. The benzene extract was dried over magnesium sulphate 
and evaporated to dryness. The crude product [ 97.5 mg;l was shown 
to be the starting material. S/X-cholestan-3-one.as observed from T.L.C. 
and spectroscopic data. 
The aqueous washing was acidified to Congo Rsd with dilute 
hydrochloric acid and extracted with ether ( 3 x 150 ml). The combined 
ether extract was dried over anhydrous magnesium sulphate. and evaporated 
to dryness. The crude product was crystallised from chloroform-methanol to 
obtain crystals of 2-hydroxy-methylene-S oC-cholestan-3-one. 
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Yield: 592.0 mgl 71.5% 
LR. v· max 3640-2300 (£H, H-bondedl, 2975, 2950, 2885, 2870, 1562 
( ~,fl-unsaturated-ft-hydroxyketonesl, 1455, 1419, 1390, 1353, 
1332, 1279, 1255, 1235, 1219, 1146, 950, 943, 920, B06, 740, 
709. 
NMR. t 9.31 ( S, 3H, C18-CH3J. 9.22 ( S, 3H, C19-CH3l, 
7.B1 ABq, 2H, C4-H, J = 15.0 Hz, 18.0 Hzl. 
2.60 S, 1H, C=CH-OHl, 1.34 ( S, 1H, C = CH - OHl 
U.V. (.. max 283 nm ( E 16,837l. 
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2.PREPARATIDN OF CHDLEST-4-EN-3-DNE (2021 283 
Distilled toluene ( 400 mll was added to a 1 litre three-necked 
flask, equipped with a stirrer, a dropping funnel and a Dean-Stark trap. 
The openings of the dropping funnel and the condenser were protected 
with drying tubes. A portion of toluene ( 40 mll was distilled off, 
in order to dry the system by azeotropic distillation, then cholesterol 
( 201, 20.0g, 0.052Ml and cyclohexanone ( 100 mll was added to the 
flask. After an additional toluene ( 10 mll had been distilled off, a 
solution of aluminium isopropoxide* ( 5.6g, 0.028Ml in toluene ( 80 mll 
was added dropwise aver a period of approximately 30 minutes. During 
this time, toluene was distilled at a rate slightly greater than the 
rate of addition of the catalyst solution, sa that when the addition was 
complete, about 120 ml of toluene had been distilled. After an additional 
toluene 60 mll had been distilled, the. murky-orange coloured reaction 
mixture was allowed to cool to room temperature. 
A saturated solution of Rochelle salt ( potassium sodium tartarate, 
(80 mll was added to the reaction mixture and the organic layer became of 
clear orange colour. The stirrer assembly was removed and the mixture 
was steam-distilled until 1200 ml of distillate had been collected. 
The residual mixture was cooled and extracted with chloroform ( 3 x 100 mll. 
The combined extract was washed with water ( 2 x 50 mll, dried over 
anhydrous magnesium sulphate, filtered and evaporated to dryness. 
The residual viscous ail (amberl was dissolved by heating in methanal 
( 15 mll. When the solution had cooled to about 400 e, seeds of 
cholest-4-en-3-one were added and the flask was wrapped with a small 
towel to ensure slow cooling. After the bulk of the material had 
crystallised, which required several hours, the flask was stored overnight 
at DOe. 
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The product was collected by suction fi1teration washed with 
methanol ( 4-5 ml), previously cooled in an ice-salt bath, and then 
dried at reduced pressure at room temperature obtaining light cream 
coloured crystals of cholest-4-en-3-one (202). 
M.P. 77-790 C ( Lit. M.p. 283 79-81 oC) 
Yield: 13.95g, 70% 
IR V max 3020, 2950, 2935, 2870, 1673 ( C=O), 1612 (C=C ), 
1470, 1443, 1430, 1415, 1380, 1375, 1330, 1265, 1232, 1227, 
1190, 1172, 1125, 955, 945, 929, 899, 868, 772, 729, 681. 
NMR ( COC1 3) t 9.27 ( S, 3H, C18-CH3), 8.81 ( S, 3H, C19-CH3), 7.62 
. (m, 2H, C2-H), 4.25 (bs., 1H, C4-H) 
• Aluminium isopropoxide was taken up in dry, distilled chlorofor~ 
and filtered rapidly to remove aluminium hydroxide ( white gelatinous 
precipitate). The filterate was evaporated to dryness and solid 
then employed in the reaction. 
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3. PREPARATION OF 4-0XA-5~-CHOLESTAN-3-0NE (203)264 
Potassium persulphate ( 27.0g) and concentrated sulphuric acid 
( 30.0g) were mixed in a mortar and diluted with glacial acetic acid 
(300 mll. The resulting mixture was added to a solution of Cholest-4-
en-3-one (202, 9.0g) in glacial acetic acid ( 600 ml). Following 
a 7-day period of intermittent shaking at room temperature, in the 
absence of light, the mixture was cooled and treated with aqueous 50% 
potassium hydroxide ( 180 mll. The precipitated salt was removed 
o by filtration and the filterate was evaporated to dryness ( in vacuo at 60 Cl. 
The residue was taken up in ether ( 250 mll, washed successively with 
water ( 3 x 100 mll, 5% sodium hydrogen carbonate ( 3 x 100 mll and water 
( 3 x 100 mll. The ether solution was dried over anhydrous magnesium 
sulphate and evaporated to dryness. The crude solid was crystallised 
from ethanol to obtain light cream-yellow crystals of 4-oxa-5~-cholestan 
-3-one (203l. 
M.P. 113-1150 C (Lit M.p. 264 116-118oCl 
Yield: 3.64g ( 40%l 
IR -V max: 2950, 2935, 2870, 2855, 1730 (C=O l, 1467, 1459, 1390, 1380, 
1374, 1364, 1259, 1190, 1130, 1112, 1076, 1047, 991, 955, 940, 664. 
NMR (COC1 3l 9.32 ( S, 3H, C18-CH3l, 9.06 ( S, 3H, C19-CH3l 
7.38 ( dd, 2H, C2-H, J = 6.0HZ' J 10.0 HZ) 6.02 ( q, 1H, 
C5-~H, J = 4.6 and 11.4 HZ1. 
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4. PREPARATION OF 2-HYOROXYMETHYLENE-4-0XA-5 0< -CHOLESTAN-3-0NE (222) 160 
Sodium hydride ( 960 mg; 20.0 mM. 50% dispersion) was weighed 
into a drY three-necKed 500 ml round-bottom flask and washed twice with 
dry benzene followed by dry ether with nitrogen passing through the 
reaction flask all the time. To a suspension of sodium hydride in 
dry ether ( 200 ml). 4-oxa-5o<:-cholesterrS-one (203; 388.0 mg; 1.0 mM) 
was added with stirring. After about 5 hours of stirring. distilled. 
dry ethyl formate ( 1.58g;'20.0 mM) was added and the reaction mixture 
was left stirring at room temperature under a nitrogen atmosphere. 
( The course of the reaction was checked. at intervals. by thin-layer-
chromatography (T.L.C) ). 
When the reection was complete ( on T.L.C.). after about 70 hours. 
the reaction mixture was acidified carefully with dilute hydrochloric acid 
and washed with water ( 3 x 100 ml). The ether solution was dried over 
anhydrous magnesium sulphate. filtered and evaporated to dryness. The 
light-yellowish residue was crystallised from ethanol to obtain crystals of 
2-hydroxymethylene-4-oxa-5 Ot-cholest-3-one (222). 
Yield: 374.0 mg ( 84%). 
IR V max 3600-2400 ( H bonded OH). 3020. 2940. 2880. 2860. 1715. (CsO) 
1620 (C=C J. 1450. 1388. 1345. 1282. 1171. 1140. 1105. 
1040. 1025. 998. 950. 937. 920. 760. 742. 668. 
3 U.V. ~ max251 mm ( E 6.95 x 10 ) 
Ace. Mass. Cal: 416.3291 
Found: 416.3293 
(LX) 0 (+) 104.17 (C. 0.12) 
NMR ( COC13/0MSO)t9.33 ( S. 3H. C18-CH3)' 9.15 ( S. 3H. C19-CH3) 6.13 
(m, 1H. Cs"'-Hl. 2.82 and 2.2 (bs. 1H. Z-and E- HO _ CH = ~ -J. 
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The 'H n.m.r. spectrum of the hydroxymethylene lactone (222) 
displayed signals for both ~-(minor) and E- (major) isomers whereas 
the absence of H-bonding evidence in the infra-red ( K Br disc) was 
characteristic of the E- isomer only. It appears that the E-isomer 
preferentially crystallises and equilibrates to give a mixture of 
~ - and ~ isomers in CDC1 3 solution. Similar observations were 
made for compounds (235), (223) and (236). 
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5. PREPARATION OF 2- ( N,N-oIETHYLAMINo METHYLENE) -4-oXA-5 0(- CHoLESTAN-
3-oNE ( 223)160. 
To a solution of 2-hydroxymethane-4-oxa-5 ~-cholestan-3-one 
(222, 374.0 mgl 0.9 mM) in dry benzene ( 150 ml), distilled diethylamine 
(1.46g1 20.0 mM) was added and the reaction mixture was refluxed using 
a Dean-StarK trap. When the reaction was complete; after about 85 hours 
(T.L.C.) the solution was evaporated to dryness. The crude residue was 
crystallised from acetone/pet-ether (60-800 ) to obtain light-yellowish 
orystals of 2iN, N-diethylamino)methylene-4-oxa-5 ~-cholest-3-one (223). 
Yield: 382.0 mg ( 90.0%) 
IR \l max 2920, 2850, 1675 (C=O), 1560 (C=C), 1455, 1375, 1350, 
u. v. >. max 
Ace. Mass. 
1312, 1237, 1170, 1120, 1070, 1051, 939, 805, 751, 739 
301 nm (€ 2.84 x 104) 
Call 471.4076 
Found: 471.4087 ( M, C31 H53 N02 l 
(-) 16.20 ( C, 0.46) 
NMR 't 9.'32 (S, 3H, C18-CH3)' 9.11 S, 3H, C19-CH3), 
8.79 ( t, 6H, 2X - N-CH2-C~3' J = 7.0 HZ)' 6.64 and 6.73 
I (q, 4H, ~- and I- CH3-CH2-N-CH=C-, J = 7.0 HZ), 6.11 
( q, 1H, CS- H), 2.82 and 2.30 ( 1H, bs, I- and E-(CH3 CH2 )2 
1 
NCH=C-). 
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6. PREPARATION OF 2-METHYLENE-4-oXA-5 ~-CHoLESTAN-3-oNE (225)160 
2-N,N-Diethylamino methylene-4-oxa-5 ex-cholestan-3-one C.~), 
375.0 mgl 0.8 mM) was taken up in glacial acetic acid 40 mll and 
hydrogenated using the Adams' catalyst-Platinum oxide 50.0 mg). 
The hydrogenated product was filtered and evaporated to dryness. 
The residue (224) was ta~en up in glacial acetic acid ( 40.0 ml) 
and sodium acetate ( 400 mg) was added. The reaction mixture was 
heated under reflux for four hours and the course of the reaction 
followed on T.L.C. 
On completion of the reaction, the reaction mixture was 
concentrated and treated with saturated sodium hydrogen carbonate solution 
until there was no more evolution of carbon dioxide. The aqueous solution 
was extracted with ether ( 3 x 100 ml). The combined ether extract 
was washed with water ( 2 x 50 ml), dried over anhydrous magnesium 
sulphate and evaporated to dryness. The crude product was crystallised 
from methanol giving white crystals of 2-methylene-4-oxa-5 ~-cholestan-3-one 
(225). 
Yield: 243.0 mg ( 76% from 224), 58% overall 
IR V max 2940, 2870, 1725 (C=O ), 1620 ( C=C), 1473, 1460, 1383, 1310, 
1283, 1260, 1190, 1151, 1076, 1042, 1029, 995, 945, 912, 605. 
NMR ( CoC1 3 ) L 9.3 ( S, 3H, C18-CH3), 9.07 ( S, 3H, C19-CH 3). 
5.95 ( q, 
o 
" o - C - C 
I 
1H, CS-c(H, J = 11.0 and 
f.I 
, 
5.0 HZ) 
o 
4.43 (m, 
It 
= C - !!.), " 3.50 ( m, 1H, 0 -C - C = C - H) 
I 
1H, 
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u.V ?- max (EtOH) 213 nm (6. 7.19 x 103) 
(Hexane) 217-8 nm ( E 5.0 x 103) 
Ace. Mass 
Analysis: 
Cal: 400.3341 
Found: 400.3329 ( M, C27 H44 O2) 
(+) 90.51 (C, 0.16) 
Expected:C, 80.94J H, 11.07 
Found: C, 80.7, H, 11.2 
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7. REACTION OF L-CYSTEINE WITH 2-METHYLENE-4-0XA-5O',-CHOLESTAN-3-0NE 
(225)18S. 
2-Methylene-4-oxa-5 0< -Cholestim-3-on .. (225, 40 mgl 0.4 mM) 
, -
and L-cysteine ( 12.1 mg: 0.4 mM) were mixed in SO% aqueous ethanol 
( 5.0 ml) and heated under reflux for one hour over a water-bath. 
The reaction mixture was allowed to cool to room temperature. 
The white precipitate was collected, washed well with the solvent 
( 60% aqueous ethanol) and dried. Recrystallisation from aqueous 
ethanol gave white crystals of the Cysteine adduct (227). 
Yield: 41.2 mg, (7.9%) 
IR V max 3700 - 2300 ( COOH and NH2), 2930, 2865, 1725 (C=O) 
of carboxylic acid and lactone) ( COO- 1466, 1381, 1345, 1238. 
1219, 1185, 1131. 1075. 1040. 990. 950. 
Acc. Mass. Found ( M - C3 HS N02 S)+ = 402.3492, C27 H4602 (Cal: 402~3947) 
(M - C3HS N02S)+ : 401.3388, C27 H4S O2 (401.3419). 
(M - C3 H7 N02 S)+ = 400.3333, C27 H44 °2 ' (400;3341) 
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B. PREPARATION OF ANDROST-4-EN-3, 17-DIDNE ( 229)283 
To a litre three-necKed ~ound bottom flasK, equipped with a 
stirrer, a dropping funnel and a Dean-Stark trap, toluene ( 200 ml) 
was added. The openings of the dropping funnel and the condenser 
were protected with drying tubes. A portion of toluene ( 20 ml) 
was distilled in order to dry the system by azeot ropic distillation. 
Androst-4-en-3-~-01-17-one (228, 10.0g; 30.0 mM) and cyclohexanone 
( 50 ml) were added to the flasK. After an additional toluene ( 5 ml) 
had been distilled, a solution of aluminium isopropoxide* (2.8g; 
O.028Ml in toluene ( 40 ml) was added dropwise over a period of 
approximately 30 minutes. During this period, toluene was distilled 
at a rate slightly greater than the rate of addition of the catalyst 
solution, SO that when the addition was complete, about 60 ml of 
toluene had been distilled. After an additional toluene ( 30 ml) 
had been distilled, the orange-yellowish solution was allowed to cool 
to room temperature. 
A saturated solution of Rochelle salt (potassium-sodium tarterate, 40mt) 
was added to the reaction flask and the organio layer became clear and 
light yellow. The reaction mixture was steam -distilled until about 
600 ml of the distillate had been collected. The residual mixture was 
cooled and extracted with chloroform ( 3 x 100 ml). The combined 
extract was washed with water ( 2 x 50 ml), dried over anhydrous 
magnesium sulphate and evaporated to dryness. Crystallisation of the 
crude solid from acetone-hexans (Pet-ether 60-800 ) gave white crystals 
of androst-4-en-3,17-dione (229). 
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M.P. Lit. M. p. 331 173-174oCl 
Yield: 6.44g1 ( 65%l 
IR Y max 3030, 2960, 2925, 2655, 2625, 1730 ( C17C=O l, 1660 (C3-C=Ol, 
1615 (C=Cl, 1452, 1431, 1421, 1407, 1360, 1350, 1331, 1292, 
1272, 1250, 1235, 1227, 1192, 1175, 1155, 1123, 1111, 1093, 
1056, 1031, 1016, 950, 936, 930, 919, 900, 870, 831, 625, 780, 
713, 670, 655. 
NMR (CDC1 3l T 9.07 ( S, 3H, C16-CH3l, 8.77 ( S, 3H, C19-CH3l, 
7.60 ( m, 2H, C2-Hl 
4.24 ( bs, .1H, C4-Hl 
• See footnote for preparation of cholest-4-en-3-one 
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9. SODIUM BOROHYDRIDE REDUCTION OF ANDROST-4-EN-3,17-0IDNE (229)292 
Ta a solution of androst-4-en-3,17-dione (229, 3.50g; 12.24 mM) 
in methanal ( 400 mll at OOC, sodium borohydride ( 555.0 mg; 14.7 mM; 
1.2 equiv) was added. After stirring far one hour at OOC, glacial acetic 
acid ( 15-20 drops) was added and the solution was evaporated to 
dryness in vacua. The residue was taken up in hat ethyl-acetate and the 
precipitate was filtered. The precipitate was washed thoroughly with 
hat ethyl acetate and the fil t:· rate was evaporated to dryness. The 
crude product ( 3.38g) was separeted an silica ( solvent; chloroform/ 
methanal; 99/1) and obtained two products. 
The non-polar crude product was crystallised from acetone and 
obtained white crystals of androst-4-en-17j'-ol-3-one (230). 
M.P. 151-1530 C ( Lit M~9l54-154.50C) 
Yield: 2.85g: (81%) 
IR v max 3700 -3100 (OH) 3030, 2955, 2930, 2875, 2855, 1660 ( C=O) 
1612 ( C=C), 1469, 1448, 1432, 1418, 1382, 1348, 1331, 1320, 
1301, 1278, 1271, 1231, 1192, 1173, 1131, 1111, 1079, 1058, 
1020, 955, 939, 915, 861, 828, 780, 685. 
NMR (COC1 3)'C 9.21 ( S, 3H, C1S-CH3J, 8.80 ( S, 3H, C19-CH3J, 7.62 ( m, 2H, 
6.57 (bs, jH , C1rOHJ , 6.36 ( t, 1H, C17- 0< -H, J = 8.0 HZ) , 
4.28 ( bs, 1H, C4-H). 
C2-H) 
-139-
The polar compound was crystallised from acetone to obtain white 
crystals of androst-4-en-3p717~-diol (234J. 
M.P. 150-2oC (Lit. M.f.9~53-4oCJ 
Yield: 428.0 mgl (12.0%) 
NMR (CDC1 3Jl9.26 ( S. 3H. C18-CH3J. B.95 ( S. 3H. C19-CH3)' 
7.41 ( bs. 2H. C3: ,C17-0HJ. 6.39 ( t. 1H. C17 CJ(-H. 
J s 8.0 HZ)' 5.89 (m. 1H. C3 ~-H). 4.70 ( bS. 1H. C4-H) 
• 
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10. ALLYLIC OXIOATION293 WITH MANGANESE DIOXIDE 
Androst-4-en-3~,17~-diOl (~, 
in chloroform ( 67.0 mll and stirred 
Tor ten hours at room temperature. 
3.0g, 10.0mMl was suspended 
294 
with manganese dioxide (11.9g) 
Manganese dioxide was removed by 
filteration. The precipitate was washed thoroughly with hot chloroform 
and the combined washing was dried over anhydrous magnesium sulphate 
and evaporated to dryness. The crude solid was crystallised from acetone 
to obtain white needles of androst-4-en-17~-ol -3-one (230). 
Yield: 2.59g ( 87%) 
IR V max 3620-3100 (OH), 2955, 2930, 2875, 2855, 1675 (C=O), 
1612, (CaD), 1469, 1448, 1432, 1418, 1381, 1347, 1331, 1320, 
1305, 1280, 1231, 1180, 1172, 1131, 1111, 1079, 1065, 1057, 1020, 
995, 956, 939, 915, 861, 828, 780, 685. 
NMR (COC1 31 't 9.21 ( S, 3H, C18-CH 3) , 8.80 ( S, 3H, C19-CH3) , 7.62 
(m, 2H, C2-H, ) 6.57 ( bs 1H, C17-0H) , 6.36 ( t, 1H, C17 -IX-H,-
J = 8.0 HZ)' 4.28 ( bs, 1H, C4-H). 
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11. PREPARATION OF 17P-ACETOXY-ANDROST-4-EN-3-0NE ( TESTOSTERONE ACETATE 1 (2311 
To a solution of androst-4-en-17p-ol-3-one (230' 3.6g1 12.5mMl 
in pyridine ( 60 mll. acetic anhydride (30 mll was added with stirring. 
The solution was stirred for two hours and then left to stand overnight 
at room temperature. 
The reaction mixture was poured over ice-water and extracted with 
ether ( 3 x 150 mll. The combined ether extract was washed with 
dilute hydrochlorio acid ( 3 x 50 mll to remove pyridine. followed by 
water ( 3 x 50 mll. dried over anhydrous magnesium sulphate and evaporated 
to dryness. Crystallisation of the crude product from aqueous acetone 
gave white crystals of 17p-acetoxy-androst-4-en-3-one (2311. 
Yield: 3.63g ( 88%1 
IR. V max 3030. 2940. 2910. 2880. 2855. 1735 (Acetate CoO). 1670 ( C3 -
Coo ). 1618 ( C=C). 1450. 1435. 1421. 1390. 1375. 1356. 1332. 1310. 
1290. 1270. 1245. 1187. 1130. 1118. 1070. 1031. 1021. 998. 975. 958. 
938. 919. 860. 831. 775. 750. 685. 661. 
NMR (CDC131"'C 9.16 ( S. 3H. C18-CH31. 8.82 ( S. 3H. C18-CH31 7.97. (5. 
o 
" 3H. C17j3 - 0 - C - CH31. 7.63 ( m. 4H. C2• C16-H). 5.40 ( t. 1H. 
Cn c<-H J = 8.0HZ)' 4.27 ( bs 1H. C4 H). 
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12. PREPARATION OF 17~-ACETOXY-4-0XA-5 0<- ANDROSTAN-3-0NE [232l 264 
Potassium persulphate [12.1gl was grounded with concentrated 
sulphuric acid [ 13.4gl and diluted glacial acetic acid ( 160 mll. 
The resulting mixture was added to a solution of 17~-acetoxy-androst-
4-en-3-one [231, 3.0g, 9.1mMl in glacial acetic acid ( 320 mll. 
The reaction mixture was shaken intermittently and left in the dark 
at room temperature for seven days. 
The reaction mixture was cooled and treated with 50% potassium 
hydroxide solution [ 60 ml). The precipitated salts were removed by 
filteration and the filterate was evaporated to dryness. The residue 
was taken up in ether [ 250 mll, washed with water ( 3 x 100 mll, 
5% sddium carbonate solution ( 3 x 100 ml) and finally with water 
( 3 x 100 mll. The ether solution was dried over anhydrous magnesium 
sulphate and evaporated to dryness. The crude product was crystallised 
from acetone-pet ether [ 40-600l to obtain white crystals of 17P-
a~etoxy-4-oxa-5 ~-androstan-3-one (232). 
Yield: 1.35g [ 44%l 
IR \l max 2940, 2865, 1735 [C=O l, 1450, 1403, 1388, 1376, 1363, 1255, 
1235, 1212, 1201, 1143, 1121, 1083, 1060, 1049, 1042, 1025, 1017, 
963, 950, 924, 810, 874, 845, 815, 803, 788, 752, 
NMR [COCI 3l '( 9.27 S, 3H, C18-CH3l, 9.09, Cl 
[ S, 3H, C19-CH3l 
" 8.01 S, 3H, C17~ - O-C-CH3), 7.44 [m, 4H, C2 and C16-Hl, 
6.10 ( q, 1H, CS-o( H, J = 4.4 and 10.4 Azl, 5.50 
( t, 1H, C1704H, J = 8.0 HZl 
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13.PREPARATION OF 4-0XA 5-0<- ANOROSTAN-17~-OL-3-0NE (233)295 
17~-Acetoxy-4-oxa-5 0< -androstan-3-one (232, 1.47g1 
4.37 mM) in methanol ( 58.4 ml) and water ( 7.3 ml) was saponified 
by refluxing with 10% methanolic potassium hydroxide ( 8.03 mll for one 
hour. Then the solution was acidified with 3N hydrochloric acid ( 8.03 ml), 
diluted with water ( 73 mll and heated on a steam-bath for one hour 
in a current of nitrogen. 
The reaction mixture was allowed to cool to room temperature 
and extracted with ether ( 3 x 100 mll. The combined ether extract was 
washed once with water ( 50 mll, dried over anhydrous magnesium 
sulphate and evaporated to dryness. The crude product was crystallised 
from acetone/pet-ether (BO-800Cl to obtain white crystals of 4~oxa-5 
androstan-17~-01-3-one 233). 
Yield: 9861.0mg ( 77%) 
IR V max 3700 - 3100 (OH). 2945, 2875, 1720 (C=O ), 14S1, 1411, 1397, 1386, 
1350, 1318, 1274, 1260, 1232, 1210, 1173, 1140, 1120, 1080, 1051, 
1010, 958, 910, 901, 868, 835, 800, 743, 
NMR (COC1 3) -C 9.27 ( S, 3H, C18-CH3), 9.08 S, 3H, C19-CH3l, 7.97 (bs, 1H, 
C17 -OH ), 7.39 ( dd, 2H, C2-2H, J = 6.2 HZl, 6.311 (t, 1H, C1701.-H, 
J = 8.4 HZ)' 6.03 ( q, 1H, CSc(-H, J = 4.4 and 12.0 HZ ). 
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14. PREPARATION OF 2-HYOROXYMETHYLENE-4-0XA-5 ~-ANDROSTAN-17P-OL 
-3-0NE (235}160. 
Sodium hydride ( 1. 574g1 32.8 mM't 50% dispersion) was weighed 
into a 250 ml three-necked round bottom flask and washed with dry 
benzene followed by dry ether with nitrogen passing through the 
reaction flask. To a suspension of sodium hydride in ether ( 150 ml), 
4-oxa-5 0< -androstan-17p-ol-3-one (233, 480.0 mgl 1.64 mM) was added 
with stirring. After five hours of stirring, distilled ethyl formate 
( 2.34g1 32.8 mM) was added and the reaction mixture was allowed to 
stir at room temperature under a nitrogen atmosphere. 
When the reaction was complete ( as observed on T.L C ), after 
about 90 hours, the reaction mixture was acidified carefully with dilute 
hydrochloric acid. The ether solution was washed with water ( 3 x 50 ml), 
dried over anhydrous magnesium sulphate and evaporated to dryness. 
The crude product was crystallised from acetone-pet ether ( 40-600 ) 
to obtain white crystals of 2-hydroxymethylene-4-oxa-5 0(-androstan-17~"?1-3-0r:te 
(235) • 
o ~'.P. 221-3 C 
Yield: 458.0 mg, 87% 
IR V max 3420 (OH), 3700-2400 (H bonded OH). 2950, 2940, 2860, 1706 fc=o J 
1612 (C=C},,1446, 1385, 1334, 1276, 1208, 1168, 1134, 1101, 
1016, 945, 931, 760, 665, 
UV 'I-. max (EtOH) 252.3 nm (t' 7863) 
(+) 94.87 C, 0.18) 
Acc. Mass. Expected: 320.1987 
Found: 320.1986 ( M, C19 H28 04) 
NMR '( 9.25 ( S, 3H, C18-CHg), 9.11 ( S, 3H, C19-CH3) 
6.40 t, 1H, C17C)(- .H, J = 8.0 HZ}, 6.11 ( q, 1H, C5 H, J = 5.0 
and 11.0 HZ)' 2.78 and 2.16 ( bs, 1H, Z- and E- HO-C~=CH-) 
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15. PREPARATION OF 2 N,N-oIETHYLAMINo METHYLENE-4-oXA-5~-ANDRoSTAN-
17P-oL-3-oNE ( 236). 
To a solution of 2-hydroxymethylene-4-oxa-5 ~-androstan-17p-ol-
3-one (2351 450.0 mgl 1.41 mM) in dry benzene (150 ml), distilled 
diethylamine ( 2.o6g1 28.2mM) was added and the reaction mixture was heated 
under reflux employing a Dean-Stark trap. When tne reaction was complete 
( as observed on T.L.C.), after about 85 hours, the solution was 
evaporated to dryness (Yield: 490.0 mg (93.0%). The crude product 
was crystallised from acetone/pet-ether 60-800 ) to obtain light 
yellowish crystals of 2-N,N-diethylamino methylene-4-oxa-5~ -androstan-
17b-ol-3-one (236). 
o M.P. 121-3 C 
Yield: 490.0 mg ( 93.0%) 
IR V max 3420 (OH), 2980, 2950, 2880, 2860, 1670 (C=O), 1570 (C=C), 
1471, 1449, 1385, 1355, 1330, 1252, 1192, 1168, 1134, 1097, 
1088, 1045, 1030, 949, 927, 885, 857, 825, 819, 767, 753, 
NMR ( CDCl 3) 1:" 9.23 [ S, 3H, C18-CH3)' 9.05 ( S, 3H, C19-CH3J. 
UV. 
8.78 ( t, 6H, 2(-N-CH2-C!:!3' J = 7.4 HZ)' 7.68 (q, 2H, C-r-2H, 
J = 14.2 HZ)' 6.64 ( q, 4H, 2( N-C~-CH3' J= 8.8HZ), 
6.32 ( t, 1H, C17o(-H) 6.04 ( q, 1H, CS"'-H, J = 5.0 and 11.oH) 
2.83 and 2.30 ( bs, 1H, ~- and §.-(CH3CH2hNCIj= 
i\ max EtoH) 3oo-1nm ( :1: 1.3171 x 104) 
(+) 41.74 ( C, 0.11) 
C j 
Acc. Mass. Calculated: 375.2774 
Found: 
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16. PREPARATION OF 2-METHYLENE-4-DXA-5o< -ANOROSTAN-17~-OL-3-0NE (238) 
2-N,N-Diethylamino methylene-4-oxa-5 ~-androstan-17~-ol-3-one 
(236, 530 mg: 1.41 mM) was taken up in glacial acetic acid ( 40.0 ml) 
and hydrogenated by using the Adam's catalyst-Platinum oxide ( 75.0 mg). 
The hydrogenated product was filtered to remove the catalyst and 
evaporated to dryness. 
The residue, saturated product (237) was dissolved in glacial 
acetic acid ( 40.0 ml) and sodium acetate ( 726.0 mg) was added. The 
reaction mixture was refluxed for four hours. The solution was concentrated 
and treated with a saturated solution of sodium hydrogen carbonate until 
there was no evolution of carbon dioxide. The aqueous solution was 
extracted with ether ( 3 x 100 ml). The combined ether extract was 
washed with water ( 3 x 50 ml), dried over magnesium sulphate and 
evaporated to dryness. 
The crude product ( 407.0 mg) appeared to be a mixture of two 
compounds. The crude product was separated on preparative thin-layer-
chromatography ( solvent system: chloroform/methanol: 85/15). The 
crude compound, with higher Rf value, was crystallised from 
aqueous methanol to obtain white crystals of -17~-acetoxy-2-methylene-4 
-oxa-5 IX-androstan-3-one (~). 
Yield 147.0 mg, 30% 
(0<)0 (+) 72.35 ( c, 0.11) 
Acc. Mass 
Calculated: 346.2144. 
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IRV max 2965,2940, 2BBO, 2B45, 1735 (C=OJ, Acetate), 1723 (C=O) 
1625 (C=C J, 1460, 1437, 1393, 1369, 1355, 1315, 1303, 12B5, 1246, 
1220, 11B1, 1141, 1117, 1079, 1027, 999, 94B, 917, 679, 653, 632, 
755, 660. 
NMR ( CDCl 3 J 1. 9. 18 ( 
7.92 ( S, 3H, 
S, 3H, C16-CH3)' 9.07 ( 
o 
C17 -0~-CH3)' 7.52 ( q, 
S, 3H, C19-CH3), 
2H, C1-2H, J = 16.0 HZ)' 
5.94 ( q, 1H, C5OC-H, J 
J = 8.0 HZ)' 4.39 ( m~ 
= 11.0 and 4.0 HZ)' 5.36 ( t, 1H, C17~ -H, ~ ~ 
o H 
1H, 0 - C - C = C-~), 3.48 ( m, 1H, 
" , o - C - C = C -H) 
UV max 214-5mm (€~ 7936) 
ANALYSISjEXPECTED: C, 71.80, H, 8.73, FOUND: C, 72.45, H, 8.9. 
The mqre polar of the two compounds was crystallised from 
aqueous methanol to obtain white crystals of 2-methylene-4-oxa-5 
androstan-17p-ol-3-one. 
M.P. 144-6oC 
Yield: 120.0 mg 2B% 
Acc. Mass. Found: 304.2071 ( M, C19 H2B 03) 
Calculated: 304.2079 
IR V max 3440 (OH), 3015, 2955, 2930, 2B55, 1712 (C=O), 1623 (C=C), 
1460, 1445, 1375, 1317, 12BO, 1215, 11B9, 1145, 1040, 1026, 
950, BOB, 664. 
NMR (CDCl 3) 'C 9.23 (S, 3H, C18-CH3)' 9.07 ( S, 3H, C19-CH3)' 7.53 (q, 2H, 
C1-2H, J = 15.0 HZ), 6.34 ( t, 1H, C17o(-H, J = B.O Hz), 
UV 
5.88 (q, 1H, CSoc-H, J 
~ ~ 
= 11.0 and 4.0 HZ)' a H 
O-C-C=C-~), 3.51 ( m, 1H, 11 'j" O-C-C=C-H) • 
~ max 214-5 nm (€ 6680). 
4.42 ( m, 1H, 
------------------------------------------------------------ -
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17. REACTION OF L-CYSTINE WITH 17~-ACETOXY-4-METHYLENE-4-0XA-5~­
ANDROSTAN-3-0NE (239)85 
17~-Acetoxy-2-methylen8-4-oxa-5~-androstan-3-one 
(~, 57.0 mgl 0.16 mM) and L-cystine ( 29.0 mgl 0.16 mM) were 
dissolved in 60% aqueous ethanol ( 7.5 ml) and heated over water-
bath for one hour, . 
The reaction mixture was allowed to cool to room temperature. 
The light-yellowish crystals were filtered, washed thoroughly with 
60% aqueous ethanol and dried. Recrystallisation from aqueous ethanol 
gave white crystals of the cysteine-adduct ( 240). 
M.P. 
Yield: 
IR\)max 
53.0 mg, ( 69%) 
3700-2300 ( CDDH and NH2 J, 2940, 2870, 1735 (C=O of carboxylic 
acid and lactone), 1621 ( COO- ), 1586, 1489, 1412, 1385, 1341, 
1300, 1249, 1196,'1129, 1091, 1046, 967, 878, 852,783, 676. 
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18. PREPARATION OF 3~-ACETOXY-ANOROST-5-EN- 17-0NE (2421 
To a solution of androst-5-en-3~-ol-17-one (2411, 
10.0g, 0.03Ml in pyridine ( 100 mll, acetic anhydride ( 100 mll 
was added with stirring. The solution was stirred for two hours 
and left to stand overnight at room temperature. The reaction 
mixture was poured onto ice-water and extracted with ether ( 3 x 100 mll. 
The combined ether extract was washed with ice-cold water ( 3 x 100 mll, 
dilute hydrochloric acid ( 3 x 50 mll, followed by water ( 3 x 50 mll, 
dried over anhydrous magnesium sulphate and evaporated to dryness. 
The crude product was crystallised from methanol to obtain white 
crystals of 3p-acetoxy-androst-5-en-17-0ne (2421. 
Yield: 9.74g ( 85%1 
I.R. \l max 3040, 2965, 2875, 1740 (C=O 1, 1475, 1448, 1415, 1384, 1373, 
1259, 1228, 1148, 1069, 1039, 1020, 965, 915, 855, 841, 
822, 810, 690, 676, 
NMR ( COCl 31! 9.08 ( S, 3H, C18-CH 31, 8.92 ( S, 3H, C19-CH31, o 
7.94 (S, 3H, C3-0-~-CH31 7.S5 ( m, 4H, C2, Ci6 -Hl 
5.35 (m, 1H, C3-O<Hl, 4.55 ( d, 1H, Cs-H, 5.0 HZl 
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19. PREPARATION OF 3P-ACEToXY-51X-ANOROSTAN-17-0NE (243) 
To a solution of 3~-acetoxy-androst-5-en-17-one (242, 5.og) 
in glacial acetic acid ( 200 ml), 10% palladium charcoal ( 200 mg) 
was added. The solution was hydrogenated until there was no more 
uptake of hydrogen as observed from the manometer. The reaction 
mixtuFB was filtered, concentrated to half of its original volume 
and poured onto ice-water. The product was extracted with ether 
( 3 x 100 ml). The combined ether extract was washed with saturated 
sodium hydrogen carbonate solution ( 3 x 100 ml) followed by water 
( 2 x 100 ml), dried over anhydrous magnesium sulphate and 
evaporated to dryness. The crude product was crystallised from 
aqueous methanol to yield white crystals of 3p-acetoxy-5tX-androstan-
17-one (243). 
Yield: 4.45g ( 88%) 
I.R V max 2940, 2860, 1730 (C=O )" 1480, 1460, 1410, 1380, 1260, 1160, 1140, 
1110, 1065, 1030, 990, 975, 960, 910, 900. 
NMR (CoCl 3n: 9.13 ( S, 6H, C18,19,-CH 3), 7.96 ( S, 3H, C3 
5.30 (m, 1H, C3 oc-HJ. 
- ---------------------------------------------------------------------
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20. BAEYER-VILLIGER OXIOATION295 OF 3~-ACETOXY-5 0< -ANOROSTAN-17-
ONE (243). 
A solution of 3p-acetoxy -5 D< -androstan-17-one (243, 
500 mgl 1.55mM) in glacial acetic acid ( ~.O ml) and 28% aqueous 
hydrogen peroxide ( 3.0 ml) was allowed to stand in the dark at 
3SoC for 53 hours. A large volume of water was added dropwise until 
crystallisation began to precipitate. The precipitate was extracted 
with ether ( 3 x 100 ml) and the combined ether extract was washed 
with saturated sodium hydrogen carbonate solution ( 2 x 100 ml), 
followed by water ( 2 x 100 ml). The ethereal solution was dried over 
. magnesium sulphate and evaporated to dryness. The crude product 
was crystallised from benzene-pet ether ( 6o-8ooC) to obtain white 
crystals of 3p-acetoxy-17-oxo-17,a-oxa-O-homo-5~-androstane (244). 
M.P. 155-157oC ( Lit. M.p. 295 158-159.50 C) 
Yield: 340.0 mg ( 65%) 
IR \l max 2960, 2870, 1730 (C=O), 1460, 1386, 1364, 1332, 1303, 1283, 
1244, 1225, 1171, 1153, 1137, 1122, 1105, 1090, 1066, 1032, 994, 
974, 960, 948, 915, 897, 867, 855, 824, 808, 732, 700, 670. 
(S, 3H, 
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295 
21. PREPARATION OF 3P-HYOROXY-17-0XO-17a-OXA-O-HOMO-5 IX-ANDROSTANE (251) 
A solution of 3p-acetoxy-17-oxo-17a-oxa-O-homo-50< -androstane 
(~, 3.07g; 10.0 mM)in methanol (124 ml) and water ( 15.5 ml) was 
saponified by refluxing for one hour with 10% methanolic-potassium 
hydroxide ( 17.5 ml). The reaction mixture was acidified with 3N 
hydrochloric acid (17.5 ml), diluted with water ( 155 ml) 
and heated on a water-bath for one hour in a current of nitrogen. 
The reaction mixture, on cooling, was extracted with ether 
3 x 100 ml) and the combined ether extract was washed with water 
( 2 x 50 ml), dried over anhydrous magnesium sulphate and evaporated 
to dryness. The crude. product was crystallised from ethyl acetate-
pet ether ( 60-800 ) to yield white crystals of 3~-hydrOXY-17-oxo-17a­
oxa-O-homo-5 0<. -androstane (251). 
M.P. 168-1690 C ( Lit M.p. 295 169.7 - 169.90 C). 
Yield; 2.21g ( 82%) 
IR. ~ max: 3420 (OH), 2940, 2865, 1723 (C=O ), 1455, 1389, 1367, 1305, 
1218, 1170, 1153, 1110, 1087, 1064, 1045, 990, 963, 956, 
944, 852, 665, 
NMR (COCI 3) L 9.20 ( S, 3H, C19-CH3) , 8.68 ( S, 3H, C1a-CH 3), 7.36 
(m, 2H, C16-CH2), 6.35 ( m, 1H, C3 -0< H). 
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22. PREPARATION OF 3 P -HYOROXY-16-HYOROXYMETHYL-17-0XO-17A- OXA 
0-HOMO-5 IX -ANDROSTANE (256)203A 
Nitrogen gas was passed through tetrahydrofuran (THF. - 100 ml) 
for about 30 minutes 0 at -78 C ( acetone/dry CO 2), Diisopropyl amine 
(1.93g. 19.3 mM) was added with stirring and after fifteen minutes. 
butyllithium ( 3.0 ml. 2. OM.) was added ~ia a dry syringe. 
The solution was left 0 at -78 C for one hour to equilibrate. 
To the solution of lithium diisopropylam1de at -78oC. was 
added very slowly a solution of 3 ~ hydroxy-17-oxo-17a-oxa-0-homo-5 0< -andros-
tane (251. 175.0 mg. 0.57 mM) in THF ( 5.0 ml) under nitrogen. After 
thirty minutes. the temperature of the solution was raised to -20oC 
t carbon tetrachloride/dry CO 2) and treated with formaldehyde vapours 
( prepared by heating paraformaldehyde ( 3.0g. Xs) to 1800 C and vapours 
were carried by a nitrogen gas flow into the reaction mixture). After 
all the paraformaldehyde had been consumed. stirring was continued for 
further thirty minutes. The reaction was quenched by the addition of 
10% hydrochloric acid and extracted with ether ( 3 x 100 ml). The 
combined ether extract was washed with saturated sodium chloride 
( 3 x 50 ml) followed by water ( 3 x 50 ml). dried over magnesium sulphate 
and evaporated to dryness. The crude product ( 265.0 mg) was separated 
on silica preparative plate ( solvent system. chloroform/methanol. 
97/3) and obtained two fractions. The non-polar fraction ( 136.0 mgl 
78%) was the starting lactone as concluded from T.L.C. and spectroscopic 
data. 
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The polar compound was shown to be the ~-hydroxymethyl lactone, 
3p-hYdroxY-16-hYdroxymethYl-17-0xO-17a-oxa-O-homo-5 0< -androstane (256). 
Yield-= 34.0 mgl ( 18.0%) 
I.Rvmax = 3430 (OH), 2945, 2875, 1725 (C=O.), 1460, 1391, 1370, 1355, 
1338, 1309. 1288. 1225, 1178. 1158. 1120. 1092. 1070. 1050. 
994, 962. 950. 911. 899. 805. 673. 
(o()O (-) 26.37 ( c. 0.06) 
NMR '"( 9.21 ( S. 3H. C14-CH3). 8.64 S, 3H. C18-CH3). 
6.36 ( d. 2H. C16-CH~ -OH. J = 8.0 HZ)' 6.04 - 6.52 ( m, 1H. 
C3 ",-H). 
Mass Spectrum: (M - 30) + = 306. 
Acc. Mass. + Found (M-H20) = 318.2222 ( M. CZOH30 03) 
Calculated: = 318.2195 
"'+ Found: CM - CH20) = 306.2198 ( M, C19H3003) 
Calculated: = 306.2195 
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23. REACTION 'OF 3 p-HyoRoXY-16-HyoRoXYMETHYL-17-oXO-17a-oXA-0-HoMo-
5~-ANoRoSTANE (256) WITH METHANE SULPHONYL CHLoRIoE203A • 
3p-Hydroxy-16-hYdroxymethyl-17-oxo-17a-oxa-0-homo-5 ~-androstane 
(256, 81.0 mg; 0.24 mM) was taken up in pyridine (2.0 mU and 
methane sulphonyl chloride ( 10 dropsl 0.5 ml) added. The temperature 
of the reaction mixture was kept at -20oC ( carbon tetrachloride? 
dry carbon dioxide) for ten hours and then at oOC overnight. 
The reaction mixture was poured over ice-water and extracted 
with ether ( 4 x 50 ml). The combined ether extract was washed with 
ice-cold water ( 3 x 50 ml), dried over anhydrous magnesium sulphate 
and evaporated to dryness to obtain 3fl-hydroxy-16-hydroxy-methyl-
17-oxo-17a-oxa-0-homo-5 0< -androstan-3, 16-dimeth~ne sulphonate (~). 
Yield: 97.4 mg, 82% 
IR v max. 2042, 2865, 1724, (C=O), 1456, 1355 ( - S~zD), 1235, 
1176 ( - SO- 0 ), 2 
NMR ~ 9.18 ( S, 3H, C19-CH3)' 8.64 ( S, 3H, C18-CH3)' 6.98, 6.92 
(S, 6H, C3 and C16 - 0 - S02 CH 3), 5.08 - 5.78 ( m, 3H, C3 
~-H, C16-CH - 0 - Msl 
_2 
(o()o (-) 13.07 ( c, 0·1). 
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24. PREPARATION OF 16-METHYLENE-17-0XO-17a-OXA-0-HOMO-50(-
ANOROST-2-ENE (2591 203A • 
A solution of 3ft-hYdrOXy-16-hydroXymethyl-17-oxo-17a-
oxa-D-homo-5 c<. -androstan-3b-16-dimethanesulphonate (~. 101.7 mg; 
0.21mM1 ~n pyridine ( 2.0 ml1 was heated under reflux for 6 hours. 
( The reaction was followed by T.L.C. for the disappeapance of the 
starting material. 2581. The reaction mixture, on cooling, was 
poured over ice-water and, extracted with ether ( 3 x 15 mll. The 
combined ethereal extract was washed with water ( 3 x 15 mll, 
5% hydrochloric acid t 3 x 15 ml1 and water ( 3 x 15 mll, dried 
over magnesium sulphate and evaporated to dryness. The crude product 
was separated on preparative T.L.C. (Solvent system, ether/Pet ether; 
25/75, 2 runs) to obtain 16-methylene-17-oxo-17a-oxa-D-homo-
• 
5O<-androst-2-ene (259). 
Yield: 17.5 mg, 2B.3 % 
I.R \lmax 3030, 2925, 2855, 1709, (c=ol, 1620 ( c=Cl, 1597, 1543, 1521, 
1460, 1455, 1381, 1344, 1202, 1106. 980, 951. 925, 872, 851, 
NMR 
780, 723, 661. 
9.28 ( S, 3H. C19-CH3l. 8.71 
o 
(m, 3H, C2,3-H and -O-C-C = 
? ~ 
-O-C-C = C - H) 
u. V r. max 213-4 nm (E 5939) 
Mass Spec. + M = 300 
( s, 
H 
. 
C-H l, 3.60 (m, 1H, 
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25. REACTION OF 3~-HyoRoXY-17-oXo-17a-oXA-0-HoMo-5 ex -ANDROSTANE (251) 
WITH FoRMALoEHyoE300 • 
A solution of 3~-hydroxy-17-oxo-17a-ox~-0-homo-5 0<-
androstane l 251, 53.0 mgl 0.16 mM) and para formaldehyde ( 30.0 mgl 
0.8 mM) and potassium hydroxide ( 10.0 mg) in ethanol ( 1.0 ml) - water 
l 0.5 ml) were mixed, refluxed for ten minutes and diluted with water 
l 3.0 ml). After standing it overnight at room temperature, the 
reaction mixture was cooled to 100 C, acidified with dilute hydrochloric 
acid and diluted with water ( 5.0 ml). The reaction mixture was 
extracted with ether ( 3 x 20 ml) and the combined ether extract was 
washed with water ( 10 ml), dried over anhydrous magnesium sUlpnate 
and evaporated to dryness. The crude product was separated on 
silica preparative plate ( solvent system, ether/chloroforml 80/20) 
and obtained two products. The polar material ( 18.0 mg, 34%) was 
the starting lactone as observed on T.L.C. and spectroscopic data. 
The non-polar fraction was crystallised from methanol and obtained white 
crystals of 3ft-hydroxy-16-methylene-17-oxo-17a-oxa-0-homo-5 ~-androstane 
(252) • 
Yield: 15.0 mg l27%1 
IR \I max 3420 (OH), 3030, 2965, 2875, 1715, (C~O), 1631 ( C~C), 1455, 
1389, 1310, 1220, 1169, 1155, 1115, 1089, 1065, 1045, 989, 
958, 945, 907, 853, 668. 
NMR (COC1 3) T 9.22 ( S, 3H, C19-CH3), 8.71 ( S, 3H, C18-CH3) 
4.37, (m, 1H, o ~ C3-oc: H), 4.30 (m. 1H, O-C-C = C-H) 
,0 H 
3.52 ( rn. 1H, If r O-C-C = C-H) 
(0°0 + 89.0 C, 0.04) 
uv i\ max 214-5 nm ( e: 3760) 
Acc. Mass. 
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Found 318.2241, ( M. C20 H30 03 ) 
Calculated: 318.2238 
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26. MANNICH REACTION WITH 3 ~-HYOROXY-17-0XO-17a-OXA-HOMO-51)1.­
ANDROSTANE (251) 305 
To a mixture of 3~-hYdroxy-17-0xo-17a-oxa-D-homo-
5 o<-androstane ( 251, 136.0 mgl 0.44 mM) and 37% aqueous 
formaldehyde 0.5 ml, 4.84 mM) was added a solution containing 
diethylamine 150 mgJ 2.05 mM), diethylamine hydrochloride 
( 170.0 mg, 1.55 mM) and dioxane ( 10 ml). The resulting mixture 
was refluxed for 8 hoUrs under nitrogen atmosphere. Then sOdium 
hydroxide (2N) was added until basic and the reaction mixture was 
extracted with benzene ( 3 x 25 ml). The combined benzene extract 
was washed with saturated sodium chloride solution, dried over 
anhydrous magnesium sulphate and evaporated to dryness. The crude 
product was separated on silica preparative plate in ether/chloroform 
(80/201 2 runs). The polar fraction ( 45.0 mg) was the starting 
lactone as observed on T.L.C. and by spectroscopic data. The non-
polar fraction was crystallised from methanol to obtain white 
crystals of 3fi-hydroxy-16-methylene-17-oxo-17a-oxa-0-homo-5 "'-
androstane (255). 
Yield: 38.0 mg ( 27%) 
IRVmax 3420 (OH), 3030, 2965, 2875, 1715 (C=O ), 1631 ( C=C), 1455, 
1389, 1310, 1220, 1169, 1155, 1115, 1089, 1065, 1045, 989, 
958, 945, 907, 853, 668, 
4.37 {m, 1H, C3«-H), 4.3 ( m, o H 
3.92 ( m, 1H, - O-C-C = t-H) 
o 
" 1H, -O-C-C 
- ------------------------------
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UV A max 214-5 rim ( C 3760) 
Acc. Mass. Found: 318.2241 ( M, C20 H30 03) 
Calculated: = 318.2238 
(O()o + 89.0, C, ( 0.04). 
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27. PREPARATION OF 3-PHENYL-4-0XA-5 ~-CHOLEST-2-ENE t 278)313 
Dry magnesium ( 2.25g, 93.8 mM), (Magnesium turnings washed 
with dry ether and dried in an oven) was added to a three-necked 
flask fitted with a condenser and nitrogen passing through the flask. 
Dry ether (250 ml) was added and the solution stirred. 
In order for the reaction to proceed a crystal of iodine was 
, 
added to the reaction mixture followed by a few drops of bromobenzene 
( 180.3g, 115.0 mM), and the solution was warmed to reflux over a 
water-bath. Once the reaction mixture had started refluxing, water-
bath was removed and brom.ob81zene was added at such a rate that the 
reaction mixture was under reflux all the time. 
After 15 minutes ~f the addition of bromobenzene, the ether-
benzene solution of 4-oxa-5 ~-chlostan-3-one (203, 3.20g, 8.25mM) 
was added dropwise with stirring. The reaction mixture was allowed to 
stir overnight at room temperature. The reaction was worked up 
by the dropwise addition of saturated ammonium chloride solution 
( 13.8 ml). The clear ether layer was decanted and the precipitated 
magnesium salts were washed with ether ( 3 x 100 ml). The combined 
ether washings were dried over anhydrous magnesium. sulphate and 
evaporated to dryness. Reddish-orange oily residue was crystallised 
from methanol to yield light-yellow crystals of 3-phenyl-4-oxa-5~-cholest-2-
ene ( 276). 
M.P. 123 - 1250 C 
Yield: 1 .64 g (50%) 
I.R. 2960, 2860, 1655 (C 'C), 1602, 1580, 1497, 1468, 1445, 1380, 1365, 
1335, 1320, 1306, 1280, 1260, 1209, 1161, 1126, 1080, 1071, 1017, 995, 
973, 940, 930, 910, 900, 860, 861, 750, 715, 690, 640. 
( 0< 10 
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8.03 ( d, 2H, Cr2H, J = 4.4Hz), 6.43 ( q, 1H, Cs CI-H, 
J = 4.2, 11.0 HZ)' 4.71 ( t, 1H, C2-H, J = 4.0HZ)' 2.3 -2.82 
( m, SH, C3-Aromat1c H). 
(+) 91 .70 ( C, 0.10) 
Acc. Mass: Calculated: 448.3705 M, C32 H48 0 ) 
Measured: 448. 3702 
u.v. ~ max 264 nm lE 9250). 
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28. REACTION OF 3-PHENYL-4-0XA-5~-CHOLEST-2-ENE ( 278) WITH MONOPERPHTHALIC 
ACID. 
3-Phenyl-4-oxa-5~-cholest-2-ene ( 278, 1.16g, 2.59mM) was taken 
up in dry ether ( 150 ml) and monoperphthalic acid316 25 ml, 
0.51M, 13.0mM, 5XS) was added. The reaction mixture was stirred 
at room temperature for 48 hours. The solution was filtered and the 
precipitate washed with dry ether ( 2 x 50 ml). The combined ether 
solution was washed with saturated sodium hydrogen carbonate solution 
( 3 x 50 ml), dried over magnesium sulphate and evaporated to dryness. 
The crude product ( 1.24g), a mixture as appeared on T.L.C. ( ether/ 
pet ether 40-60) (50/50), was plated. The major fraction was crystallised 
from acetone/pet-~ther ( 40-60) to obtain white crystals of 3-hydroxy-
3-phenyl-4-oxa-5 C<-cholestan-2-one (281). 
M.P. 170-172oC 
Yield: 659 mg ( 53%) 
I.R.: 3300 (OH), 2940, 2875, 1730 (C ~O) 1585, 1468, 1448, 1382, 
1379, 1368, 1315, 1272, 1160, 1118, 1080, 1030, 1001, 947, 
914, 860, 697. 
NMR: -C 3p-HYOROXY EPIMER 9.37 S, 3H, C18-CH3)' 9.17 ( S, 3H C19-CH3) 
7.53 ( AB q, 2H, C-2H, J ~ 13.6 HZ)' 
6.45 q, 1H, C5-((-H, J ~ 4.6, 10.4HZ), 2.51 ( m, 5H, C3-Aromatic H). 
3 ~ -HYDROXY EPIMER: 9.33 ( S, 3H, C18-CH3), 9.11 ( S, 3H, C19-CH3) 
7.43 ABq, 2H, C1-2H, J ~ 14.0 HZ)' 5.7 ( q, 1H, C5~- H, J~4.8,10.4HZl 
2.51 m, 5H, C3-Aromatic H 1. 
(+1 85.2 (c, 0.08). 
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29. REACTION OF 3-HYOROXY-3-PHENYL-4-0XA-S ~-CHOLESTAN -2-0NE (3) 
WITH ACETYLCHLORIOE/ETHANOL. 
3-Hydroxy-3-phenyl-4-oxa-S~-Cholestan-2-one 281, 66.S mg: 
0.14 mM) was taKen up in ethanol ( 10 ml) and aoetyl ohloridel 
ethanol solution 10 drops) was added. The reaotion mixture was 
left standing at room temperature for 48 hours and then the solvent 
was evaporated to dryness. The crude product was crystallised from 
ethanol to obtain white cyrstals of 3-ethoxy-3-phenyl-4-oxa-S <x'-oholestan-
2-one (282). 
M.P. 126 - 1280 C 
Yield: 46.0 mg ( 6S%) 
I.R: 2945, 287S, 1730 (CO{)), 160S, 1468, 1450, 138S, 1369, 1317, 1279, 
1177, 1160, 1119, 1087, 1071, 1D29, 1005, 984, 950, 932, 920, 700 
NMR: ~ 9.32 ( S, 3H, C18-CH3)' 9.04 ( S, 3H, C19-CH3) 
8.80 ( t, 3H, -0-CH2-CH3, J = 7.0Hz), 7.42 (q, 2H, C1-2H 
J = 14.0~Z)' 6.68 ( overlapping quartets-diastereotopio -0-CH2-CH 3) 
5.96 (q, 1H, C5OC'H, J = 5.0, 10.0 HZ)2.S6 (m, SH, C3-Aromatio-H) 
( 000 (+) 183.69 (0, 0.22) 
Aoo. Mass: Caloulated = 508,3917 ( M, C45 HS203) 
Found = 508.3890 
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30. REACTION OF 3-HYoRoXY-3-PHENYL-4-oXA-5 ~-CHoLESTAN-2-oNE (281) 
WITH LEAD TETRA ACETATE409 • 
Lead tetra-acetate paste was washed with acetic acid followed 
by dry benzene. The crystals were dried by employing suction pump. 
Lead tetra-acetate crystals ( 130.0 mgl 0.29 mM) were added 
to a rapidly stirring solution of 3-hydroxy-3-phenyl-4-oxa-5 0<-
cholestan-2-one ( 281, 130 mg, 0.27 mM) in the dry benzene (30 ml). 
The reaction mixture was stirred for five hours at room temperature. 
The solution was filtered to remove inorganic salts and washed with 
dry benzene. The filtrate was evaporated to dryness. The residue 
was plated silic~, solvent: ether/pet-ether 40-601 50/50) to 
obtain the major product which was crystallised from ether/pet-ether 
40-60, giving white crystals of 3,4-seco 5p-benzoate, 5~-cholesta~-
2-carboxylic acid (299). 
M.P. 220-222oC 
Yield 86.5 mg ( 64.4%) 
I.R: 3640 - 2600 (OH) 2950, 2870, 1720, (C=Dl 1700, 1600, 1580, 
1467, 1449, 1381, 1315, 1270, 1173, 1149, 1109, 1068, 1024, 972, 
930, 905, 805, 710, 683, 677. 
NMR 1" 9.32 ( S, 3H, C18-CH3), 9 08 ( S, 3H, C19-CH3)' 7.68 (ABq, 2H, 
C1-2H, J=14.0 HZ)' 4.91 ( q, 1H, CS-O<-H, J=4.0, 11.oHZ) 1.82 - 2.60 
( m, SH, Aromatic H). 
(o()o (-) 25.1 (c, 0.09) 
+ ( M - C6HS CooH) = 374 
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31. REACTION OF 3,4-SECO-SP- BENZDATE-5x-CHOLESTAN-2~CARBOXYLIC ACID (299) 
WITH DIAZDMETHANE. 
3,4-Se co-sp-benzoete-5 ~-cholestan-2 -carboxylic acid (299), 
29.0 mgl 0.06 mM) was taken up in dry ether and diazomethane was 
added dropwise until there was a slight excess of diazomethane410 
as observed by the presence of a yellow colour of the reaction mixture. 
The solution was left overnight in a fume-cupboard and then the 
colourless solution was evaporated to dryness. The crude product 
L 29.6 mg) was crystallised from methanol giving white crystals of 
3,4-seco-5p-benzoate-S t><-cholestan-2-methoxy carboxylic acid (300). 
M.P. 109-111 0 C 
Yield: 23.5 mg ( 79%) 
IR 2955, 2935, 2865, 2855, 1735, 1721 (C=O ), 1600, 1580, 1466, 
1451, 1440, 1392, 1381, 1363, 1329, 1313, 1271, 1228, 1217, 1191, 
1173, 1140, 1115, 1096, 1068, 1024, 973, 932, 917, 902, 886, 807, 
711, 679, 640. 
NMR ~ 9.32 ( S, 3H, C18-CH3), 9.08 (S, 3H, C19-CH3)' 
7.6 CABq, 2H, C1-2H, J = 14.0 HZ)' 6.53 ( S, 3H, Ester-CH 3), 
4.97 [q, 1H, C50<- H, J = 5.0, 11.0 Hz:), 1,;84-2.61 (m, 5H, 
Aromatic-H) 
(~) 68.4 ( C, 0~07) 
Acc. Mass: Calculated: 510 • 3709 ( M, C33 H50 04) 
Found: 510.3724 
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32. PREPARATION OF - 3,4-SECO-2-CARBOXY-5~-CHOLESTAN-5~-OL (301) 
3,4-seco-5p-benzoate-5 ~-cholestan-2-carboxylic acid £299, 
35.6 mgl 0.091mM) was taken up in methanol ( 10.0 ml) and 5% 
potassium-hydroxide-methanol ( 3.0 ml) was added. The reaction 
mixture was heated under reflux for thirty minutes. After cooling 
to room temperature, the reaction mixture was extracted with ether 
( 3 x 15 ml), washed with water ( 2 x10 ml), dried over anhydrous 
magnesium sulp~ate and evaporated to dryness, to obtain 3,4-seco-
2-CarboXy-5~-cholestan-5~-Ol (301). 
Yield: 25.5 mg ( 91%) 
IR ~ max 3600-2500 (OH), 2960, 2930, 2855, 1709 (C=O), 1461, 1442, 
1380, 1313, 1300, 1195, 1155, 1120, 1079, 1021, 987, 949, 926, 907, 
895, 669. 
NMR L 9.33 S, 3H, C18~CH3 ), 9.05 ( S, 3H, C19-CH3) 
7.49 ( ABq, 2H, G-2H, J = 14.0 HZ)' 6.29 ( q, 1H, C5-~ H, 
J = 4.4, 11.0 HZl 5.20 ( b m 1H, C5-~-0~l. 
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33. PREPARATION OF 3,NOR-4-0XA-5«-CHOLESTAN-2-0NE (274) 
A solution of 3, 4-seco-2-carboxy-5 0( -cholestan-5p-ol 
(301, 24.0 mgJ 0.061 mM) and toluene p-sulphonic acid mono-
411 hydrate (1-2 mg) in benzene ( 25 ml) was heated under reflax 
with stirring under nitrogen for 15 minutes using a Dean-Stark 
azeot'vrope set-up. The solution was cooled in an ice-bath, 
washed with saturated sodium hydrogen carbonate solution ( 3 x 20 ml), 
followed by water ( 2 x 10 ml), dried over magnesium sulphate and 
, 
evaporated to dryness. The crude product was crystallised from 
methanol to obtain white crystals of 3-nor-4-oxa-5~-cholestan-2-one (274) 
Yield 17.5 mg ( 73%) 
(+) 25.1 ( c, 0.04) 
IR 2950, 2930, 2870, 2855, 1785, (c~a, ¥-lactone), 1467, 1445, 1422, 
1381, 1365, 1273, 1250, 1180, 1148, 1126, 1103, 1082, 1075, 1031, 
1016, 1000, 982, 935, 925, 836, 695, 662. 
NMR L 9.33 ( 5, 3H, C18-CH3), 9.02 ( S, 3H, C19-CH3) 
7.73 ( bs,,2H, C1-2H), 6.15 ( q, 1H, C5-()( H, J = 4.0, 11.0 HZ) 
Mass spec. 
Ace Mass. Found 374.3192 ( M, C25 H42 02J 
Calculated = 374. 3185 
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34. REACTION OF 4-0XA-S ~-CHOLESTAN-3-0NE(1) WITH E-METHOXY PHENYL-
MAGNESIUM BROMIDE. 
Dry magnesium ( 330.0 mg. 13.6 mM) was placed in a dry three-
necked flask fitted with a condenser and nitrogen passing through 
the flask. Dry ether ( 150 ml) was added and the stirrer was set 
in motion. 
In order for the reaction to proceed a crystal of iodine was 
added to the reaction mixture followed by a few drops of distilled 
p-bromo anisole ( 2.6Sg). 14.2 mM) and the solution was warmed to 
reflux on a water-bath. Once the reaction mixture had started 
refluxing. the water-bath was removed and 4-bromo anisole was added 
at such a rate that the reaction mixture was under reflux all the time. 
After 15 minutes of the addition of p-bromo-anisole. the ether 
benzene solution of 4-oxa-5 oc-cholestan-3-one ( 203. 385.0 mg; 
1.0 mM) was added.dropwise. The reaction mixture was stirred overnight 
at room temperature. The reaction was worked up by the dropwise 
addition of saturated ammonium chloride solution ( 1.7 ml). 
The clear ether layer was decanted and the precipitated magnesium salts 
were washed with ether ( 3 x 100 ml). The combined ether fractions 
was dried over magnesium sulphate and evaporated to dryness. The only 
residue was evaporated under vacuum to remove anisole. The crude product 
was plated ( solvent. ether-pet-ether ( 40-600 )/ 10/90) to obtain 
three major products. 
The first. non~polar fraction was crystallised from ethanol to obtain 
white crystals of 3- ( 4-methoxy phenyl) -4-oxa-5 0( -cholest -2-ene (304). 
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Yield: 51.2 mg ( 10.8%) 
IR V max 2960, 2940, 2880, 2860, 1661 (C ~ C) , 1616, 1580, 1515, 1470, 
1446, 1383, 1368, 1339, 1321, 1306, 1267, 1250, 1166, 1113, 
1045, 1000,977, 944, 932, 917, 885, 866, 839, 809, 795, 780, 
770, 701, 669. 
NMR '"C 9.31 C S, 3H, C18-CH3l. 9.11 ( S, 3H, C19-CH3) 
8.03 ( d, 2H, C1-H, J = 4.0 HZ)' 6.42 ( q, 1H, C· 5 -Q( H, 
J = 4.0, 11.0 HZ) 6.18 (S, 3H, - O-CH3), 4.92 ( t, 1H, 
C2-H, J = 4.0 HZ)' 2.48 
- 3.15 (,4~, Aromatic H). 
U.V. >- max 265 nm (E~ 8118) 
Acc. Mass: Found 478.3826 ( M1 C33 H50 02) 
Calculated: 478.3810 
( O()O (+) 111.0 ( C,0.34) 
The second fraction ( 401.0 mg) was crystallised from ethanol 
to obtain white c:rystals of 3,3-C.di:: (4-methoxy phenyl) ) - 4-oxa-
5 <:<-cholestane (305). 
M.P. 151-30 C 
Yield: 215.0 mg ( 37%) 
IR V max 2960, 2935, 2875, 1611, 1585, 1512, 1466, 1445. 1386, 
1368, 1309, 1276, 1250, 1178, 1079, 1039, 994, 959, 935, 
889, 835, 812, 789, 669. 
NMR L 9.36 ( S, 3H, C18-CH3)' 8.93 ( S, 3H, C19-CH3) 
Acc Mass: 
(O()o = 
6.96 ( q, 1H, Cs -0< H, J = 5.0, 10.0 HZ)' 6.17, 6.25 ( S, 6H, 
2X O-CH3), 2.5 - 3.4 ( m, 8H, Aromatic H). 
Expected: 586.4386 M. C40 H58 03 
Found: 586.4388 
(+) 165.7 ( c, 0.29) 
1087
1 
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The third more polar-fraction -3.4-seco-3.3-di-( 4-methoxyphenyl.J-
5 0( cholest-2-en-5~-01 (306J was obtained as an oil. 
Yield: 98.0 mg (17%) 
IR V max (CHC1 3 ) 3640 - 3200 (OH). 2960. 2945. 2875. 1609. 1575. 
1515. 1467. 1445. 1418. 1386. 1369. 1290. 1250. 1182. 1175. 
1112. 1085. 1040. 990. 913. 838. 810. 679. 
NMR "( 9.39 ( S, 3H, C1S-CH3), 9.26 ( S. 3H, C19-CH3). 
6.64 ( 1. 1H, Cs -I)( H, J = 3.6, 10.0HZ) 6.20, 6.27 (S. 6H, 
2 x - 0 - CH3 ), 4.09 t, 1H. C2-H, J = 8.0 HZ)' 2.91 - 3.38 
( m. 8H, Aromatic H) 
[+) 40.8 ( C. 0.22), 
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35. HYOROGENOL YSIS OF 3,3 -OI- ( 4 -METHOXYPHENYLl ) -4-0XA-50(-
CHOLESTANE (305) 
3,3- (Oi ( 4 - methoxyphenylJ -4-oxa-5 o<-cholestane (305, 
43.3 mg, 0.074 mM) was taken up in ethyl acetate ( 10.0 ml) and 
concentrated hydrochloric acid ( 3.0 drops) and hydrogenated for 
36 hours using 10% Palladium/Charcoal (13.0 mg) as a catalyst. 
The reaction mixture was filtered through high flow-super cel filter 
aid and washed with ethyl acetate. The solvent was evaporated to 
dryness. The crude product [ 46.4 mg) was separated on silica gel, 
preparative-plate, solvent systemJ ether/pet ether (50/50), to 
obtain three products. 
The non-polar fraction was the starting material, 3,3-
(di-(4-methoxyphenyl)-4-oxa-5 ~-cholestane 305, 15.6 mgl 36.0%) as 
indicated by T.L.C. and spectral data. 
The middle fraction was 3,4-seco-3,3-di-( 4 -methoxyphenyl) ) 
-cholestan-5-one (315). 
Yield: 5.2 mgl .12.0% 
IR \lmax 2965, 2876, 1706 (C=O ), 1609, 1582, 1510,1469, 1441, 
1383, 1379, 1365, 1334, 1303, 1250, 1175, 1169, 1161, 1117, 1040, 
977, 953, 876, 830, 810, 670. 
NMR T 9.31 ( S, 3H, C18-CH3), 9.01 ( S, 3H, C19-CH31 
6.25 ( S, 6H, 2 x - 0 - CH3), 2.75 - 3.30 ( m, 8H, Aromatic Hl. 
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The third more polar fraction was 3,4-seca-3,3-di C4-methaxy-
phenyl) - 5O<-Cholestan-5p-al (314). 
Yield: 18.3 mgl 42.0% 
IR V max 3640 - 3200 (OH). 2965, 2875, 1610, 1585, 1511, 1469, 
1444, 1385, 1303, 1250, 1176, 1122, 1103, 1082, 1040, 
986, 956, 933, 890, 875, 630, 610, 700, 666. 
NMR 1: 9.38 ( S, 3H, C16-CH3l, 9.26 ( S, 3H, C19-CH3l 
6.S0 (q, 1H, CS-o(H, J • 4.6, 11.2 HZl, 6.23 
(S, 6H, 2x - 0 CH3l, 2.76 - 3.31 (m, 8H, Aromatic Hl. 
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36. PREPARATION OF 3,4-SECO-3,3- Di ( 4 -METHOXYPHENYL)- 51)(CHOLESTAN -
5p-oL (314) 
3,4- Seco3,3-di (~-methoxyphenyll-5 -cholest-2-en-5b-ol 
(306, 24.6 mgl 0.0~2 mM) was taken up in ethyl acetate ( 10 m1l 
and hydrogenated using palladium-charcoal ( 10%, 12.0 mg) 
until there was no more uptake of hydrogen. The solution was filtered 
and the flask was washed with ethyl acetate ( 20 ml). The combined 
ethyl acetate was evaporated to dryness to obtain 3,4-seco-3,3-di-
( 4-methoxyphenyl) - 5 0( -cholestan-5~-ol (314). 
Yield: 20.7 mg ( 84%) 
IR V max: 3640 - 3200 (OH), 2965, 2875, 1610, 1585, 1511, 1469, 1444, 1385, 
1303,· 1250, 1176, 1122, 1103, 1082, 1040, 986, 956, 933, 890, 
875, 830, 870, 700, 668. 
NMR (CDC13 ) ~ 9.37 ( 5, 3H, C18-CH3l, 9.27 ( S, 3H, C19-CH3)' 
6.50 ( q, 1H, C 50(-H, J = 4.8, 11.2 HZ)' 6.23 (S, 6H, 
2X - 0 - CH 3 ), 2.76 - 3.31 ( m, 8H, Aromatic HJ. 
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37. REACTION OF 3,4-SECO-3,3-0i (4 -METHOXYPHENYL) -50<-
CHOLESTAN-5P-OL (306) WITH JONES' REAGENT. 
3,4~Seco-3,3-di (4-methoxyphenyl)-5 -cholestan-
5b-ol (306, 24.5 mgl 0.042 mM) was taken up in acetone ( 3.0 ml) 
aod cooled to ODC ( ice-water) followed by a dropwise addition of 
Jones' reagent ( 4 drops) with stirring. The reaction mixture was 
stirred for 5 minutes and washed up by adding water(5.0 ml) and extracted 
with ether ( 4 x 10 ml). The combined ether extract was washed 
with water ( 2 x 10 ml), dried over magnesium sulphate and evaporated 
to dryness to y'ield 3,4-seco-3,3-di-(4-methDxyphenyll-cholestan-5-
one (315). 
Yield: 17.0 mg ( 70%) 
IR 2965, 2876, 1706 (C=O l, 1609, 1582, 1510, 1469, 1441, 1383, 
NMR 
1379, 1365, 1334, 1303, 1250, 1175, 1169, 1161, 1117, 1040, 977, 953, 
876, 830, 810, 670. 
L 9.31 
6.25 
S, 3H, C18-CH3), 9.01 ( S, 3H, C19-CH3l, 
S, 6H, 2 ( - 0 CH3) 1 
2.75 - 3.30 ( m, 8H, Aromatic-Hl • 
• 
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38. REACTION OF 3,4-SECO-3,3-0i ( 4-METHOXYPHENYLl-Sor-CHOLEST-2-EN-SP-OL 
(306) WITH TOLUENE-p-SULPHONIC ACID. 
A solution of 3,4-seco-3,3-di (4-methoxyphenylJ-S ~-cholest-2-
en-Sp-ol ( 306, 4.7 mgJ 0.008 mMJ in benzene ( S.O mlJ was heated 
under flux for two hours in the presence of toluene-p-sulphonic acid 
( 1.0 mg). The reaction mixture was washed with water ( 2 x S ml) 
and the benzene layer evaporated to dryness to obtain 3,4-seco-3,3-
di- (4-methoxy-phenyl)-cholestan-S-one (315). 
Yield: 3.2 mg; 68% 
NMR t 9.31 S, 3H, C18-CH3J, 9.01 ( S, 3H, C19-CH3), 
6.25 ( S, 6H, 2 ( -O-CH3), 
IR 
2.75 - 3.30 ( m, 8H, Aromatic-H). 
2965, 2876, 1706 (C=O)' 1609, 1582, 1510, 1469, 1441, 1383, 1379, 
1365, 1334, 1303, 12S0, 117S, 1169, 1161, 1117, 1040, 977, 9S3, 
876, 830, 810, 670. 
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39. REACTION OF 3,4-SECO-3,3-01 (4-METHOXYPHENYL)-CHOLESTAN-5-0NE 
(315) WITH HYDROXYLAMINE-HYDROCHLORIDE. 
To a solution of 3,4-seco-3,3-di (4-methoxyphenyl)-cholestan-
5-one ( 315, 17.0 mg; 0.02SmM) in ethanol ( 3.0 ml) was added 
a solution of hydroxylamine-hydrochloride 10.4 mg; 0.149 mM; 
5M xs) and sodium acetate ( 18.6 mgl 0.23 mM; 8 M xs) in water 
( 2 drops) and diluted with ethanol ( 5 drops). The reaction was 
heated under reflux for 30 minutes, water ( 3 drops) added and 
allowed to cool. 
A white precipitate, not crystalline, was extracted with 
ether ( 3 x 15 ml). The combined ether extract was washed with 
water ( 2 x 10 ml), dried over magnesium sulphate and evaporated to 
dryness. The crude product was crystallised from aqueous ethanol 
to obtain white crystals of 3,4-seco-3,3-di (4-methoxyphenyl)-
cholestan-5-one-oxime (321). 
Yield: 6.8 mg; 39% 
IR V max ( CHC1 3); 3620-2700 ( OH, 4- bonded), 2940, 2875, 
1609, 1585, 1510, 1465, 1443, 1379, 1303, 1250, 1218, 
1177, 1118, 1040, 995, 951, 928, 852, 830, 810, 668. 
NMR: t 9.33 ( S, 3H, C18-CH3) 9.03 ( S, 3H, C19-CH3)' 6.22 ( S, SH, 
,2X-O C~3) , 2.S3 - 3.30 ( m, 8H, Aromatic H) 
(o()D + 10.6 ( C, O.OS) 
U.V. ~ max 276-7 nm (e = 4036), ( ( Me O-CSH4)-2 CH2; max 281.4 nm; 
(= 4150)) 412. 
-178-
40. REACTION OF 3, 4-SECO-3, 3 ( Oi - ( 4-METHDXYPHENYLl- 5 IX -CHOLEST,-.2-EN-
5~-OL (3061 WITH 3,5-DINITROBENZDYL CHLORIDE. 
3, 4-Seco-3, 3-di- (4-methoxyphenyl 15 0( -cholest-2-en-5~-01 
306, 22.6 mgl 0.05 mM1 was taken up in pyridine ( 5.0 ml1 
and 3,5-dinitrobenzoyl chloride ( 34.0 mg'; 0.15 mM, 3.75 M Xs1 was 
added and the solution was stirred for 48 hours at room temperature. 
The reaction mixture was poured into ice-water and extracted with 
ether ( 3 x 50 ml1. The combined ether extract was washed with 
ice-cold water ( 2 x 20 ml), saturated sodium hydrogen carbonate 
solution ( 2 x 20 ml) followed by water ( 2 x 20 ml1. Ether extract 
was dried over magnesium sulphate and evaporated to dryness. The 
crude product was crystallised from acetone-methanol to obtain yellow 
crystals of 3,4-seco-3,3-di ( 4-methoxyphenyl) - 5 0( ~cholest-2-en-
5~ - ( 3151-di;itrobenzoate) (322). 
Yield: 22.6 mg, ( 78.5%) 
I.R: 2940, 2875, 1730 (C=O), 1630, 1605, 1550 (N02), 1512, 1465, 
1345 (N021, 1282, 1250, 1175, 1121, 1075, 1035, 971, 922, 875, 
835, 830, 808, 732, 723, 667. 
NMR: l 9.31 ( S, 3H, C18-CH3), 8.90 ( S, 3H, C19 -CH3). 6.21, 6.46 
(S, 6H, C3-2X-OCH3), 5.10 ( q, 1H, C5K H, J = 4.0, 10.4Hz) 
6.12 ( t, 1H, C2-H, J = 6.8HZ)' 2.91 - 3.70 m, 8H, C3-Aromatic 
H 5)' 0.8 - 1.33 ( m, 3H, C5-EsterAromatics). 
Analysis: Calculated: C, 72.32; H, 7.69; N, 3.59 
Found: C, 72.201 H, 7.9; N. 3.5 
(M, C47 H60 08 N2)' 
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41.REACTIoN OF 3, 4-SECo-3, 3 Oi- (4-METHoXYPHENYLl-5 0< -CHOLESTAN-5P-
oL (314) WITH 3,5-oINITRoBENZoYL CHLORIDE. 
3,4-Seco-3,3-di- (4-methoxyphenyl)-5 -cholestan-5b-ol 
(314, 23.4 mgl 0.04mM) was taken up in pyridine ( 5.0 ml) 
and 3,5-dinitrobenzoyl chloride ( 33.0 mg, 0.14mM, 3.5M Xs) was 
added and the solution was stirred at room temperature for 48 hours. 
The reaction mixture was poured into ice-water and extracted with 
ether ( 3 x 50 ml). The combined ether extract was washed with 
ice-cold water ( 2 x 25 ml) sodium hydrogen carbonate solution 
( 2 x 25 ml) and water ( 2 x 25 ml). Ether extract was dried over 
magnesium sulphate and evaporated to dryness. The crude product 
was crystallised from acetone-methanol yielding yellow crystals of 
3, 4-seco-3, 3-di- (4-methoxyphenyl) - 5 iX.-cholestan-5b{3151 -dinitrobenzoate) 
(323) • 
M.P. 157-90 C 
Yield: 25.4 mgl ( 82.0%) 
LR 2960, 2945, 2875, 2855, 1728 (C=o l, 1630, 1610, 1550 (N02l, 
1511, 1463, 1346 (N02), 1280, 125S, 117S, 1121, 1076, 1035, 970, 921, 
875, 829, 806, 731, 722, 688. 
NMR r ( CDC1 3) 9.32 ( S, 3H, C18-CH31. 8.97 ( S, 3H, C19-CH31. 6.S8, 
6.29 S, 6H, 2X 0-CH31. 5.04 ( q, 1H, CSQ(H, J = 4.8, 11.0HZ)' 
2.83 - 3.90 ( m, BH, Aromatic Hs )' 0.76 - 1.34 ( m, 3H, Aromatic ester 
Hs)· 
Analysis: Calculated, C, 72.10, H, 7.98; N, 3.S8 
Found; C, 72.10; H, B.2, N, 3.40 
(M, C47 H62 08 N2)' 
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42. PREPARATION OF CHOLESTERYL-3~-ACETATE (3241 
To a solution of cholesterol (201. 20.0gl 0.052M) 
in pyridine ( 200 mll. acetic anhydride 30 ml 1 was added and 
the solution was stirred for one hour and left to stand overnight 
at room temperature. The reaction mixture was poured over ice-water 
and extracted with ether ( 5 x 100 mll. The combined ether extract 
was washed with dilute hydrochloric acid ( 3 x 50 mll followed by 
water ( 3 x 50 mll. dried over magnesium sulphate and evaporated to 
dryness. The crude product was crystallised from acetone to obtain 
white crystals of cholesteryl-3fi-acetate (3241. 
Yield: 19.B5g ( 89.5%1 
I.R.V max 2960. 2930. 2890. 2850. 1733 (C=O ). 1665 (c-Cl. 1468. 
1445. 1386. 1375. 1366. 1335. 1316. 1289. 1250. 1235. 1175. 
1162. 1145. 1135. 1114. 1088. 1037. 1025. 997. 982. 963. 957. 
943. 929. 921. 906. 895. 886. 859. 846. 833. 825. 819. 805. 
795. 771. 743. 705. 690. 665. 
NMR ( CO Cl 31t 9.32 ( S. 3H. C18-CH31. 8.98 S. 3H. C19-CH31 
o 
7.98 (5. 3H. 3P-0-C CH31. 5.41 ( m. 1H. C3<X Hl. 4.62 (d. 1H. 
C6-H. J = 4.6 Hzl. 
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43. PREPARATION OF 50< -CHOLESTAN-3P-ACETATE (3251 
Cholesteryl acetate ( 324. 5.og1 11.68 mM1 was taken up in 
ether ( 25.0 ml1 and glacial acet~c acid ( 50.0 ml1 and hydrogenated 
using platinum oxide ( 106 mg1. as a catalyst. at room temperature. 
until there was no more uptake of hydrogen. The reaction mixture 
was filtered through high-flow supercel filter aid •. using ether 
to dissolve any cyrstallised product. and the filtrate was evaporated 
to dryness. The crude product was crystallised from ethyl acetate-
methanol to obtain white crystals of 5 ()( -cholestan-3p-acetate (3251. 
Yield: 4.83g (96.2%1 
I.R. V max: 2956. 2940. 2880. 2865. 1740 (c=O l. 1472. 1450. 1388. 
1379. 1368. 1362. 1242. 1176. 1160. 1152. 1135. 1125. 1078. 1030. 
963. 933. 913. 890. 867. 842. 801. 757. 745. 727. 670. 
NMR: 1" 9.34 ( S. 3H. C18-CH31. 9.19 ( S. 3H. C19-CH31. 
o 
" 8.0 ( S. 3H; C3 - 0 - C - C!:!31. 5.35 ( m. 1H. C3 -t<H1 
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44. PREPARATION OF 50<.-CHOLESTAN-3P-OL ( 326)413 
5o<-Cholestan-3,B-acetate ( ~25, 4.80 gl 11.16 mM) was taken 
up in ethanol ( 22 ml) and a solution of sodium hydroxide ( 1.4g) in 
water ( 5.6 ml) was added. The reaction mixture was heated on 
steam bath for three hours and then allowed to cool. The precipitate 
was collected washed and crystallised from ethanol to yield white 
crystals of 5 IX -cholestan-3~-ol ( 326). 
M.P. 139 -140oC (Lit. MP 413 140-141·50 C) 
Yiel~ 4.08g ( 94%) 
IR V max 3700-3100 (OH), 2945, 2925, 2875, 2855, 1475, 1453, 1392, 1373, 
1345, 1309, 1176, 1160, 1144, 1085, 1045, 967, 938, 890, 786, 679, 
NMR (CDC1 3 J 't" 9.35 ( S, 3H, C18-CH3), 9.20 ( S, 3H, C19-CH.,), 7.02 
(Cs, 1H, C3-OH) 6.43 ( rn, 1H, C3 0<. H) 
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45. PREPARATION OF 50( -CHoLESTAN-3P-ToLUENE-p-SULPHoNATE (327) 
To a solution of 50< :-cholestan-3p-ol ( 326. 4.0g; 10.31 mM) 
in pyridine ( 100 ml). toluene-p-sulphonyl chloride ( 18.6g. 103.1 mM) 
was added. The reaction mixture was stirred for two hours and then 
allowed to stand .. overnight at room temperature. The reaction mixture 
was poured onto ice-water and extracted with ether ( 3 x 150 ml). The 
combined ether extract was washed with dilute hydrochloric acid 
( 2 x 50 ml) followed by ice-cold water ( 3 x 50 ml). Ether extract 
was dried over magnesium sulphate and evaporated to dryness. The crude 
product (5.35g) was crystallised from acetone to obtain white crystals 
of 5o<-cholestan-3,B-toluene-p-sulphonate (327). 
M.P: 
Yield: 4.77g ( 85.4%) 
IR V max 2955. 2935. 2870. 1600 (C=C Aromatic). 1495. 1469. 1455. 1447. 
1404. 1385. 1360 ( S02-O-). 1335. 1312. 1298. 1210. 1192. 1180 
(-S02-0-). 1156. 1132. 1121. 1100. 1073. 1040. 1021. 1015, 1001, 
985. 953, 940. 931. 907. 890, 870, 855, 817. 810. 755. 731, 
708. 689. 672, 665. 
NMR (CoC1 3)T 9.36 S, 3H, C18-CH3)' 9.22 ( S, 3H. C19-CH3) 
7.54 ( S, 3H. - CSH4 - CH3), 5.57 ( m, 1H, 3c:<-H), 2.20-2.66 
( 4H, Aromatic J = 8.0 HZ)' 
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46. PREPARATION OF 5 ~- CHOLEST-2-ENE (6)415 
A solution of 5 ~-cholestan-3~-toluene-p-s~lphonate (327. 4.0g) 
in dry dimethylsulphoxide ( 60 ml) was heated at 100°C for three hours. 
( The temperature of the oil-bath was 115-120oC). The reaction 
mixture was poured into water ( 100 ml) and extracted with ether 
( 3 x 100 ml). The combined ether extract was washed with water 
4 x 100 ml). 2N hydroc~loric acid ( 2 x 100 ml). water ( 100 ml). 
saturated sodium hydrogen carbonate 2 x 100 ml) and finally with 
water ( 3 x 100 ml). Ether extract was dried over magnesium sulphate 
and evaporated to dryness. The crude product was columr.led on alumfna. 
Elution with pet-ether ( 40-60) gave 50( -cholest-2-ene ( 328). pet-ether-
benzene gave 5O<-cholestan-3-one ( 220). ether+benzene gave 50< -cholestan 
-30<-01) and washing the column with chloroform afforded a gum which 
was mainly 50( -cholestan-3p-ol l 326). 
5 tl( -Cholest-2-ene- (3281 was crystallised from acetone to obtain 
white crystal s. 
M.P. : 
Yield: 1.84g1 67.4% 
IR: -V max 3030 (C=C) 2970. 2950. 2875. 2855. 1471. 1445. 1431. 1385. 1380. 
1375. 1348. 1299. 1256. 1211. 1186. 1180. 1170. 1155. 1138. 1117. 
1050. 1032. 996. 988. 968. 960. 943. 932. 920. 909. 890. 675. 
848. 829. 810. 773. 731. 667. 1ii50. 
NMR ( CDC1 3) L 9.33 ( S. 3H. C18-CH3). 9.25. ( S. 3H. C19-CH3) 
4.46 ( bs. 2H. C2}3-H) 
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5~-Cholestan-3-one ( 220, 0.82g) was crystallised from ethanol 
to obtain white crystals. 
M.P. 125-1270 C (Lit. M.p. 408 128-1290 C) 
Yield 0.62g1 21.8% 
I.R. V max 2980, 2940, 2880, 2865, 1715 (C=O .. ) 1471-1446, 1421, 
1387,1377, 1368, 1355, 1336, 1315, 1287, 1277, 1258, 1232, 
1214, 1205, 1187, 1176, 1157, 1133, 1076, 1033, 1001, 959, 
945, 932, 90S, 875, 850, 811, 762, 738, 710, 687. 
NMR "[ 9.31 ( S, 3H, C18-CH3), 8.97 ( S, 3H, C19-CH3) 
7.51 - 7.96 ( m, 4H, C2 and C4 -H). 
Crystallisation of the crude third fraction ( 0.21g) from 
methanol produced white crystals of 50( -Cholestan-3 0( -01. 
M.P. 183-1850 C ( Lit M.P. 408 187-188oC) 
Yield: 0.18g1 6.3% 
IR \) max 3700-3100 (OH), 2940, 2925, 2875, 2855, 1470, 1447, 1386, 1377, 13SE 
1335, 1310, 1277, 1252, 1231, 121', 1185, 1168, 1127, 1119, 1107, 
1075, 1035, 1005, 977, 960, 938, 919, 906, 884, 846, 832, 729. 
NMR L 9.35 ( S, 3H, C18-CH3), 9.22 S, 3H, C19-CH3)' 7.63 
(S, 1H, C3o(-OH) 5.93 ( d, 1H, C3-~H, -J = 2.0HZ) 
Crystallisation of the fourth, the very polar fraction (0.13gJ 
from ethanol ~ielded white crystals of 5 c<-cholestan-3~-ol (326). 
M.P. 138-1400 C (Lit. M.p. 408 140-141.50 CJ 
Yield: 95 mgl 3.3% 
I.R. Y max 3600 - 3160 (OH), 2945, 2880, 1475, 1453, 1392, 1373, 1345, 1309, 
1176, 1160, 1144, 1085, 1045, 967, 938, 890, 786, 679. 
NMR r 9.35 (S, 3H, C1S-CH3J, 9.20 (S, 3H, C19-CH3)' 7.02 ( bs, 1H, C3-0H ) 
6.43 m, 1H, C3 -Il<H). 
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47.PREPARATION OF 3-(21-ACETIC ACIO)-2-HYOROXY-5 O(-CHOLESTAN-O'-LACTONE 269F 
. (329) Manganous acetate tetrahydrate ( 530 mg, 2.2 mM) was dissolved 
o in glacial acetic acid ( 10 ml) by raising the temperature to 90 C. 
At this temperature potassium permanganate ( 100 mg, was added with 
stirring. When the exothermic reaction had subsided and temperature 
dropped to 90oC, aoetic anhydride ( 0.8 ml) was added followed by 
sodium acetate ( 1.20g). 
5o<-Cholest-2-ene ( 328, 350 mg; 0.96 mM) was added and the 
reaction mixture was refluxed until the brown colour had disappeared. 
approximately one hour). The reaction mixture was diluted with water 
50 mll and extracted with ether ( 3 x 150 ml). The combined ether 
extract was washed with saturated sodium hydrogen carbonate solution 
( 2 x 150 ml) and water ( 2 x 100 ml). The ether extract was dried over 
anhydrous magnesium sulphate and evaporated to dryness. The crude product 
was separated by preparative T.L.C. ( solvent system, Pet-ether/Ether; 
60/40). The fraction corresponding to the t-lactone was crystallised 
from methanol to obtain white crystals of 4 ( 21-acetic acid)-2-hydroxy-
5 o<-cholestan- ~-lactone (329). 
M.P. 121-30 C 
Yield: 41.0 mg; 10.0% 
IR V max 2960, 2945, 2880, 1768 (C=O), 1470, 1460, 1451, 1420, 
1385, 1378, 1346, 1332, 1298, 1247, 1174, 1111, 1000, 974, 
941, 869, 840. 
NMR -C 9.35 ( S, 3H, C18-CH3), 9.22 ( S, 3H, C19-CH3)' 
5.34 ( quintet, 2-overlapping triplets, 1H, C2-H). 
()( )0 (+) 20.5 ( C, 0.15) 
Acc. Mass: Exp. 428. 3654 
Found 428.3648 (M, C29 H48 O2), 
APPENDIX 
-187-
TABLE 2 
TOT AL VIAB6E % GROWTH % DEATH CONCENTRATION 
CELLS X 10 (}Jg/ml) 
17.96 100.0 0.0 0.0 
13.58 75.6 24.4 0.1 
8.42 46.85 53.1 0.25 
5.50 30.S 69.4 0.50 
3.85 21.4 78.6 0.75 
1.19 6.7 93.3 1.0 
1.02 5.7 94.3 5.0 
o CH2 
11 11 
1111 O-C- C -CH3 
(7A) . 
:r: 
~ 
w 
o 
, ' 
i. 
100 
BD 
60 
40 
, 
, 20 
, 
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TABLE 3 
TOTAL VIABLE % GROWTH % DEATH CONCENTRATION 
CELLS X 106 (jJg/ml) 
7.85 100.0 0.0 0.0 
7.55 96.0 4.0 0.5 
4.65 59.0 41.0 0.75 
2.56 33.0 67.0 1.0 
1.25 16.0 84.0 2.0 
0.97 12.0 88.0 3.0 
0.18 2.0 98.0 5.0 
H (225) 
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TABLE 4 
TOTAL VIABLE % GROWTH % DEATH CONCENTRATION 
CELLS X 106 (j.lg/ml) 
-
43.14 100.0 0.0 0.0 
25.76 59.7 40.3 0.5 
23.71 55.0 45.0 1.0 
19.03 44.1 55.9 2.5 
4.40 10.2 89.8 5.0 
2.57 6.0 94.0 7.5 
1.25 2.9 97.1 10.0 
(230) 
, 
i 
! 
.) ., 
.1 
"1" 
100 ,. 
I' I I 
'I 
:1 
I , 
,. I ,. 
, 
I 
"'11 
: i i. I 
I 'r' ! ·1'· 
"'i' 
1.1 
I 
i 
l' 
r r 
TOTAL VIABLE 
CELLS X 106 
42.11 
34.10 
23.15 
21.05 
9.26 
5.05 
0.00 
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TABLE 5 
% GROWTH 
100.0 
81.0 
55.0 
50.0 
22.0 
12.0 
0.00 
o _ 
H 
% DEATH CONCENTRATION 
(f g/m1 ) 
0.0 0.0 
19.0 0.5 
45.0 0.75 
50.0 0.85 
78.0 1.0 
88.0 2.5 
100.0 5.0 
(238) 
I ~ 
I. 
! 
! . 
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I. 
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I 
I 
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I, 
1 
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i 
I, 
I 
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:: 
. 
I 
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I ,. 
sLo 1 
, I I 
1" 
.. 1 
",' 
.1':. 
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TABLE 6 
TOTAL VIABLE % GROWTH % DEATH CONCENTRATION 
CELLS X 106 (}lg/ml) , 
42.11 100.0 0.0 0.0 
32.00 76.0 24.0 0.5 
18.99 45.0 55.0 0.75 
17.76 42.0 58.0 0.85 
6.32 15.0 B5.0 1.0 
2.oB 5.0 95.0 2.5 
0.00 0.0 100.0 5.0 
OAc 
(239) 
leo 
o 
! 
I, 
o 
, ,I I,> i ;: I., 
, 
, 
1:1 
" 1 I , 
" , 
, 
1 
::j ,I 
!i 
I, 
[' 
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TABLE 7 
TOTAL VARIABLE % GROWTH % DEATH CONCENTRATION , 
CELLS x 106 (j-lg/ml) 
2.89 100.0 0.0 0.0 
2.31 80.0 20.0 0.5 
1.87 65.0 35.0 0.75 
1.42 49.0 51.0 1.0 
1.18 41.0 59.0 2.0 
0.51 18.0 82.0 3.0 
0.096 3.0 97.0 5.0 
H 
1-1 (255) 
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TABLE 8 
TOTAL VIABLE % GROWTH % OEATH CONCENTRATION 
CELLS CjJg/ml) 
x 105 
6.48 100.0 0.0 0.0 
5.96 92.0 8.0 0.5 
5.17 80.0 20.0 0.75 
2.75 42.0 58.0 1.0 
1.37 21.0 79.0 2.0 
0.77 12.0 88.0 3.0 
0.0 0.0 100.0 5.0 
. 
H (259) 
__ I 
REFERENCES 
-201-
REFERENCES 
1. A Gilman and F.S. Philips, Science, 1946, 103, 409. 
2. W.C.J. Ross, "Biological Alkylating Agents", Butterworth and Co. Ltd., 
London, 1962. 
3. A. G.P. Wheeler, Cancer Res., 1962, 33., 651. 
B. F. Bergel, Pure Appl. Chem., 1963, ~, 351. 
4. A. T.A. Geissman and M.A. Irwin, Pure Appl. Chem., 1970, 31, 167. 
B. S.C. Chattacharyya, J. Indian Chem. Soc., 1970,~, 299. 
5. E. Rodrignez, G.H.N. Towers and J.C. Mitchell, Ph;itochem. , 1976, 
21, 1573. 
6. A. R.W. Doskotch and FIS. EI-Feraly, J. Pharm. Sci. , 1969, ~, 877. 
B. R.W. Doskotch and F.S. EI-Feraly, J. Org. Chem. , 1970, ~, 1928. 
C. R.W. Doskotch, C.D. Hufford and F.S. EI-Feraly, J. Org. Chem., 
1972, E, 2740. 
7. P.M. Baker, C.C. Fortes, E.G. Fortes, G. Gassinelli, B. Gilbert, 
J.N.R. Lopes, J. Pellegrino, T. Tomassini and W. Vichnewski, 
J. Pharm. Pharmac., 1972, 3,i, 853. 
8. E. Rodrignez, M.O. Dillon, T.J. Mabsy, G.H.N. Towers and 
J.C. Mitchell, Experientia., 1976, 32, 236. 
9. L.J. Haynes, Quart. Rev. (London), 1948, 3., 46. 
10. A. T.K. Devon and A.!. Scott, "Handbook of Naturally Occurring 
Compounds", Tsrpenes, Acad. Press, New York, N. Y. 1972, 3., 79. 
B. H. Yoshioka, T.J. Mabry and B.N. Timmermann, "Sesquiterpene 
Lactones", University of Tokyo Press, Tokyo, 1973. 
11. A. s. M. Kupchen, Trans. N.Y. Acad. Sci. , 1970, E, 85; 
B. S.M. Kupchan, Am. Acad. Brasil. Ciene., 1970, 42, 25; 
C. s. M. Kupchan, Pure Appl. Chem. , 1970, 21, 227; 
D. S. M. Kupchan, M.A. Eakin and M.A. Thomas, J. Med. Chem. , 1971, 
1147 and references cited therein; 
~, 
-202-
11. E. S.M. KupchBft, Izv. Oto. Khim. Nauki. Bulg. NBUk. lEng)., 
1972, ~, 325. 
F. S.M. Kupchan, Intra-Sci. Chem. Rep., 1974, ~, 57. 
G. S.M. Kupchan, Cancer Treat. Rep., 1976, ~, 1115. 
12.A·S.M. Kupchan, J.M. Cassady, J.E. Kelsey, H.K. Schnoes, D.H. Smith 
and A.L. Burlingame, J. Amer. Chem. Soc. 1966, 88, 52921 
and references cited therein. 
B A.S. Rao, G.R. Kelkar and S.C. Bhattacharyya, Tet., 1970,2E, 275. 
13. S.M. Kupchan, R.J. Hemingway, D. Werner and A. Karim, J. Org. 
~., 1969, 34, 3903. 
14. A. S.M. Kapchan, Y. Aynehchi, J.M. Cassady, A.T. McPhail, 
G.A. Sim, H.K. Schnoes and A.L. Burlingame, J. Amer. Chem. Soc., 
1966, ~, 3674. 
B. S.M. Kupchan, Y. Aynehchi, J.M. Cassidy, H.K. Schnoes and 
A.L. Burlingame, J. Org. Chem., 1969, 34, 39~~. 
15. A. R.A. Adams and W. Herz, J. Amer. Chem. Soc., 1949,~, 2546) 
and references cited therein.· 
B. K.H. Lee, H. Furukawa and E.S. Huang, J. Med. Chem., 1972, ~, 
609. 
C. K.H. Lee, R. Meck, C. Piantadosi and E.S. Huang, J. Med. Chem., 1973 
~, 2291 
D. G.R. Pettit and G.M. Cragg, Experientia ., 1973, ~, 781. 
16.A. S.M. Kupchan, J.C. Hemingway, J.M. Cassady, J.R. Knox, 
A.T. McPhail and G.A. Sim, J. Amer. Chem. Soc., 1967, ~, 465: 
B. S.M. Kupchan, J.E. Kelsey, M. Maruyama, J.M. Cassady, J.C. Hemingway 
and J.R. Knox, J. Org. Chem., 1969, 34, 3876: 
C. G. Rucker, Dent. Apoth. Ztg. 1972, 112, 263) 
O. S.M. Kupchan, A.T. McPhail and G.A. Sim, ~., 1973, 29, 1751. 
-203-
17. R.W. Doskotch and E.D. Hufford, J. Pharm. Sci., 1969. ~, 186 
18. J.L. Hartwell and B.J. Abott. Advan. Pharmacol. Chemother •• 1969, 
7... 117. 
19. K.H.Lee. E.S. Huang. C. Piantadosi. J.S. Pagano and T.A. Geissman. 
Cancer Res.. 1971.~, 1649. and references cited therein. 
20. S.M. Kupchan. T.A. Giacobbe. I.S. Krull. A.M. Thomas. M.A. Eakin 
and D.C. Fessler. J. Org. Chem.. 1970. l§.. 3539. 
21. S.M. Kupchan. in "Recent Advances in Phytochemistry". ed. V.C. 
Runeckles. Plenum. New York, 1975. ~, 167. 
22. W.H. Watson. M.G •. Reinecke and J.C. Hitt, Rev. Latinoamer Quim .• 
1975, .§.. 1. 
23. M.J. T±sdale, L.A. Elson and W.C.J. Ross. Eur. J. Cancer •• 1973, 
~. 89. 
24. J .A. Montgomery in "Medicinal Chemistry". Ed. A. Burger, Wlley-
Interscience, New York, N.Y. 1970, Part 1. Chapter 28, p 680. 
25. G.A. Howie. I.K. Stamos and J.M. Cassady, J. Med. Chem., 1976, 
~, 309. 
26. G.E. Foley and H. Lazarus, Bio. Chem. Pharmacol •• 1967. ~. 659 
27. G.E. Foley. E.F. Barell, R.A. Adams and ~. Lazarus. Exp. Cell Res .• 
1969.27.., 129. 
28.A.S.M. Kupchan, D.C. Fessler, M.A. Eakin and T.A. Giacobbe, 
Science., 1970, 168, 376. 
B. R.L. Hanson, H.A. Lardy and S.M. Kupchan, Science., 1970 ~ 378. 
29. A. Rosowsky, N. Papathanasopoules. H. Lazarus, G.E. Foley and 
E.J. Modest. J. Med. Chem •• 1974 • .,!Z., 672. 
30. S.M. Kupchan. Fed. Proc. Fed. Am. Soc. Exp. BioI.. 1974.~, 2288. 
31. V. Zikan, L. Vibra, B. Kakac and M. Semonsky. ColI. Czech. Ehem. 
Commun., 1973, ~, 1091, and references therein. 
-204-
32. G.A. Howie. P.E. Mann and J.M. Caesady. J. Med. Chern., 1974.~. 840. 
33. S.M. Kupchan. C.W. Siegel. L.J. Guttman, R.J. Restivo and R.F. 
Bryan, J. Amer. Chem. Soc.,1972, 94, 1353. 
34. S.M. Kupchan and G. Tson. J. Org. Chem.. 1973.~. 1055. 
35. S.M. Kupchan. R.M. Smith. Y. Aynechi and M. Maruyama. J. Org. Chem •• 
1970. ~, 2891. 
36. B. Shohat. S. Gitter and O. Levine, Cancer Chemother. Rep., 1962. 
No. 23, 19l and references cited therein. 
37.A. S.M. Kupchan. A.H. Gray and M.D. Grove, J. Med. Chem., 1967. 10. 337. 
B. S.M. Kupchan. G. Tson and C.W. Siegel. J. Org. Chern •• 1973. ~. 1420. 
38. D. Burk. J. Laszlo. J. Hunter. K. Wight and M. Woods. J. Nal. 
Cancsr Inst. 1960, 24. 57. 
39. S.M. Kupchan. R.W. Doskotch. P. Bollinger. A.T. McPhail. G.A. Sim and 
J.A. SaenzRenauld. J. Amerc. Chem. Soc •• , 1965, !E.... 5805. 
40. S.M. Kupchan. W.K. Anderson. P. Bollinger. R.W. Ooskotch. R.M. Smith. 
J.A. SaenzRenauld. H.K. Schmoles. A.L. Burlingame and D.H. Smith. 
J. Org. Chem •• 1969. 34. 3858. 
41. D. Lavie. E. Glotter and Y. Shvo. J. Chem. Soc •• (Cl. 1965. 9517. 
42. D. Lavie. S. Greenfield and E. Glotter. J.Chern. Soc. (Cl. 1968. 1753. 
43. K.H. Lee. Y.S. Wn and I.H. Hall. J. Med. Chem .. 1977. 3..9.- 911. 
44. P. Calabresi and R.E. Parks. Jr •• in "The Pharmacological Baeis of 
Therapeutics". 5th Edition. Ed. L.S. Goodman and A. Gilman •• 
MacMillan. New York, ~.Y. 1975, 1254 and references cited therein 
45. K.H. Lee. T. Ibuka. S.H. Kim. B.R. Vestal. I.H. Hall and E.S. Huang. 
J. Med. Chem •• 1975. ~. 812. 
46. U. Schaeppi. A. Heyman. R.W. Fleischman. H. Rosenkerantz, V. Ilievski. 
R. Phelan. D.A. Cooney and R.D. Davis. Cancer Chemother. Rep., 
1973. i, Part 3. 85 and references cited therein. 
-205-
47. E.P. Vollmer, D.J. Taylor, L.J. Masnyk, D. Cooney, B. Levine, 
C. Piczak and L. Trench, Cancer Chemother. Rep., 1973, ±, 103. 
48. M.E. Wall, G.S. Abernethy, Jr., F.r. Carroll and D.J. Taylor, 
J. Med. Chem., 1969, £, 810. 
49. E.P. Vollmer, D.J. Taylor, r.J. Masnyk, D. Cooney, B. Levine and 
C. Piczak, Cancer Chsmother. Rep., 1973, ±. Part 3, 121. 
50 • .R.B. Everson, T .C. Hall and J.L. Wittl1ff, Cancer Chemother Rep., 
1973, 57 Part 1, 353 and references cited therein. 
51. P. Catsoulacos and L. Bontis, Cancer Chemother. Rep., 1973, 57 
Part 1. , 363. 
52. F.r. Carrell, A. Philip. J.T. Blackwell, b.J. Taylor and M.R. Wall, 
J. Med. Chem., 1972,.!i, 1158. 
53. P.A. Grieco, J.A. Noguez, Y. Masaki, K. Hiroi, M. Nishizawa, 
A Rosowski, S. Oppenheim and H. Lazarus. J. Med. Chem., 1977, 
3£, 71. 
54. J.A. Montgomery, J.P. Johnston and Y.F. Shealy, in "Medicinal 
Chemistry", Ed. A. Burger, Interscience, New York, N.Y. 1970, 699, 
700 and references cited therein. 
SS. S.M. Kupchan, R.J. Hemingway and R.M. Smith, J. Org. Chem. , 1969, 
1±, 3898. 
56. W. Herz, P.S. Subramaniam, P.S. Santhanam, K. Aota and A.L. Hall, 
J. Org. Chem., 1970, ~, 1453. 
57. S.M. Kupchan, W.A. Court, R.G. Dailey, Jr., C.J. Gilmore and 
R.F. Bryan, J. Amer. Chem. Soc.. 1972,~, 7194. 
58.A. K.H. Lee, J. Pham. ScL, 1973. 62, 1028; 
B. K.H. Lee, S.H. Kim, H. Furukawa, C. Piantadosi and E.S. Huang, 
J. Med. Chem., 1975.~, 59. 
59. F.E. Ziegler, A.F. M~rina, O.A.C. Petroff and W.L. Studt, Tet. Lett., 
1974, 2035. 
60. J.C. Mitchell, Trans. St. John's Hasp. Dern. Soc. (London), 1969, 
~ ·.174. 
-206-
61. H. Knocke, G. Ourisson, G.W. Perold, J. Foussereau and J. 
Maleville, Science, 1969, 166, 239. 
62. l.C. Mitchell, B. Freitig, B. Singh and G.H.N. Towers, 
J. Invest. Derm.,. 1970, 54, 233. 
63. J.C. Mitchell, A-X Roy and G. Dupuis, Arch. Derm.,1971, ~, 
73. 
64. J.C. Mitchell and G. Dupuis, Brit. J. Darm., 1971, 84, 139. 
65. J.C. Mitchell, G. Dupuis and G.H.N. Towers, Brit. J. Darm., 
1972, 87, 235. 
66. G.W. Parold, J.C. Muller and G. Durisson, Tet., 1972, 3!, 5797, 
and references cited therein. 
67. E. Bleumink, J.C. Mitchell and J.P. Nater, Arch. Darmatol., 
1973, ~, 220. 
68. A. Lonkar, J.C. Mitchell and C.D. Calnan, Trans. St. John's Hosp. 
Derm. Soc. (London'), 1974, 60, 43. 
69. Y. Asakawa, J.C. Muller, G. Ourisson, J. Foussarcone and G. Ducombs, 
Bull. Soc. Chim. Fran" 1976, 1465, 1489. 
70. G. Dupuis, J.C. Mitchall and G.H.N. Towers, Can. J. Bio Chem., 1974, 
g, 575. 
71. J .C. Mitchell in "Recent Advances in Phytochemistry", Ed. V.E. 
Runeckles, Plenum Press, New York, 1975, ~, 119. 
72. J.C. Mitchell, T.A. Ge1ssman, G. Dupuis and G.H.N. Towers, J. Invest. 
Derm. 1971,~, 98. 
73. G.A.W. Verspyck Mijnssen, Brit. J. Derm, 1969, ~, 737. 
74. D. Gross, Phytochem., 1975, ~ 2105. 
75. M.N. Gailbraith, D.H. S. Horn, S.Ito, M. Kodama and J.M. Sasse, 
Agr. B101. Chem., 1972, 36, 2393. 
76. M.N. Gailbra1th, D.H.S. Horn, J.M. Sasse and D. Adamson, J. Chem. 
Soc. Chem. Commun., 1970, 70. 
77. M.N. Gailbraith, D.H.S. Horn and J.M. Sasse, Experient1a, 1973, 3!, 253. 
-207-
78. S. Ito, M. Kodama, M. Sunagowa, M. Koreeda and K. 'Nakanishi, 
J. Chem. Soc., Chem. Commun., 1970, 170: 1971, 855, 1362. 
79.A. T. Hayashi, H. Kakisawa, S. Ito, Y.P. Chem. and H.Y. Hsu, 
Tet. Lett .. 1972, 3385. 
B. Y. Hayashio, V.I. Yuk1 and T. Matsumoto, Tet. Lett., 1977,3637. 
80. J.M. Sasse, M.N. Gailbraith, D.H.S. Horn and D. Adamson, 
"Proceedings of the 7th International Conference on Plant Growth 
Regulators", Canberra, Australia, Springer Verlag, Berlin, 1970, 299. 
81. D. Adamson,R; Hinde and S. Kamisaka, "Proceedings of the 7th 
International Conference on Plant Growth Regulations", Camberra, 
Australia, Springer Verlag. Berlin, 1970, 428. 
82. T. Yamaki. H. Shibaoka. K. Syono, H. Morimoto and H. Oshio, 
Bot. Mag. Tokyo, 1966, ~, 339. 
83. A. H. Shibaoka, M. Shimokosiyama. S. Irmichijima and S. Tamura. 
Plant and Cell Physiol •• 1961, ~, 175. 
B. H. Shibaoka, Plant and Cell Physiol. 1967. ~. 297: 
C. H. Shibaoka, M. Mitsuhashi and M. Shimokoriyama. Plant and 
Cell Physiol., 1967, ~, 161. 
84. L. Sequ1ra. R.J. Hemingway and S.M. Kupchan. Science, 1968, 
2.§!. 790. 
85. M.R. Garcidnenas. X.A. Dominguez. J. Fernadoz and G. Alanis, 
Rev. Latinoamer. Quim., 1972. ~, 52. 
86. S.D. Kanchan, Curr. Sci., 1975. 44, 358. 
87. C.B. McCahon. R.G. Kelsey. R.P. Sheridan and F. Shafizadeh. 
Bull. Toney. Bot. Club. 1973. ~, 23. 
88. R.R. Dalvi, B. Singh and D.K. Salunkhe, Chem-Biol Interactions: 
1971,~. 13. 
89. L.A. Mitscher in "Recent Advances in Phytochemistry". Ed. V.E. 
Runechles, Plenum Press, New York, 1975. ~, 243. 
90. S.B. Mathur, P.G. Tello. C.M. Fermin and V. Mora-Arellano, 
Rev. Latinoamer. Quim •• 1975, B, 201. 
-208-
91. W. Olechnowicz and S. Stepien, Dissert. Pharm., 1963, ~, 17. 
92. M.B.S. Char and S. Shankarabhat, Experientia, 1975,~, 1164. 
93. S.A. Vichkanova, V.V. Adgina and S.B. Izosimova, Rastit Resur., 
1977, E, 428. 
94. W. Vichnewski, S.J. Sarti, B. Gilbert and W. Herz, Phytocheml 
1976, ~, 191. 
95. D.E. Sperry, J.W. Dollahite, G.O. Hoffman and B.J. Camp,"Texas 
Plant Poisonous to Livestock", Texas, A and M. University, 
College Station, 1964. 
96. E.M. Schutz, B.N. Freeman and R.E. Read, "Livestock Poisoning 
Plants of Arizona," UniveFsity of Arizona Press, Tucson. 
97. G.W. Ivie, D.A. Witzel, W. Herz, R. Kannen, J.P. Norman, 
0.0. Rushing, J.H. Johnson, L.D.Rowe and J.~. Veech, 
J. Agric. Food Chem., 1975, 23, 843. 
98. G.W. Ivie, D.A. Witzel and 0.0. Rushing, J. Agric. Food Chem., 
1975, 2, 843. 
99. W. T. Kock, K.G.R. Pachler and P.L. Wessels, ~., 1968, 3!, 6045. 
100. S.M. Kupchan, J.R. Knox, J.E. Kelsey and J.A. Saenzhenauld, 
Science) 1969, 146, 1685. 
101. R.B. Kally, F.G. Daniels, and L.B. Spaulding, J. Med. Chem., 
1965, ~, 547. 
102. S.M. Kupchan, R.J. Hemmingway and R.W. Doskotch, J. Med. Chem., 
1964, z., 803. 
103. S.M. Kupchan, I. Ornyanov and J.L. Monoit, Bio-Organic Chem., 
1971, 1, 13. 
104. T.Z. Csaky, Federation Proc., 1863,~, 3. 
105. H.N. Christensen, T.R. Riggs, H. Fischer and J.M. Palatine, J. Biol. 
Chem., 1952,~, 1. 
-209-
106. H.J. Schatzmann. Helv. Phys. Acta •• 1953. 1!.. 346. 
107. I.M. Glynn, Pharmacol. Rev., 1964, ~, 381. 
10B. J.C. Skou, Pharmaool. Rev •• ~. ~. 596. 
109. A. H.J. Portins and K.R.H. Repke, Arzn. Forsch •• 1964. ~. 1073. 
B. A. Sohwarz. H. Matsui and A.H. Laughter. Scienoe. 1966. ~. 323. 
110. S.M. Kupohan. M. Mokotoff. R.S. SandhJ and L.E. Hokin. J. Med. Chem •• 
1967, ~. 1025. 
111. R.E. TenEick. A.L. Basset and G.T. Okita. J. Pharmac. Expt. Ther •• 
1973. 165. 12. 
112. G.T. Okita, F. Richardson and B.F. Roth~Schechter. J. Pharmac. Expt. 
~ .. 1973. 165. 1. 
113. G.T. Okita. Proc. West. Pharmac. Soc •• 1975. ~. 14. 
114. R. Mundez. G. Pastelin and E. Kabela. J. Pharmac. Expt. Ther •• 
1974. 166. 169. 
115. H. Lullman and T. Peters. Adv •• Cardiol. 1974. ~. 174. 
116. T. Peters. R.H. Raben and O. Wassermann, Eur. J. Pharmac •• 1974. 
26. 166. 
117. B.G. Katzung. J.A. Munoz. O.Y. Shirachi, A.J. Trevor. H.H. Chang 
and M.E. Wolff. Experientia. 1970, 26. 1189. 
11B. N.B. Glick in "Metabolic Inhibitors". Ed. R.M. Hochster and 
M. Kates, Acad. Press. New York. 1972. 2, 1. 
119. A. Sohwarz, G.E. Lindenmayer and J.C. Allen, in "Current Topios 
in Membranes and Transport." Ed. F. Bronner and A. Kleinzoller, 
Acad. Press., New York, 1972, 2. 1. 
120. K.R.H. Repke in. "Drugs and Enzymes", Ed. B.B. Brodie and 
J.R. Gilette, Pergamon Press Ltd., Oxford, 1965, 65. 
121. K.K. Chen, "Prooeedings of the 1st International Pharmacological 
Meeting, " StOCKholm, Ed. W. Wilbrandt and R. Lindgren. Pergamon 
Press Ltd •• Oxford (1963), 1961, ~, 27. 
122. Ch. Tamm, Raf 120 p. 11. 
-210-
123. F.G. Henderson and K.K. Chen, J. Med. Chem., 1965, ~, 557. 
124. G. Kuschinsky and H. lullman, in "Kurzes lehrbuch der 
Pharmakologie", Thieme, Stuttgart, 1970, ±, 51. 
125. R. Thomas, J. Boutagy and A. Gelbert, J. Pharmac. Expt. Ther., 
1974, ~, 219, and references cited therein. 
126. Th. W. Guntert and H.H.A. linde, Experientie, 1977,~, 
697, and references cited therein. 
127. K.R.H. Repke and H.J. Portius, "In Sciential Pharmaceuticae. 
"Ed .. O. Hane and J. Hubik, Butterworth, london, Czechoslovak 
Medical Press, Prague, 1966, 1, 31. 
12B. D.S. Fullerton, T.M. Gilman. M.C. Pankaskie, K. Ahmed, A.H.l. 
From, W.l. Duax and D.C. Rohrer, J. Med. Chem., 1977. 20, 841 
129. K.R.H. Repke, Pharmazie, 1972, 27, 693. 
130. Y. Saito, Y. Kanemasa and M. Okada, Chem. Pharm. Bull., 1970 • 
• 
.2.§.. 629. 
131. R. Thomas, J. Boutagy and A. Gelbert, J. Pharm. Sci., 1974, ~, 1649. 
132. J. Boutagy, A. Gelbert and R. Thomas. Aust. J. Pharm. Sci., 1973, 
£, 41. 
133. J.W. Moncrief and K.S. HelIer, Cancer Res., 1967, ~, 1500, 
and references cited therein. 
134. A. T. Posner, Chem. Ber.; 1902, 35, 799; 
B. T. Posner, Chem. Ber., 1904, ~, 502. 
135. T. Bersin, Ergel. Enzymforsch, 1935, ±, 18. 
136. T.S. Hauschka, G. Toemies and A.P. Swain, Science, 1945, ~, 383. 
137. W.B. Geiger and J.E. Conn, J. Amer. Chem. Soc., 1945, 67, 112. 
138. C.J. Cavallito and T.H. Haskill, J. Amer. Chem. Soc .. 1945,67, 1991. 
139. A. 
B. 
C. 
-211-
F. Dickens, Brit. Med. Bull •• 1964, 20. 96. 
J. Cooke and F. Dickens. Brit. J. Cancer. 1965. ~. 404) 
D. Black. J. Chem. Sac. (Cl. 1966. 1123. 
140. K.V. Thimann and W.D. Banner. In •• Proc. Nat. Acad. Sci. U.S •• 
1945, ~. 272. 
141. C.H. Smith. J. Lerner. A.M. Thomas and S.M. Kupchan. Biochem 
Biophys. Acta •• 1972. ~. 94. 
142. S.M. Kupchan. A. Karim and C. Marchs. J. Amer. Chem. Sac •• 1968 • 
.!!9.. 5923. 
143. S.M. Kupchan. A. Karim and C. Marcks. J. Drg. Chem.. 1969. 34. 3912. 
144. J.B. Jones and J.M. Young, J. Med. Chem.. 1968, 21, 1176. 
145. A. F. Dickens and H.R.H. Jones, Brit. J. Cancer, 1961. 15, 85) 
1963, 17, 69) 
B. P. Brooks and P.D. Lawley, J. Chem. Sac •• 1961. 539. 3923. 
C. P. Brooks and P.D. Lawley, J. Mal. BioI. 1962. !. 216) 
D. P. Brooks and P.D. Lawley. Brit. Med. Bull •• 1964. 3£. 91. 
146. I.H. Hall. K.H. Lee. E.C. Mar. C.D. Starnes and T.G. Waddell. 
J. Med. Chem •• 1977. 3£. 333. 
147. S.M. Kupchan. C.W. Siegel. M.J. Matz. T.A. SaenzRenauld. R.C. 
Haltiwanger and R.F. Bryan. J. Amer. Chem. Sac •• 1970. ~. 4476. 
148. J.R. Lillehang, K. Kleppe, C.W. Sigel and S.M. Kupchan, 
Biochem. Biophys. Acta., 1973, 327. 92. 
149. S.M. Kupchan and R.M. Schubert, Science, 1974, 185. 791. 
150. E.R.H. Jones, T .Y. Shen and M.C. Whiting, J. Chem. Soc., 1950, 230. 
151. A. 
B. 
C. 
W. Parker, J.S. Roberts and R. Ramage, Quart. Rev., 1967, ~, 331. 
J. Romo and A. Romode Vivar. Prog. Chem. Org. Natur. Prod. 1967, 
25, 90l 
W. Stocklin, T.G. Waddell and T.A. Geissman, Tet., 1970, 26, 2397, 
and references cited therin. 
152. C.J. Cavallito, in "Medicinal Chemistry", Ed. C.M. Suter, WHey. 
New York, N.V., 1951, Vol 1, 221. 
-212-
153. P.A. Grisco, ~., 1975. 67. 
154. R.B. Gammill. C.A. Wilson and T.A. Bryson. Syn. Commun. 1975. 
5. 245. 
155. A. J.R. Norton. K.E. Shenton and J. Schwartz. Tet. Lstt •• 1975. 51, 
B. T.F. Murrey, V. Vsrma and J.R. Norton, J. Chem. Soc. Chem. Commun •• 
1976. 907. 
156. A. R.G. Carlson and O.E. Henton. J. Chem. Soc •• Chem. Commun. 
1969. 674. 
B. H.C. Brown and C.P. Garg. J. Amer. Chem. Soc.. 1961. 83. 2952. 
157. H.C. Brown and S. Krishnamurthy. J. Amsr. Chem. Soc •• 1972. 94. 7159. 
158. S.F. Martin and O.R. Moore. Tet. Lett., 1976, 4459. 
159. A. A.D. Harmon and C.R. Hutchinson. Tst. Lstt •• 1973. 12931 
B. C.R. Hutchinson, J. Org. Chem., 1974, ~, 1854. 
160. K. Yamada. M. Kato and Y. Hirata, Tet. Lstt •• 1973. 2745. 
161. P.F. Hudrlik. L.R. Rudnick and S.H. Korzsniowski. J. Amer. Chsm. 
~., 1973. ~; 6848. 
162. R.K. Singh and S. Danishefsky. J. Org. Chem •• 1976. 4~ 1668. 
163. 
164. 
165. 
166. 
S. Danishefsky and R.K. Singh. J. 
R.K. Singh and S. Danishsfsky. J. 
S. Oanishefsky and R.K. Singh. J. 
F.E. Ziegler. A.F. Marino. O.A.C. 
Tst. Lett. 1974. 2035. 
Amer. Chem. Soc. 6 1975. 97. 
Org. Chem •• 1975. ~. 2969. 
Drg. Chem •• 1975. 40. 3807. 
Pstroff and W.L. Studt. 
3239. 
167. P.A. Grieco and C.S. Pogonowski. J. Org. Chem.. 1974. 39, 1958. 
168. H. Zimmer and T. Pampalone. J. Heterocycl. Chem., 1965. ~. 95. 
169. D.C. Lankin. M.R. Scaliss, J.C. Schmidt and H. Zimrner. J. Hetero-
cycl. Chem •• 1974. 11. 651. 
170. T. Minami. I. Niki and T. Agawa, J. Org. Chem .• 1974, ~. 3236. 
171. W.J. McGraw. U.S. Patent, 2, 624.723 ( Chem. Abs •• 1953. 
£. 11232). 
172. C. Alexandrs and F. Rousessac. Tet. Lett •• 1970, 1011. 
173. C. Alsxandre and F. Rousessac, C.R. Acad. Sci. Ser. C. 1972, 274. 1585. 
-213-
174. J.N. Marx and L.R. Norman, Tat. Lett., 1973, 4375. 
175. L.F. Fieser and M. Fisser, " Reagents in Organic Synthesis," 
John Wiley and Sons, Inc. 1967, Vol 1, 1249. 
176. A. H. Minato and J. Horibe, J. Chem. Soc., Chem •• Commun. 
1965, 531l 
B. H. Minato and I. Horibe, J. Chem. Soc. (C), 1967, 1575. 
177. H. Minato and T. Nagasaki, J. Chem. Soc. Chem.Commun., 1965, 377. 
178. A. H. Minato and I. Horibe, J. Chem. Soc., Chem. Commun., 1967, 358. 
B. H. Minato and I. Horibe, J. Chem., Soc. Chem. Commun •• 1968, 2131. 
179. R.A. Kretchmer and W.J. Thompson, J. Amer. Chem. Soc., 1976,~, 
3379. 
180. J.A. Marshall and W.R. Snyder, J. Org. Chem., 1975. i£. 1656. 
181. A. E.E. van Tamelan and S.R. Bach, J. Amsr.Chem. Soc., 
1955, !l.... 46831 
B. E.E. van Tamelen and S.R. Bach, J. Amer. Chem. Soc., 1958, 
~ 30791 
C. E.E. van Tamelen and S.R. Bach, Chem. and Ind., 1956, 1308. 
182. R.B. Miller and E.S. Behare, J. Amer. Chem. Soc., 1974, ~, 8102. 
183. A. E.S. Behare and R.B. Miller, J. Chem. Soc. Chem., Commun.,1970, 
4021 
B. R.B. Miller and B.F. Smith, Tet. Lett., 1973. 5037. 
184. S. Coffey, Rec. Trav. Chim. Bays-Bas., 1923, 42, 387. 
185. A. J. Martin, P.C. Watts and F. Johnson, J. Chem. Soc. Chem. Commun., 
1970, 27l 
B. H.L. Finkbeiner and M. Stiles, J. Amer. Chem. Soc., 1963,~, 616. 
188. L.K. Oalton and B.C. Elmes, Anst. J. Chem., 1972, ~, 825. 
187. A. 
B. 
M. Stiles and H.L. FinKbeiner, J. Amer. Chem. Soc., 1959, ~, 5051 
J. Martin, P.C. Watts and F. Johnson, J. Org. Chem., 1974, ~,1676. 
188. A. W.L. ParKer and F. Johnson, J. Amer. Chem. Soc., 1969,~, 72081 
B. K. Yamada, M. Kato, M. Iyoda and Y. Hirata. J. Chem. Soc. Chem. 
Commun., 1973, 499. 
-214-
189. W.L. Parker and F. Johnson, J. Org. Chem., 1973, ~, 2489. 
190. H. Ohmi and S. Imoto, Tet. Lett., 1975, 3657. 
191. G. Zvilichovsky and U. Fotadar, Org. Prop. Proc. Int., 1974, ~, 5 
192. A. P. Oeslonglchamps and L. Ruest, Org. Syn. 1974, 
B. S. Inayama and T. Kawamata, Chem. Pharm. Bull. Japan, 
1973, 31, 461. 
193. J.A. Marshall and R.H. Ellison, J. Amer. Chem. Soc., 1976, ~, 4312. 
194. E. Campaigne and J.E. Beckman, Syn., 1978, 385. 
195. P.A. Grieco and K. Hiroi, J. Chem. Soc. Chem. Commun., 1973, 500. 
196. N. Bensel, H. Marschalland P. Weyerstahl, Chem. Ber., 1975, 108, 2697. 
197. J.L. Roberts, P.S. Borromeo and C.O. Poulter, Tet. Lett., 1977, 1621. 
198. A. J. Schreiber, H. Maag, N. Hashimoto and A. Eschenmoser, 
Angew. Chem. Int. Ed., 1971, 1~ 330; 
B. G. Kinast and T.F. Tietz9, Angew. Chem. Int. Ed., 1976, ~, 239. 
199. J.L. Roberts, P.S. Borromeo and C.O. Poulter, Tet. Lett., 1977, 1299. 
200. S. Danishefsky, T. Kitahara, R. McKes and P.F. Schuda, J. Amer. Chem. 
Soc. # 1976, 98, 6715. 
. -
201. J. Hooz and J.N. Bridson, J. Amsr. Chem. Soc., 1973,~, 603. 
202. M.L. Holy and Y.F. Wang, J. Amer. Chem. Soc., 1977,~, 944. 
203. A. P.A. Grieco and K. Hiroi, J. Chem. Soc. Chem. Commun., 1972, 1317; 
B. P.A. Grieco, M. Nishizawa, s.o. Burke and N. Marinovic, J. Amer. 
Chsm. Soc., 1976,~, 1612. 
204. G. Stork and J. D'Angelo. J. Amer. Chsm. Soc •• 1974. ~. 7114. 
205. A.E. Greene, J.C. Muller and G. Ourisson, Tet. Lett., 1972, 2489. 
206. P.A. Grieco and M. Miyashita, J. Org. Chem., 1970, ~, 120. 
207. E.W. Colvin, R.A. Raphael and J.S. Roberts, J. Chem. Soc. Chem. Commun., 
1971, 858. 
208. G.H. Posner and G.L. Loomis, J. Chem. Soc. Chem. Commun .. 1972, 892. 
'. ',~, 'I' 
• 209. J.H. Herrmann.and R.H. Schlsssinger, J. Chem. Soc. Chem. Commun., 
1973. 711. 
210 • A. F.D. Gunstone and R.M. Heggie, J. Chem. Soc., 1952. 1354; 
-215-
B. H.J. Ringold, E. Bates, O. Halpern and E. Nocoechea, J. Amer. 
Chem. Soc., 1959, ~, 427, 
C. O.H.R. Barton and A.J.L. Beckwith, Proc. Chem. Soc., 1963, 
335, 
O. E.I. Heiba and R.M. Oessau, J. Amer. Chem. Soc., 1971, 93, 995, 
E. W. Sincrow and U. Klein, Chem. Ber., 1975,~, 48. 
211. A.E. Greene, J.C. Muller and G. Ourisson, J. Org. Chem., 
1974, 39, 186. 
212. A.E. Greene, J.C. Muller and G. Ourisson, Tet. Lett., 1971, 4147. 
213. S.M. Ali and S.M. Roberts, J. Chem. Soc., Chem. Commun., 1975, 887. 
214. A. W.T. Brady, R. Roe, E.E. Hoff and F.H. Parry, J. Amer. Chem. Soc., 
1970, 92, 146, 
B. W.T. Brady, R. Roe, E.E. Hoff and F.H. Parry, J. Amer. Chem. Soc., 
1970, ~, 4618. 
215. A. P.A. Grieco and K. Hiroi, Tet. Lett., 1974, 3467, 
B. P.A. Gr1eco, N. Marinovic and M. Miyashita, J. Org. Chem., 
1975, ~, 1670. 
216. A.a.Greene, J.C. Muller anQ G. Ourisson, Tet. Lett., 1972, 3375. 
217. A. S.M. Kupchan, R.J. Hemingway, O. Werner, A. Karim, 
A.T. McPhail and G.A. Sim, J. Amer. Chem. Soc., 1968,~, 3596, 
B. P.A. Grieco and K. Hiroi, Tet. Lett. 1973, 1831. 
218. A. P.A. Grieco, and Y. Masaki, Tet. Lett., 1975, 4213, 
B. P.A. Grieco, J.J. Reap and J.A. Naguez, Syn. Commun., 1975, ~, 155, 
C. P.A. Grieco, K. Hiroi, J.J. Reap and J.A. Noguez, J. Org. Chem., 
1975, ~, 1450, 
D. P.A. Grieco, M. Nishizawa T. Ognri, S.D. Burke and N. Marinovic, 
J. Amer. Chem. Soc., 1977,~, 5773, 
E. P.A. Grieco.- J.A. Noguez and Y. Masaki, J. Org. Chem., 1977, 
£, 495. 
-216-
219. A. S. Danishefsky and T. Kitahara. J. Amer. Chem. Soc •• 
1974.~. 7807; 
B. S. Danishefsky and T. Kitahara. J. Drg. Chem.. 1975.~. 538; 
C. S. Dabishefsky. P.F. Schuda and K. Kato. J. Org. Chem •• 
1976. ±1. 1081; 
D. S. Danishefsky. T. Kitahara. P.F. Schuda and S.J. Etheredge. 
J. Amer. Chem. Soc.. 1976.~. 3028; 
E. S. 'Danishefsky. P.F. Schuda. T. Kitahara and S.J. Etheredge. 
J. Amer. Chem. Soc •• 1977. ~. 6066. 
220. A. J.A. Marshall. C.T. Buse and D.E. Seitz. Syn. Commun. 
1973. ~. 85; 
B. 
C. 
221. A. 
B. 
C. 
D. 
J.A. Marshall and D.E. Seitz. Syn. Commun •• 1974. i. 395; 
J.A. Marshall and D.E. Seitz. J. Org. Chem •• 1975. ~. 534. 
R.D. Clark and C.H. Heathcock. Tet. Lett •• 1974. 1713; 
C.G.Chavdarian and C.H. Heathcock. J. Drg. Chem.. 1975. 
~. 2970; 
R.D. Clark and C.H. Heathcock. J. Drg. Chem •• 1976. ±1. 1396; 
C.G. Chavdarian. S.L. Wood. R.D. Clark and C.H. Heathcock. 
Tet. Lett.. 1976. 1759; 
E. P.M. Wedge. R.D. Clark and C.H. Heathcock. J. Drg. Chem •• 
1976. ±1. 3144; 
F. C.G. Chavdarian and C.H. Heathcock. Syn. Commun •• 1976. ~. 277. 
222. D. Caine and G. Hasenhent. Tet. Lett.. 1975. 743. 
223. D.H. Lucast and J. Wemple. ~ •• 1976. 724. 
224. M. Isobe. H. Jio. T. Kawai and T. Goto .• Tet. Lett •• 1977. 703. 
225. J.A. Marshall and W.!. Fanta. J. Org. Chem •• 1964. 29. 2501. 
226. S.M. Kupchan. T.J. Giacobbe and I.S. Krull. Tet. Lett •• 
1970. 2859. 
227. R.C. Ronald. Tet. Lett •• 1973. 3831. 
228. H.J. Reich and J.M. Renga. J. Chem. Soc •• Chem. Commun •• 1974. 135. 
-217-
229. a.M. Trost and C.H. Miller. J. Amer. Chem. Soc., 1975. ~, 7182. 
230. K. Yama~awa. K. Nishitani and T.U. Tominaga. Tet. Lett., 
1975. 2829. 
231. P.A. Grieco and M. Nishizawa, J. Chem. Soc •• Chem. Commun., 
1976. 582. 
232. A. S. Matueda and T.A. Geissman, Tet. Lett., 1967, 2013. 
a. A. Romo de Vivar and H. J menez. Tet., 1966, 31. 1273. 
C. M. Ando. A. Skehane and T.K. Takase. Bull. Chem. Soc., Japan, 
1978 • .2.1.. 283. 
D. K. Yamakawa, T. Tominega and K. Nishitani, Tet. Lett., 
1975. 4137. 
233. 
Syn;'j 
N. Petragnani and H.M.C. Ferra~978, 476. 
234. B.M. Trost and T.N. Salzmann, J. Amer. Chem. Soc •• 1973,~, 6840. 
235. P.A. Grieco and J.J. Reap. Tet. Lett •• 1974. 1097. 
236. J.L. Herrmann. M.H. Berger and R.H.Schlessinger. J. Amer. Chem. Soc •• 
1973, ~. 7923. 
237. B.M. Trost and K.K. Leung, Tet. Lett.. 1975. 4197. 
238. A. Loffer. R.D. Pratt, J. Pucknat, G. Geibard and A.S. Dreiding, 
Chimia., 1969, 23. 413. 
239. E. Ohler, K. Reininger and U. Schmidt. Angew. Chim. Int. Ed., 1970. 
~, 457. 
240. J. Dickinstein. M. Bodnar and R.M. Hoegerb. U.S. Patent,3,094,554. 
241. A. J.A. Marshall and N. Cohen. Tet. Lett., 1964, 1997, 
B. J.A. Marahall and N. Cohen, J. Org. Chem., 1965. ~, 3475, 
242. J.A. Marshall and N. Cohen. J. Amer. Chem. Soc., 1965, ~, 2773. 
243. J .A. Marshall. and A.R. Hochsteller, J. Amer. Chem. Soc., 1966, 
~, 3408. 
244. V.R. Tadwalkar and A.S. Rao, Ind. J. Chem., 1971. ~. 1416. 
245. M. Golfier and T. Prange, Bull. Chim. Soc. France •• 1974. 1158. 
-218-
246. J.D. Bacha and J.K. Kochi. ~.. 1968. 24. 2215. 
247. A. K.J. Divakar. P.P. Sane and A.S. Rao. Tet. Lett .. 1974. 399. 
B. T.L. Ho and C.M. Wang. Syn. Comm •• 1974.~. 133. 
248. A. Tanaka. T. Nakata and K. Yamashita. Agr. Biol. Chem •• 
1973. l2'... 2365. 
249. A. D.S. Hoffenberg and L.M. Zaccardo. U.S. Patent. 1965. 
3.213.072. (C.A. 1965.~. 17909a); 
B. J.M. McEven. R.P. Nelson and R.G. Lawton. J. Org. Chem •• 
1970. 35. 1901 
C. H. Marschall. F. Vogel and P. Weyerstahl. Chem. Ber •• 
1974. 107. 2852. 
250.' A. U.M. Kempe. T .K. OasGupta. K. Blatt. P. Gygax. O. FeUx and 
A. Eschermonser. Helv. Chim. Acta •• 1972.~. 2187. 2198. 2205; 
M. Petryilka. D. Felix and A. Eschenmoser. Helv. Chim. Acta •• 
1973. 2.§.. 2950; 
C. S. Shatziller. P. Gygax. O. Hall and A. 
\ 
:!:bid; 
Eschenmoser.,,1973. ~. 2961. 
251. G.M. Ksander, J.E. McMurry and M. 'Johnson, J. Org. Chem., 1977,~, 
1180. 
252. R.M. Carlson. Tet. Lett .• 1978. 111. 
253. R.M. Carlson and A.R. Oyler. Tet. Lett.. 1975. 4099. 
254. R.M. Carlson and A.R. Oyler. J. Org. Chem.. 1976.~. 4065. 
255. A. J.B. Jones and J. Young. Can. J. Chem .. 1966.~. 1059; 
B. N.R. Unde. S.V. Hiremath. G.H. Kulkarin and G.R. Kelkar. 
Tet. Lett •• 1968. 4861; 
C. S.V. Hiremath. G.H. Kulkarni. G.R. Kelkar and S.C. Bhattacharyya. 
Ind. J. Chem.. 1968. .§.. 339 I 
D. T.C. Ja1n. C.M. Banks and J.E. McCloskey. Tet. Lstt •• 1970.841; 
E. T. Kawamata and S. Inayama. Chem. Pharm. Bull.. 1971.~. 643; 
F. T.e. Jain and J.E. McClosk,y. Tet. Lett •• 1971. 1415; 
G. T.C. Ja1n. C.M. Banks. and J.E. McClaskey. ~ •• 1976. ~. 765. 
-219-
256. P.A. Grieco and M. Miyashita, Tet. Lett., 1974,1869. 
257. P.A. Grieco and M. Miyashita, J. Org. Chem., 1975, 40, 1181. 
258. A. K.B. Sharpless, M.W. Young and R.F. Lauer, Tet. Lett., 
1973, 19791 
B. K.B. Sharpless and M.W. Young, J. Org. Chem., 1975, 40, 947. 
259. D.N. Jones, D. Mundy and R.D. Whitehouse, J. Chem. Soc. Chem., 
Comm. 1970, 86. 
260. A. N. Prllej aeff, Bull'. Sac .. Chim. France, 1927, ~, 6871 
B. J. Boesekin and A.L. Soesman, Rec. Trav. Chim. , 1933, g, 874. , 
C. J. Boesekin and Jacobs, Rev. Trav. Chim. , 1936, 2i, 
D. H.M. Walton, J. Org. Chim. , 1957, ~, 1161. 
E. G.B. Payne and P.H. Williams, J. Org. Chem., 1959,~, 2841 
261. A. Salamon, Z. Physiol. Chem., 1941, 272, 61 
262. R.B. Turner, J. Amer. Chem. Soc., 1950, ~, 579. 
263. G.R. Pettit and T.R. Kasuri, J. Org. Chem., 1961, 26, 986. 
264. G.R. Pettit and T.R. Kasturi, J. Org. Chem., 1961,~, 4557. 
265 •. E. Caspi, Y.W. Chang and R.I. Dorfman, J. Med. Pharm. Chem., 1962, 
2., 714. 
266. A. J.T. Pin hey and K. Schaffner, Tet. Lett., 1965, 601. 
B. M. Gorodetsky, N. Danieli and Y. Mazur, J. Org. Chem., 
1932, 32, 700. 
268. A. M. Fetizon, M. Golfier and J.M. Louis, Tet., 1975, ~, 171. 
B. M. Kondo, M. Matsumoto and F. Mori, Angew. Ghem. Int. Ed., 
1975, .1,i, 103. 
269. A.i.E.I. Heiba, R.M. Dessan and W.J. Koehl, Jr., J. Amer. Chem. Soc., 
1968, ~, 2706. 
A.1i. E.I. Heiba, R.M. Dessau and W.J. Koehl, Jr., J. Amer. Chem. Soc., 
1968, ~, 5905. 
B.1. E.I. Heiba and R.M. Dessau, J. Amer. Chem. Soc., 1971, ~, 995. 
-220-
269. B ii. E.I. Heiba and R.M. Dessau, J. Amer. Chem. Soc., 1971, 93, 995. 
C. E.I. Heiba and R.M. Dessau, J. Amer. Chem. Soc., 1972,~, 2888. 
D. Y. Mori and J. Tsuji, ~., 1972, ~, 29. 
E. G.I. Nikishin, M.G. Vinogradov and T.M. fedorova, 
J. Chem. Soc. Chem. Commun., 1973, 693. 
F. E.I. Meiba, R.M. Dessau and P.G. Rodewald, J. Amer. Chem. Soc., 
1974,~, 7977. 
G. F.J.McQuillin and M. Wood, J. Chem. Soc., 1977, 61. 
270. A. J. Fried, R.W. Thoma and A. Klinsberg, J. Amer. Chem. Soc., 
1953,~, 576, 5764. 
B. D.H. Peterson, S.H. Eppstein, P.D. Meister, H.C. Murray, 
H.M. Leigh, A. Weintraub and L.M. ·Reineke, J. Amer. Chem. Soc., 
1965, ~, 5768. 
C. D.R. Brannon, J~ Martin, A.C. Dcheleschlager, N.N. Durham 
and L.H. Zalkow, J. Org. Chern., 1965, ~, 76, 3475. 
D. J.A. Marshall, N. Cohen and K.R. Arenson, J. Org. Chem., 
1965, 30, 762. 
E. A. Wettstein and E. Vischoer, U.S. Patent 2,904,472. 
271. A. D.M. Piatak, H.B. Bhat an E. Caspi, J. Org. Chem., 1969, ~! 112. 
8. D.G. Lee and M. Van Den Engh, Can. J. Chem., 1972,~, 3129. 
C. J.E. Lyons, J. Chem. Soc. Chem. Commun., 1975, 412. 
272. R.D. Clark and C.H. HeathcocK, Tet. Lett., 1974, 1713, 2027. 
273. A. G.D. Zindema, E. Van Tamelen and G. Van Zyl, Drg. Syn. ColI. Vol 4, 
1963, 10. 
8. C.H. DePuy, F.W. Breitbeil and K.L. Eilsrs J. Org. Chem., 
1964, ~, 2810. 
C. P.L. Creger, J. Org. Chern., 1972, 37, 1907. 
D. G.C. Wolf and R.T. Blickenstaff, J. Drg. Chem., 1976,~, 1254. 
274. P.A. Grieco, C.L. Wang and S.D. Burke, J. Chem. Soc. Ch ern. Cornrnun., 
1975, 537. 
-221-
275. A.I. Meyers, E.O. Mihelich and R.L. Nolan, J. Org. Chem., 
1974, ~, 2783. 
276. A. J.F. LeBorgne, T. Cuvigny, M. Larcheveque and H. Normant, 
Syn, 1976, 238. 
B. P. Hullot, T. Cwigny, M. Larcheveque and H. Normant, 
Can. J. Chem. , 1977, ~, 266. 
277. M. Itoh, T. Taginchi, V.P. Chung, M. Tokuda and A. Suzuki, 
J. Org. Chem., 1972, 37, 2357. 
278. D.L. J. Clive and G. Chittache, J. Chem. Soc., Chem. Commun., 
1977, 484. 
279. M.J. Bogdanovicz, T. Ambelang and B.M. Trost, Tet. Lett., 
1973, 923. 
280. A. P. Kurath and W. Cole, J. Org. Chem., 1961, ~, 4592 
B. P.E. Eaton, G.I. Cooper, R.C. Johnson and R.H. Mueller, 
J. Org. Chem.. 1972, 37, 1947. 
281. J.A. Marshall, F.N. TulleI' and R. Ellison, .§..yn. Commun., 1973, 
1. 465. 
282. M. Rosenberger. O. Andrews, F. OiMaria. A.J. Ouggan and G. Saucy. 
Helv. Chim. Acta.. 1972.~, 249. 
283. J.F. Eastham and T .R. Taranishi. Org,' Syn. Coll. Vol IV, 1963. 192. 
284. J. March, J. Chem. Edn., 1963,~. 212. 
285. A. J. March. in "Advanced Organic Chemist ry" • 2nd Ed •• 
McGraw-Hill Book Company, New York. 1977. P 569. 
B. W.P. Jencks. "Catalysis in "Chemistry and Enzymol ogy, " 
McGraw-Hill Book Company, New York. 1969, p 116. 
C. O.B. Bigley and J.C. Thurman, J. Chem. Soc.(B), 1967, 941. 
O. G.G. Smith and F.W. Kelly. Prog. Phys. Org. Cheml 1971.~, 150. 
286. C.G. Swain. R.F. W. BadeI'. R.M. Esteve .• Jr., and R.N. Griffin. 
J. Amer. Chem. Soc •• 1961, ~, 1851. 
287. E.J. Corey. J. Amer. Chem. Soc., 1954, ~, 175. 
-222-
288. E.J. Corey and R.A. Sneen. J. Amer. Chem. Soc.. 1956.~. 6269. 
289. A. S.K. Malhotra and H.J. Ringold. J. Amer. Chem. Sce. , 1963. ~. 1538. 
B. S.K. Malhotra and H.J. Ringold. J. Amer. Chem. Sce. , 1964. .!!..§.. 1997 ; 
C. S.K. Malhotra and H.J. Ringold. J. Amer. Chem. Sac. , 1965. ~. 3228; 
D. G. Subrahmanyam. S.K. Malhotra and H.J. Ringold. J. Amer. Chem •• 
Soc. , 1966. 
.!!..§.. 1332. 
290. R. Villotti. H.J. Ringold and C. Djerassi. J. Amer. Chem. Sce. , 
1960. E· 5693. 
291. L.N. Volovel'skii. G.V. Knorozova and M. Ya. Yakovleva. 
J. Gen. Chem. U.S.S.R., 1967. 37. 1188. 
292. A. J.K. Norymberski and G.F. Woods. Chem. and Ind. (London) • 
1954. 518. 
B. J.K. Norymberski and G.F. Woods. J. Chem. Scc. , 1955. 3426. 
293. A. F. Sondheimer. C. Amendolla and G. Rosenkranz. J. Amer. Chem. Soc •• 
195:3. Z,2.. 5930. 
B. F. Sondheimer. D. Mancora. M. Urquiza and G. Rosenkranz. 
J. Amer. Chem. Soc.. 1955.~. 4145. 
294. G.H. Rasmusson and G.E. Arth in "Organic Reactions in Steroid 
Chemistry" Ed. by J. Fried and J .A. Edwards. Van Nostrand 
Reinhold Company. New York. 1972. Vol 1. P 246. 
295. H. Levy and R.P. Jacobson. J. BioI. Chem; 1947. 171. 71. 
296. A. J.H. Markgraf and S.J. Basta. Syn. Commun •• 1972.~. 139. 
B. G. Mehta and P.N. Pandry. Syn •• 1975. 404. 
C. J.R. Williams and J.D. Leber. SynJ 1977. 427. 
297. L.R. Knox. R. Vollotti. F.A. Kincl and H.J. Ringold. J. Org. Chem •• 
1961. 26. 501-
298. B. Helferich and A. Gnuchtel. Chem. Ber.. 1938. Z!. 712; 
L.F. Fieser and M. Fiese~ Reagents for Organic Synthesis. 
John Wiley and Sons. Inc •• New York. 1967. Vol 1. 663. 
-223-
299. A. Furst and F. Koller. Helv. Chim. Acta.. 1947.~. 1454, 
A. Furst and PI. A. Plattner, Helv. Chim. Acta, 1949, 32, 275, 
W.S. Johnson, J.C. Collins, Jr., R. Paoop, M.B. Rubin, 
P.J. Kropp, W.F. Johns. J.E. Pike and W. Bartmann, 
J. Amer. Chem. Soc., 1963,~, 1409. 
300. J.E. Bridgemann, C.E. Butchers, Sir E.H.R. Jones, A. Kasal, 
G.D. Meakins and p.a. Woodgate, J. Chem. Soc. (C), 1970, 244. 
301. J. Colonge and L. Gurnet, Bull. Soc. Chim. France. 1947, 14, 838. 
302. A. J.D. Gettler and L.P. Hammet, J. Amer. Chem. Soc., 1943, 
65, 1824; 
B. O.S. Noyce and W.L. Reed, J. Amer. Chem. Soc.l, 1049, 91, 624; 
C. M. Stiles, O. Wolf and G.V. Hudson, J. Amer. Chem. Soc., 
1959, .!!2., 628; 
O. A.T. Nielson, H. Dubin and K. Hise, J. Drg. Chem., 1967, 32, 3407. 
303. A. F.F. Blicke, "Drg. Reactions", 1942, .1., 303; 
B. H. Hellmann and G. Opitz. Angew. Chem. Int. Ed., 1956,~, 265; 
C. B. Reichert, "Die Mannich Reaktion", Springer Verlag,Berlin, 1959. 
O. H.O. House, "Modern Synthetic Reactions", 2nd Ed., W.A. 
Benjamin, Inc. New York, 1972, pp 654-660; 
Eo M. Tramontini, Syn" 1973, 703. 
304. A. H. Hellmann and G. Opitz," ""-Amino alkyl1erung", Verlag-Chimie, 
Weinheim, Germany, 1960; 
B. L.W. Nobles, J. Mississippi Acad. Sci., 1962, ~, 36; 
C. M. Miocque. Ann. Pherm. Franc., 1969,~, 381. 
305. R.B. Miller and B.F. Smith, Syn. Commun., 1973, 3, 129. 
306. B.B. Thompson, J. Pharm. Sci., 1968, 2Z, 715 and references cited 
therein. 
307. S. Hirai, R.G. Harvey and E.V. Jensen, Tet. Lett., 1963, 1123. 
308. A. Ahond, A. Cave, C. Ken-Fan and P. Potier, Bull. Soc. Chim., 
France, 1970, 2707. 
-224-
309. A. A. Ahond, A. Cave, C. Kan-Fan, H.P. Husson, J. deRostolan and 
P. Potier, J. Amer. Chem. Soc., 1968,~, 5622: 
309. B. A. crav~ C. Kan-Fan and P. Potier, Bull. Soc. Chim. France, 
1970, 27071 
C. Y. Jasor, M.J. Luche, M. Gandry and A. Marquet. J. Chem. Soc. 
Chem. Commun., 1974, 253. 
310. J • L. Gras, Tet. Lett. , 1978, 2111. 
311. A. P. Barb~er and R. Locquin, Compt. Rend., 1913, 156, 1443: 
CC.A. 1913. !, 31101. 
B. H. Wieland, O. Schlichting and R. Jacobi, Z. Physio. Chem., 1926, 
161, 80: ( C.A. 1927, 31, 590). 
312. J. Hauben, Chem. Ber., 1904,~, 489. 
313. F.L. Weisenborn, D.C. Remy and T.L. Jacobs, J. Amer. Chem. Soc., 
1953, Z§.' 552. 
314. M.S. Kharasch and D. Reinmuth, "Grignard Reactions of Non-metallic 
Substances," Constable and Company Ltd., (Londonl 1954, P574 and 
references cited therin. 
315. A. J.E. Billeter and K. Miescher, Helv. Chim. Acta, 1949, 
32, 5641 
B. M.M. Regic, Hem. Druskva Beograd. , 1964, ~, 57 
(Chem. Abs., 1966, ~, 19717 fll 
C. J. Ovemell and J .5. Whitehurst, J. Chem. Soc., (Cl, 1971, 378. 
316. L.F. Fieser and M. Fieser, "Reagents for Organic Synthesis", 
1967, 1, 819. G.B. Payne, Org. Syn., 1962, 42, 77. 
317. S.S. Dehal, B.A. Marples and R.J. Stretton, Tet. Lett. , 1978, 2183. 
318. C.L. Stevens and J. Tazamuna. J. Amer. Chem. Soc •• 1954. 76, 715. 
319. A. B. Belbau and LF. Gallagher. J. Amer. Chem. Soc., 1952, 
~, 28161 
B. C.L. Stevens and S.J. Dykstra, __ J. Amer-= Chem. Soc., 1953, z..§., 5975. 
320. R.C. Cambie, K.N. Joblin and A.F. Preston, Aust. J. Chem., 
1972, 3..§., 1767. 
321. S.N. Lewis, "Oxidation", ed. R.L. Augustine, Marcel Dekker, 
New York, 1968, Vol 1, P 213. 
-225-
322. R.C. Cambie, K.N. Joblin and A.F. Preston, Anst. J. Chem., 
1971, 24, 583. 
323. M. Hinder and M. Stoll, Helv. Chim. Acta., 1950, 33, 1308. 
324. A. I.J. Borowitz, G. Gonis, R. Kelsey, R. Rapp and 
G.J. Williams, J. Org. Chem., 1966,~, 3032, 
B. I.J. Borowitz, G.J. Williams, L. Gross and R. Rapp, 
J. Org. Chem., 1968,~, 2013. 
325. T.L. Jacobs and N. Takahashi, J. Amer; Chem. Soc., 1958, 
!:!2., 4865. 
326. M. Kohn, Monatsh, 1913, ~, 1729. 
327. R.K. Hill and R.M. Carlson, J. Amer. Chem. Soc., 1965,~, 2772. 
328. J.B. Bush, Jr., and H. Finkbeiner, J. Amer. Chem. Soc., 
1968, ~, 5903. 
329. E.I. Heiba, R.M. Dessau and W.J. Koehl, Jr., J. Amer. Chem. Soc., 
1969, ~, 138. 
330. R.E. Vander Ploeg, R.W. DeKorte and E.C. Kooyman, J. Catal., 
1968, 1.£, 52. 
331. E.S. Huang, K.H. Lee, C. Piantadosi, T.A. Geissman and 
J.S. Pagano, J. Pharm. Sci., 1972,~, 1960. 
332. Cytotoxic Activity was assayed under the auspices of the 
Cancer Chemotherapy National Service Centre, by the procedure 
described in Cancer Chemotheraphy Rept., 1962, 25, 1. 
333. K.H. Lee, S.H. Kim, C. piantadosi, E.S. Huang and T.A. Geissman, 
J. Pharm. Sci., 1974, ~, 1162 and references cited therein. 
334. A.A. Loeser, Lancet, 1941, ~, 698. 
335. C. Huggins, J. Nat. Cancer. Inst., 1954, ~, 1. 
336. L.J. Lemer, A. Bianchi and A. Borman, Cancer, 1960, 22, 1201. 
337. A. Segaloff, J.B. Weeth, E.L. Rongone, P.J. Murison and C.Y. Bowers, 
Cancer, 1960, 13, 1017; 
-226-
337. B. A. Segaloff, J.B. Weeth, P.J. Murison and E.L. Rongone 
Steroidsl Growth and Cancer, in Proc. Conf. Vergenes. 
Ed. G. Pincus, 1960, 389: 
C. A. Segaloff, J.B. Weeth, K.K. Meyei, E.L. Rongone and 
M.E.G. Cuningham, Cancer, 1962, 21, 633, 636. 
338. S. Liao and S. Fang, Vitam. and Horm.. (New York). 1969. ~. 17. 
339. J.D. Wilson and R.E. Gloyna, Recent Prog. Horm. Res.. 1970, 26. 309. 
340. R.J. Moore and J.D. Wilson. ~. Biol. Chem •• 1972, 247, 958. 
341. R.E. Gloyna and J.D. Wilson. J. Clin. Endocrinol. Metab." 1969, 
29. 970. 
342. R.E. Gloyna. P.K. Suteri and J:D. Wilson, J. Clin. invest. 
1970, ~, 1746. 
343. J.D. Wilson and I. Lasntizki, Endocrinol., 1971,~, 659. 
344. J.L. Goldstein and J.D. Wilson, J. Clin. Invest., 1972, ~, 1647. 
345. J.D. Wilson, A. Bruchovsky and J.N. Chatfield, Proc. Int. Congr. 
Endocrino!., 3rd 1968- Int. Congr. Ser. No. 184: 1969, 17. 
346. J.D. Wilson and R.E. Gloyna, Recent Prog. Horm. Res., 
1970, ~, 309. 
347. M.D. Morgan and J.D. Wilson, J. BioI. Chem.~ 1970, 245, 3781. 
348. J.S. McGuire, Jr., and G.M. Tomkins, J. BioI. Chem., 1959, 234, 791. 
349. J.S. McGuire Jr., and G.M. Tomkins, J. BioI. Chsm., 1960, 235, 1634. 
350. J.S. McGuire, Jr., V.W. Hollis, Jr., and G.M. Tomkins, 
J. BioI. Chem., 1960, 235, 3112. 
351. J. Chamberlain, N. Jagarinec and P. Ofner, Biochem. J. , 
1966, ~, 610. 
352. 1. Bjorkhem, Eur. J. Biochem. , 1969, .!!.' 345. 
353. A.B. Roy, Biochimie, 1971, 22' 1031. 
354. W. VOigt, E.P. Fernandez and S.L. Hsia, J. BioI. Chem., 
245, 5594. 
1970, 
-227-
355. J. Shimazaki, T. Horaguchi, Y. Dhki and K. Shida, Endocrinoll 
Japan, 1971, 2!, 179. 
356. H.R. Levy and P. Talalay, J. Biol. Chem., 1959,~, 2014. 
357. S.J. Davidson and P. Talalay, J. Biol. Chem., 1961, 241, 906. 
358. J.S. McGuire, Jr., and G.M. Tomkins, Fed. Prec. Fed. Amer. Sac. 
Exp. Biol. , 1960, .1.§., 29. 
359. D.C. Wilton and H.J. Ringold, Prec. Int. Congr. Eridocrinol., 
3rd Int. Congr. Seg. No. 157, 1968, 105. 
360. W.R. Miller and A.P.M. Forrest, Lancet, 1972, ~, 714. 
362. T. Mineseta and K. Yamaguchi, Cancer. Res., 1965,~, 1168. 
363. K. Yamaguchi, T. Mineseta, H. Kasai, K. Kurachi and K. Matsumoto, 
Steroids, ,1971, 22, 345. 
364. W.L.P. Mainwaring and F.R. Mangan, J. Endocrinol., 1973, 
.§2., 121. 
365.A.A.K. Ray, E.E. Baulieu, T. Feyel-Cabanes, C. LeGoascoigne and 
P. Robel, Endocrinol, 1972, ~, 396. 
B. A.K. Ray, P. Robel and E.E. Baulieu, Endocrinoll 1972,~, 
1216. 
366. G.T. Beatson, Lancet, 1896, 11, 104. 
367. J. Hayward, "Hormones and Human Breast Cancer", Heinemann, London, 
1970. 
368. E.S. Henderson, Semin. Hematol., 1969, 6, 271. 
369. J.L. Burn, in "The Treatment of Breast Cancer," Univ. Park. Press., 
Baltimore, 1974, 87. 
370. E.C. Reiferstein, Gynecol. Oncol., 1974,~, 377. 
371. J .0. Fergusson, in "Endocrine Therapy in Malignant-Disease," 
W.B. Saunders and Co. Ltd., London, 1972, 237. 
372. R.J.B. King and W.I.P. Mainwaring, "Steroid Cell Interactions", 
Univ. Park Press, Baltimore, 1974. 
373: J.A. Wolff, C.A. Brubaker, M.L. Murphy, M.I. Pierce and 
N. Severa, J. Padiat. 1967, Z£, 626. 
-228-
374. M.E. Lippman. Life Sciences. 1976. ~. 143. 
375. M.E. Lippman. R.H. Halterman. B.G. Leventhal. S. Perry and 
E.B. Thompson. Nature (New Biol.) •• 1973. ~. 151. 
376. W. Pratt and D. Ishii. Biochem •• 1972. 21· 1401. 
377. W.L. McGuire and J.A. Julian. Cancer. Res.-. 1971. ~. 1440. 
378. W.L. McGuire. J .A. Jul1an and G.C. Chamnes. Endocrinol. 1971. 
379. W.L. McGuire. K. Huff. A. .:1ennings and G.C. C'hamnes. Science. 
197:2. 175. 335. 
380. E.V. Jensen. G.E. Block. S. Smith. K. Kyser and R. DeSombre. 
Nat. Cancer Inst. Monogar, 1971. 34. 55. 
381. G.C. Chamnes and W.L. McGuire. Biochem.. 1972. 21. 2466. 
382. W.L. McGuire. M. De La Garza and G.C. Chamners. Endecrinel •• 
1973. 93. 810. 
383. W.L. McGuire and M. De. La Garza. J. Endocrinol Metab •• 
1973. ~. 548. 
384. M.E. Lippman and G. Bolan. Nature. 1975. 256. 592. 
385. J.J. Jaffe. G.A. Fischer and A.D. Welch. Biochem. Pharmacol •• 
1963 • .!3.. 1081. 
~ 969. 
386. V.A. Drill and B. Riegel. Recent. Prog. Horm. Res.. 1958. 1~ 29. 
387. J. Fried. Cancer. 1757. 2Q. 752. 
388. J. Fried and A. Borman. Vitam. and Horm.. 1958.~. 303. 
389. J.M. Lampkin and M. Potter. J. Nat. Cancer. Inst.. 1958. 20. 1091. 
390. J.M. Lampkin-Hibbard. J. Nat. Cancer. Inst •• 1960. 20. 
391. I. Ringler. S. Maver and E. Heyder. Proc. Soc. Exp. Biol. (New York). 
1961. 107. 451. 
392. N.R. Stephenson. J. Pharm. Pharmacol, 196o • .!3.. 411. 
393. S. Tolksdorf. Ann. M.Y. Acad. Sci., 1959, 82, 839. 
394. F. Rupert. W. Thorne and F.L. Bygnave. Cancer Res., 1973,~. 2562. 
395. H.D. Haberman, Cancer Res., 1975,~, 3332. 
396. K.W. McKern, in "Hormone and Cancer", Academic, New York, N.Y. 
1974. 261. 
-229-
397. R.F.W. Thome and F. Bygnove, Cancer Res., 1973, ~. 
398. D.F.H. Wallach, "Membrane Molecular Biology of Neoplastic Cells", 
Elsevier, New Y iOrk, 1975, 257. 
399. I.H. Hall, K.H. Lee·and S.A. Eigebaly, J. Pharm. Sci., 1978, g, 552. 
400. K.H. Lee, I.H. Hall, E.C. Mar, C.O. Starnes, S.A. ElGebaly, 
T.G. Waddell, R.I. Hedgnaft, E.C. Ruffner and I. Weidner, 
Science, 1977, ~, 533. 
401. P. Hotten, Final Year Project, Department of Chemistry, 
University of Technology, Loughborough, 1978. 
402. D.R. Grassetti and J.F. Murray, Biochem. Pharmacol., 
1836. 
403. J.R. Traynor, Personnel Communication. 
1970, 19, 
404. W. Yotis and J. Waner, J. Microbiol. Serol., 1968, ~, 275. 
405. J .E. Pike, J.E.- Grady, J.S. Evans and C.G. Smith, J. Med. Chem., 
1964, z..., 348. 
406. M.E. Lippman, R.H. Halterman, B.G. Leventhal, S. Perry and 
E.B. Thompson, J. Clin. Invest., 1973,~, 1715. 
407. A. M. Avaro and J. Lavisalles, Bull. Soc. Chim. France., 1969, 3166; 
B. C. Huynh and S. Julia, Bull. Soc. Chim. France., 1971, 4402. 
408. "Dictonary of Organic Compounds", Ed., I. Heilbron and H.M. Bunbury, 
Eyre and Spottiswoode, London, 1953. 
409. F.J. Wolf and J. Weijhard, Org. Syn. Call. Vol. IV., 1963, 124. 
410. T.J. de Boer and H.J. Backer, Drg. Syn. Call. Vol. IV 1963, 250. 
411. W.S. -Johnson, V.J. Bauer, J.L. Margrave, M.A. Fr1sch, L.M. Dreger 
and W.N. Hubbard, J. Amer. Chem. Soc., 1961, ~, 606. 
412. H.L. Donle and G. Volkert, Zeitschrift fir Physikalische Chemie., 
1930, Abt. B Band 8, 60. 
413. H.R. Nace, J. Amer. Chem. Soc. 1952, Z±, 5937. 
414. D.N. Jones and M.A. Saeed, J. Chem. Soc., 1963, 4657. 

